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Daily nebuliser use is crucial for people with cystic fibrosis (CF) to stay healthy, but average 
adherence is only 35-50%. Making nebuliser use ‘habitual’ (i.e. automatic) may aid adherence, but 
extant CF literature has mainly focused on treatment burden and factors involving conscious 
deliberation. This thesis aims to explore a broad range of clinical and psychological factors that are 




This thesis encompassed three studies. First, a retrospective analysis of adherence data captured 
using chipped nebulisers from 2013-2016 among 126 adults was performed to explore relevant 
clinical factors. Second, a mixed-methods study was performed among 20 adults to identify the 
psychological factors differentiating high or low nebuliser adherence patterns (i.e. ≥80% or <50% 
of all nebulised treatments over one year). Third, a secondary quantitative analysis was performed 
using data from a two-centre pilot adherence trial among 64 adults to replicate findings from the 




The retrospective analysis showed a U-shape relationship between adherence and age, with 
lowest adherence levels among adults aged 19-25 years. Lower adherence was also noted for 
long term (>3 months) nebuliser regimen in comparison to shorter-term treatments.  
The mixed-methods study found stronger habit and greater opportunities among high adherers, 
though habit and perceived opportunity scores were highly positive correlated. Habit attenuated the 
relationship between treatment complexity and perceived treatment burden. Indeed, in interviews, 
high adherers reported that routinisation and greater automaticity made treatment burden more 
manageable. 
The secondary analysis using pilot trial data found stronger habit and lower concerns among high 





Adherence to long-term CF nebuliser treatments is problematic, especially among younger adults 
with CF. Habit may attenuate perceived burden and is a promising target for adherence 
interventions. 
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CHAPTER 1: INTRODUCTION TO THE THESIS 
 
Cystic fibrosis (CF) is a long-term condition in which median survival is around 45-50 years.[1] 
More than 80% of the mortality is primarily due to lung disease,[2] and daily use of preventative 
inhaled therapies is crucial to maintain lung health.[3] However, adherence to these therapies 
among adults with CF is generally low with median adherence of 35-50%.[4, 5]  
 
Nebuliser adherence among adults with CF remains poorly understood. Most of the current 
literature in this area tends not to emphasise explicit psychological behaviour change theory; and 
tends to focus on treatment burden and conscious motivational factors such as treatment 
beliefs.[6] Within the wider psychology literature, there is increasing recognition of the importance 
of automatic, non-reflective processes to improve and sustain treatment adherence.[7-11] One 
such automatic process is habit. While used in everyday language to refer to frequent repetitive 
actions, within psychology the term ‘habit’ refers to a non-conscious process by which situational 
cues (e.g. watching the BBC News at Ten) automatically prompt an impulse to perform an action 
(e.g. using nebuliser).  
 
It should be noted that low adherence is not a recent phenomenon in CF. Medication adherence 
has been recognised as a challenge in managing people with CF since 1970’s,[12] just as 
efficacious CF treatment options began to emerge. Research to develop adherence interventions 
for people with CF has begun in earnest during 1980’s,[13] yet today there are no effective 
interventions to support adherence in routine clinical practice.[14, 15] Indeed, a substantial amount 
of background work is required before such an intervention can be successfully developed and 
implemented. This PhD research was undertaken to explore various issues related to the 
development, evaluation and implementation of effective adherence interventions for adults with 
CF.       
 
The work presented in this thesis was undertaken with the specific aims of exploring a broad range 
of clinical and psychological factors that are potentially associated with objective nebuliser 
adherence among adults with CF; since understanding the determinants of adherence is an 
important step towards designing an effective adherence intervention. The remainder of this thesis 
is structured into the following chapters.  
 
Chapter 2 provides a brief introduction to cystic fibrosis; and describes changes in epidemiology, 
prognosis and treatment options over the past few decades.  
 
Chapter 3 reviews the current literature pertaining to clinical and psychological factors that are 
associated with nebuliser adherence among people with CF. Since no studies specifically looked at 
habit in the context of CF medication adherence, the role of ‘habit’ in other health-related 




Chapters 4 seeks to address the following research question: What are the clinical factors 
associated with objective adherence? In this chapter, routinely collected data from 2013-2016 
among 126 adults with CF were analysed to explore the clinical (i.e. demographic and treatment) 
factors that are associated with objective nebuliser adherence. 
 
Chapter 5 seeks to address the following research question: What are the psychological factors 
associated with objective adherence? This chapter reports the findings of a mixed methods cross-
sectional exploratory study comparing ten low and ten high nebuliser adherers. The results from 
this chapter have been recently published.[16] 
 
Chapter 6 seeks to replicate the findings of the Sheffield mixed methods study in Chapter 5. This 
chapter reports the findings of a secondary quantitative analysis using prospectively collected data 
during a pilot randomised controlled trial with 64 participants (ACtiF pilot, ISRCTN13076797). The 
results from this chapter have been recently published.[17]  
 
The final chapter (Chapter 7) ends with discussion and conclusions that draw together the findings 





CHAPTER 2: INTRODUCTION TO CYSTIC FIBROSIS 
 
This chapter summarises the relevant literature to set the scene and to provide a background on 
the management of cystic fibrosis (CF).  
 
 
Chapter 2, Section 1: What is cystic fibrosis? 
 
Cystic fibrosis (CF) is an autosomal recessive genetic condition that is caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene.[18] More than 1500 mutations 
have been identified in the CFTR gene, with F508del accounting for almost 2/3 of these 
mutations.[19] The CFTR gene encodes the CFTR protein, which is expressed in the apical 
membrane of epithelial cells and predominantly functions as a chloride channel.[20, 21] CFTR also 
has other roles, including regulating sodium and bicarbonate transport.[18] CFTR is found 
throughout the body; hence CF is a multi-system condition.[18] However, the two organs that are 
mainly affected are lungs (resulting in recurrent infections and respiratory failure) and the 
gastrointestinal tract (resulting in malabsorption and poor growth).[20] At present, more than 80% 
of the mortality in CF is primarily due to lung disease;[2, 20] hence the most important aims of CF 
treatments are to try protect the lungs from the recurrent infections, inflammation and permanent 
lung damage that are the hallmarks of CF lung disease.[22] 
 
There are two theories for the pathogenesis of CF lung disease from CFTR dysfunction. The ‘low 
volume’ hypothesis postulates that excess sodium and water reabsorption result in reduced 
volume of airway surface liquid, which then inhibits mucociliary clearance and leads to mucus 
plugging.[20, 21, 23] The ‘high salt’ hypothesis postulates that retained excess sodium and 
chloride in airway surface liquid disrupts the innate defence mechanism.[21, 24] CF lungs are 
therefore more vulnerable to infection and colonisation by pathogens. There is also 
disproportionately exuberant neutrophil-dominated inflammatory response to the pathogens due to 
dysregulated host inflammatory response.[20-22, 24] This vicious cycle of infection and 
inflammation then leads to progressive worsening of lung damage (e.g. bronchiectasis), respiratory 
failure and death.[18, 20] 
 
Given the extensive number of CFTR gene mutations that can cause CF, it is not surprising that 
there is a wide spectrum of disease severity.[25-27] The CFTR gene mutations are divided into five 
functional classes based on the different molecular defects of the CFTR proteins.[19] People who 
are homozygous for Class I-III mutations tend to have more severe disease than those with at least 
a copy of the Class IV-V mutation.[19, 28] However, there is substantial phenotypic variability even 
among people with identical CF genotype, due to presence of unlinked ‘modifier genes’ and also 
environmental influences.[28-32] The latest evidence shows that people with ‘milder phenotype’ 
tend to eventually succumb to the same trajectory of lung function decline experienced by people 
9 
 
with ‘typical CF’; suggesting that progressive lung damage is only delayed rather than completely 
avoided among people who may appear to have milder forms of CF.[33] 
 
 
Chapter 2, Section 2: Changes in the prognosis and epidemiology of people with CF 
 
The median survival was less than 6 months when CF was first recognised as a unique entity in 
1938.[34] Survival improved from the 1950’s, as people with CF began to be cared for in ‘specialist 
centres’.[34] As clinicians gained more experience, treatment options increased and quality of care 
improved, survival continued to improve year on year; and median survival in CF is now estimated 
to be around 45-50 years.[35-37] It is important to note that the survival improvement among 
people with CF outstrips the background survival improvement among the general population [38] 
and the improvement is not simply due to the increased case finding of people with milder 
disease.[39] 
 
The improvement in prognosis has altered the demography of the CF population.[40, 41] Up to the 
1970’s, CF was predominantly a disease of children.[42, 43]  From 2010, the number of adults has 
actually exceeded the number of children with CF in many developed countries.[36, 41, 44] The 
most recent (2016) UK CF registry report described a population of more than 10,000 affected 
people,[1] making CF the most common genetic life-shortening long-term condition in the UK.[20, 
21] More than 50% of the people with CF in the UK are aged ≥16 years, hence receiving care at 
specialist adult centres. The adult CF population continues to increase at more than 200 people 
per year,[39] which is equivalent to size of a moderately large adult CF centre. With the adult CF 
population projected to increase by 30-40% in the next 10 years, there will be increasing pressure 
on the current adult CF services.[35, 40] Therefore, there is a need to explore new care models in 
order to accommodate increased patient numbers without any reduction in the quality of care. 
 
 
Chapter 2, Section 3: The ‘three pillars’ of CF management 
 
Treatment regimen for a person with CF typically consists of multiple components due to the multi-
system nature of CF. In general, CF management can be summarised into the following ‘three 
pillars’:[34, 45] 
• Nutritional supplementation with appropriate pancreatic enzyme replacement, high calorie diet, 
nutritional supplement (including replacement of fat-soluble vitamins) and appropriate 
management of CF related diabetes 
• Airway clearance with inhaled mucolytics (including osmotics) and chest physiotherapy 
• Appropriate use of antibiotics to eradicate / control airway infection – antibiotics can be 




Optimal CF management is proactive. Early interventions should be initiated prior to the 
development of symptoms [34, 45] because lung damage can occur prior to the onset of any 
symptoms, as demonstrated by CT scans or lung clearance index in infants with CF.[46-48]  
 
Recent research hints at the possibility of eventual cure with new treatments targeting the 
underlying gene defect.[49-51] However, only around 5% of the UK CF population (those with the 
class III gene mutation) currently benefits from ivacaftor, a ‘CFTR potentiator’ that has been 
commercially available since 2012-2013.[52] The rest of the CF population still rely on treatments 
that target the downstream consequences of CFTR dysfunction in the lungs i.e. the impaired 
mucociliary clearance and chronic infection / inflammation. The impressive improvement in CF 




Chapter 2, Section 4: ‘Rescue’ vs ‘preventative’ therapies in CF 
 
Treatments to preserve lung health in CF can be broadly dichotomised into ‘rescue’ therapy with IV 
antibiotics to treat pulmonary exacerbations and ‘preventative’ therapy with inhaled therapies to 
minimise the risk of exacerbations.[53] “Pulmonary exacerbations” are episodic acute events 
causing damage to the lung, usually precipitated by infection and manifest as acute worsening of 
symptoms and/or drop in lung function (FEV1).[54-56] Frequent exacerbations are associated with 
excess mortality,[57, 58] accelerated FEV1 decline,[59-63] lower quality of life,[64-67] and higher 
healthcare costs.[68-70] Therefore, these are events with clinically significant consequences for a 
person with CF. In fact, it has been postulated that recurrent pulmonary exacerbations is the 
primary driver of progressive lung damage seen in people with CF.[71, 72] 
 
The use of IV antibiotics as acute treatments for exacerbations actually have very limited RCT 
evidence.[73] Nonetheless, various observational studies have highlighted the importance of IV 
antibiotics in CF. A recent analysis using the Epidemiologic Study of Cystic Fibrosis (ESCF) data 
showed that treatment of exacerbations with any additional antibiotics is associated with increased 
likelihood of FEV1 recovery, when compared with no treatment.[74] Recent studies using the US 
CF Foundation Patient Registry and ESCF data have suggested that the best outcomes (i.e. 
increased likelihood of FEV1 recovery and reduced risk of treatment failure) are achieved with IV 
antibiotics (especially in-patient IV courses) compared to additional antibiotics delivered by other 
routes.[74-76] There is also evidence that inadequate IV antibiotics use or higher threshold for 
initiating IV antibiotics in the face of an exacerbation is associated worse outcomes,[77, 78] even in 
this decade when efficacious preventative therapies are increasingly available and increasingly 
prescribed.[79] As such, IV antibiotic is widely considered to be the most potent treatment for 




Despite the importance of IV antibiotics in CF management, intensive IV use is not without its 
drawbacks. The common problems associated with widespread antibiotics use in the general 
population are different from specific problems encountered by people with CF. For example, one 
of the most common and feared complications of prolonged broad spectrum antibiotics use in the 
general population is clostridium difficile colitis.[84, 85] Clostridium difficile colitis is surprisingly rare 
among people with CF despite the industrial quantities of IV antibiotics used.[86, 87] Antibiotic 
resistance is another well-publicised and much-hyped risk with “antibiotics overuse” in the general 
population.[88-90] Antibiotic resistance is also a problem in CF,[91, 92] but there are several lung 
pathogens in CF such as P. aeruginosa whereby resistance can result from antibiotics under-use 
e.g. the use of a single IV antibiotic agent (instead of two antibiotics from different classes) can 
exert selective pressure for resistance to develop.[93-95] 
 
The specific problems due to wide-spread broad-spectrum IV antibiotic use faced by people with 
CF are just as serious. Hypersensitivity reactions to IV antibiotics are around thrice as common 
among the CF population.[96-99] Even without a full-blown anaphylaxis, other systemic side-
effects such as ototoxicity, malaise, nausea / vomiting or even candidiasis can be debilitating and 
contribute to the lower quality of life that people with CF experienced during pulmonary 
exacerbations.[65, 97, 100-102] But perhaps the most catastrophic complication of excessive IV 
antibiotics use in CF is renal failure. P. aeruginosa, which is the most common lung pathogen 
causing accelerated FEV1 decline among adults with CF,[62, 103-105] is particularly resistant and 
two common classes of anti-Pseudomonal antibiotics (aminoglycoside and polymixin) are 
nephrotoxic.[106] As survival of the CF population improves (see Section 2.2), the cumulative 
burden of these nephrotoxic antibiotics also increases. Not surprisingly, renal failure is an 
increasingly a common problem among people with CF.[107-110] In addition to the usual 
morbidities associated with renal problems, renal failure is particularly pertinent for people with CF 
because it can limit the use of IV antibiotics and preclude consideration for lung 
transplantation,[111] both of which are vital treatments to improve prognosis in CF.[34, 112]  
 
Current strategies to limit this “epidemic” of acute renal failure include using aminoglycoside with 
the least nephrotoxic profile (e.g. tobramycin instead of gentamicin)[113] and to use less toxic 
dosing regimen (e.g. once daily instead of thrice daily dosing for aminoglycoside).[114] A more 
sensible approach to limit the systemic side-effects of IV antibiotics would be to move from ‘rescue’ 
to ‘prevention’,[53] i.e. to use preventative inhaled therapies more effectively with the aim of 
achieving stability in lung health and reducing the reliance on rescue by IV antibiotics 
 
Unlike IV antibiotics, the efficacy of preventative inhaled therapies has been repeatedly and 
consistently demonstrated in RCT settings. Multiple blinded randomised control trials found that 
inhaled therapies reduce the frequency of exacerbations and improve FEV1.[115-119] In addition, 
inhaled therapies are associated with improved quality of life and better survival.[120-122] Inhaled 
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therapies are also recommended in all the major CF guidelines on the basis of their beneficial 
effects in preserving lung health and reducing the risk of exacerbations.[80, 123, 124] 
 
Preventative treatments can be divided into two categories: antibiotics and mucolytics. Inhaled 
antibiotics such as colistin, tobramycin, aztreonam lysine and levofloxacin are used in CF to 
eradicate P. aeruginosa when it is first isolated and to prevent pulmonary exacerbations among 
those who are chronically infected with lung pathogens such as P. aeruginosa.[115, 125] These 
antibiotics are available as solution for nebulisation, or as dry powder for inhalation (colistin and 
tobramycin only).[126] Inhaled mucolytics are used to aid mucociliary clearance of mucus and 
augment airway clearance.[127] Mucolytics are also available in the form of solution for 
nebulisation (e.g. dornase alfa and hypertonic saline) and dry powder for inhalation (e.g. 
mannitol).[127] 
 
Inhaled therapies have several advantages over other methods of administering medications to the 
lungs of people with CF. It is possible to achieve much higher intrapulmonary drug concentrations 
using the inhaled route compared to using systemic routes, such as IV administration.[125, 128, 
129] This is of particular importance with the administration of antibiotics, because intrapulmonary 
concentrations far exceeding the minimum inhibitory concentrations can be achieved with the 
inhaled route, thus potentially overcoming problems of antibiotic resistance.[130, 131] Crucially, 
there is minimal systemic absorption of drugs delivered by the inhaled route, thus systemic side-
effects are rare.[125, 128, 130, 132, 133] Whilst “local” side-effects such as laryngeal irritation or 
bronchospasm may occur,[127, 134] these side-effects are usually transient and can be overcame 
by pre-treatment with bronchodilator or switching to another drug.[135] 
 
 
Chapter 2, Section 5: The current state of preventative inhaled therapy prescription by CF 
clinicians 
 
A move from ‘rescue’ to ‘prevention’ would be expected to improve the quality of life and overall 
health outcomes for people with CF.[53] However, a potential obstacle to this move is the 
ineffectual utilisation of preventative inhaled therapies despite their proven track record of efficacy.  
 
In clinical medicine, there is always a lag in translating sound evidence into routine practice. 
Compelling evidence for using aspirin as secondary prophylaxis following acute myocardial 
infarction emerged around 1970’s and 1980’s,[136-139] yet more than 50% of patients did not 
receive aspirin on discharge following a myocardial infarction in the 1990’s.[140-142] Another 
example is the failure to embed hand-washing into current routine clinical practice [143] despite 
strong evidence for hand-washing emerging since 1846.[144] 
 
In CF, various quality improvement initiatives have increased the appropriate prescription of 
inhaled treatments. During the mid-1990’s, only around 60% of the eligible people with CF at the 
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Northern New England CF collaboration (NNECFC) were prescribed with inhaled antibiotic and 
mucolytic.[145] By 2000, the prescription rate has improved to 82% of the eligible people with 
CF.[145] The prescription of inhaled therapies continued to rise between 1995 and 2005, when no 
new classes of antibiotics or mucolytics were introduced.[146] With the introduction of a third class 
of inhaled antibiotics, not surprisingly prescription of inhaled antibiotics increased further and more 
people are now on multiple classes of inhaled antibiotics (usually being rotated rather than being 
used simultaneously).[147] In fact, a recent RCT aiming to randomise participants to continuous 
alternating therapy vs intermittent treatment regimen failed to recruit adequate number of 
participants, because the number of potentially eligible participants was reduced by the wide-
spread adoption of continuous alternating therapy in the US.[148]   
 
However, there remains substantial variation in the prescription of inhaled therapies.[149-151] 
Recent data from the US suggest only around two-thirds of people with CF were prescribed the 
recommended preventative inhaled therapies.[149, 152] In the UK, the most recent CF registry 
report in 2016 showed an almost 3-fold difference (86.8% vs 30.2%) in the prescription of dornase 
alfa between the adult CF centre in the UK with the highest dornase alfa use compared to the 
centre with the lowest use.[1] This difference is simply too large to be explained by just case-mix 
and chance, and must be due to differences in prescribing practices of CF clinicians.  
 
Appropriate prescription by clinicians is only one side of the coin for effective utilisation of 
preventative inhaled therapies in CF to enable the move from ‘rescue’ to ‘prevention’.[153, 154] 
The other side of the coin is medication adherence. Medication adherence, which is the focus of 
this thesis, is the subject of literature reviews in the next chapter (Chapter 3).  
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CHAPTER 3: LITERATURE REVIEW 
 
 
Chapter 3, Section 1: Introduction  
 
 
3.1.1 The definition of medication adherence 
 
Medication adherence is defined by the World Health Organisation (WHO) as “the degree to which 
a person’s behaviour corresponds with the agreed recommendations from a health care 
provider”.[155] The Ascertaining Barriers to Compliance (ABC) taxonomy for medication 
adherence outlined three distinct temporal adherence phases.[156-158] The first phase is 
‘initiation’, which is the period between medication being prescribed and the first dose being taken. 
‘Initiation’ is often operationalised as a binary event, whether a patient starts taking the medication 
or not within a given time period. The second phase is ‘implementation’, which measures the 
extent to which medication taking corresponds to an agreed dosing regimen from initiation until the 
final dose. The third phase is ‘persistence’, which is the time between ‘initiation’ and eventual 
treatment discontinuation.    
 
Most adults with CF would have already received their first dose of inhaled medication during their 
childhood. Among the minority who were diagnosed with CF in adulthood, their first dose of inhaled 
medication would still be given in hospital as all CF inhaled therapies require a supervised test 
dose. Persistence is difficult to operationalise since most adults with CF will remain on inhaled 
therapies until the end of life, though there may be long periods of non-adherence in between 
medication doses. Therefore, the ‘implementation’ phase is the most relevant component for 
medication adherence among adults with CF and is the focus of this thesis.  
 
3.1.2 Methods of capturing adherence data 
 
In general, the two most common methods of capturing adherence data are self-report (i.e. asking 
respondents to characterise their medication taking behaviour) and pharmacy refill (i.e. measuring 
how much of the prescribed medications are actually collected).[159, 160] Another method of 
capturing adherence data is with electronic data capture (EDC), whereby medication taking 
behaviour is directly monitored via specifically designed electronic devices.  
 
Self-reported measures tend to over-estimate adherence levels, even with validated tools.[4, 161-
163] This has resulted in suggestions of using “correction factors” or modelling techniques (e.g. 
hierarchical linear modelling) to obtain more accurate estimates of adherence levels from self-
reported measures.[159, 163, 164] However, these “correction factors” or modelling techniques 
may not necessarily improve the reliability of self-reported measures because mis-calibration can 
result in both under- and over-estimation of adherence levels with no clear predictors for the 
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direction of errors.[4] A significant minority of people under-estimate their adherence,[4] which 
could potentially result in poor prescribing practices if clinicians were to act upon those self-
reported measures. As such, self-reported adherence data are unreliable measures of adherence 
levels at an individual level. 
 
Pharmacy refill may be somewhat more reliable than self-report, in that it represents the maximum 
amount of medication a person can take.[165] For example, someone who only collects 20% of his 
/ her prescribed medications can only have a maximum adherence level of 20%, assuming that he 
/ she has no other sources of that medication (e.g. spare supply at home due to previous under-
use). However, not all collected medications will be used correctly and some medications may not 
even be used at all. A study found a mean adherence level of only 62% using EDC among 
hospitalised children with CF even though prescription charts recorded 100% of inhaled therapies 
as being administered.[166] If handing over an inhaled medication in a hospital setting (where 
there is less distraction and more attention is being focused on health) does not equate to the 
medication actually being used, it seems highly unlikely that all collected medications in the 
community will be used. That means pharmacy refill may over-estimate adherence. Indeed, a 
study evaluating adherence with ivacaftor among people with CF found higher adherence levels as 
measured by pharmacy refill (median 84%) compared to EDC (median 61%).[167] Perhaps even 
more worrying, there was a lack of correlation between adherence levels measured by those two 
different methods in that study.[167]  Another limitation of pharmacy refill is the inability to capture 
important granularity of behaviours involved in using preventative inhaled therapies. 
 
EDC is generally regarded as the ‘gold standard’ method to capture adherence data due to its 
accuracy.[168] In CF, tamper-proof intelligent nebuliser systems (I-neb®) which provide date- and 
time-stamped data for every dose of nebulised medication are routinely available.[169] The I-neb® 
is a third generation adaptive aerosol delivery system designed to optimise inhalation technique by 
directing flow and depth of inhalation, providing positive feedback signals to guide user, and only 
delivering aerosol when an inhalation of sufficient quality is detected.[170] By only delivering 
aerosol during active inhalation, I-neb® also avoids the issue of medication dose dumping, thus 
ensuring the adherence data are more robust. Another general advantage of EDC is that it 
provides richer quantitative data compared to other methods of data capture. By logging every 
episode of medication use, EDC provides a continuous stream of data which allows adherence 
pattern to be studied in greater detail.[156] For example, weekly ivacaftor adherence rates was 
found to vary substantially between participants and to decline by a rate of 1.93% per week using 
EDC.[167] In terms of nebuliser adherence, studies using I-neb® found that adolescents with CF 
are most adherent during weekdays of school term-time.[171] This has important implications 
towards understanding the psychological factors that influence adherence and such insight is only 




This is not to say that the current methods for EDC have no disadvantages. A specific problem 
related to nebulisers such as I-neb® is that it is sometimes used to deliver more than one type of 
medications. In that situation, it is not possible to differentiate which medication was actually being 
used or not used. A more general problem is that any electronic device may malfunction, thus 
missing data is a risk.[163] With less robust EDC, medication dose dumping (i.e. medication is 
removed but not ingested correctly) may occur but not be detected. This is less of a problem with 
more sophisticated EDC devices that can measure the technique of using the medication.[172, 
173] Availability of suitable devices is also an issue – not every treatment modality can be 
monitored using EDC. In CF, EDC for dry powder inhalers are not yet routinely available. Cost is 
often cited as another barrier to using EDC.[163] Nonetheless, EDC for nebulised medications in 
CF is already routinely available.[169] If EDC is used effectively to provide feedback and improve 
adherence, a health economics evaluation suggests those devices will more than justify their 
costs.[174] 
 
On balance, the advantages of capturing adherence data using EDC for preventative inhaled 
therapies in CF do seem to outweigh the disadvantages. Therefore, only adherence data captured 
via EDC are used for analysis for the three inter-related studies reported in Chapters 4–6 of this 
thesis. 
 
3.1.3 Methods of processing adherence data 
 
In addition to methods of capturing adherence data, methods of processing adherence data can 
also influence the calculated adherence levels. Among people with CF, adherence levels for 
inhaled therapies were generally operationalised as percentages of treatments taken over the 
expected number of doses as agreed between prescribers and people with CF (or their carers).[4, 
162, 171, 175-177] Two studies among people with CF found lower levels of adherence after 
accounting for potential nebuliser over-use by capping daily maximum use at 100% (i.e. if nebuliser 
use in a particular day exceeds the agreed regimen, adherence for that day is truncated at 100% to 
avoid inflating the calculated adherence level) – mean adherence 63% and 47% with capping of 
daily maximum use at 100% vs 66% and 50% respectively without such adjustments.[178, 179] 
This is not surprising because EDC showed that some people had periods when they used more 
medications than prescribed.[4]  
 
This “adjusted” adherence level should, in theory, better reflect effectiveness of medication use 
since there is no evidence that periods nebuliser over-use can compensate for periods of nebuliser 
under-use. In other long-term conditions, more sophisticated adherence data processing methods 
have been employed to calculate adherence levels which reflect “effective medication adherence”; 
e.g. the model-based metric by Greene et al which accounts for dose-timing errors and inhaler 




Methods of processing adherence data to reflect treatment effectiveness [181, 182] and the 
association between adherence and health outcomes have been explored as part of the PhD 
research, but these details are beyond the scope of this thesis which focusses on the clinical and 
psychological factors associated with nebuliser adherence among adults with CF. Nebuliser 
adherence is operationalised as the percentage of total nebuliser doses taken against the agreed 
dose between clinicians and adults with CF for the three inter-related studies reported in Chapters 
4–6 of this thesis. This measure corresponds with the method of quantifying the implementation of 
a dosing regimen, as outlined by the ABC taxonomy for medication adherence.[156-158] 
 
3.1.4 Setting the scene for the rest of the chapter 
 
Following a brief introduction to medication adherence, this chapter continues by reviewing and 
summarising the existing literature pertaining to nebuliser adherence among people with CF. In the 
third section of this chapter, studies without reliable adherence measures and studies looking at 
potential psychological determinants of adherence pertaining to other CF treatment modalities (i.e. 
studies excluded from the initial literature review) are summarised. The concept of ‘habit’ as a 
psychological construct, the relevance of ‘habit’ in other health-related behaviours and methods to 
measure ‘habit’ are summarised in the fourth section of this chapter. Finally, the gaps in current 
evidence are summarised and the specific objectives of the remaining chapters to address these 
gaps are outlined.  
 
 
Chapter 3, Section 2: A literature review of the clinical and psychological factors associated 
with nebuliser adherence among people with CF 
 
This literature review sets out to understand the existing literature pertaining to the clinical and 
psychological factors associated with nebuliser adherence in CF. A secondary aim of this review is 
to understand the current levels of nebuliser adherence among adults with CF. 
 
3.2.1 Search strategy for the literature review 
 
Electronic Databases search with Embase (from 1947 onwards) and Medline (from 1946 onwards) 
was performed on 31st January 2016, with the following search strategy: 
<Condition-related keyword and MeSH terms> AND <adherence-related keyword and MeSH 
terms> AND <inhaled therapy-related keyword and MeSH terms> 
The condition-related term was: 
Cystic fibrosis (MeSH) 
The adherence-related terms were: 




The inhaled therapy-related terms were: 
Nebulizers or vaporizers (MeSH) OR metered dose inhalers (MeSH) OR dry powder 
inhalers (MeSH) OR inhaled therapy (keyword) OR nebulized therapy (keyword) OR 
nebulised therapy (keyword) 
 
Only condition-, adherence- and inhaled therapy-related terms (which map to the patient, problem 
or population component of the PICO tool [183]) were used in the databases search because the 
intention is to identify all relevant literature which reported nebuliser adherence levels among 
people with CF. Hand-searching for relevant literature from the January 2012 to January 2016 
editions of the ‘Journal of Cystic Fibrosis’, ‘Pediatric Pulmonology’ and ‘Patient Preference and 
Adherence’ were performed on 31st January 2016. 
 
Unpublished work was identified by 
1. Hand searching the abstract books of both the major international cystic fibrosis conferences 
(the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference) 
for 2012–2015 and both the major international respiratory conferences (the European 
Respiratory Society International Conference and American Thoracic Society Conference) for 
2012–2015 
2. Google search with “medication adherence” and “cystic fibrosis” as the keywords 
 
Reference tracking of the relevant literature reviews [3, 184] was performed on 31/01/2016. 
Reference tracking and citation tracking for all the relevant papers retrieved by other search 
methods were performed on 31/01/2016. 
 
3.2.2 Review procedure for retrieved literature 
 
Studies were included in this review if they fulfil the following inclusion criteria: 
• Primary nebuliser adherence data were presented because the focus of this thesis is on 
nebulised medications, i.e. studies that only measured adherence to dry powder inhalers were 
excluded  
• Methods for capturing adherence data, analysis of adherence data and reporting of adherence 
levels were adequately described to ensure the reliability of reported adherence levels  
• Literature in English language due to the lack of resources for translation 
 
Conference abstracts were included in the review if adequate information were available. Studies 
were excluded if quantitative adherence data were not reported. Studies were also excluded if the 
only method for capturing adherence data is via self-report unless ecological momentary 
assessment technique is used for ‘real time’ data capture,[185] due to the known lack of reliability 
with long-term recall based self-reported adherence as discussed in Section 3.1.2.[4, 184, 186, 
187] These exclusion criteria were applied since relying on self-reported adherence can easily give 
rise to misleading conclusions. For example, a study using self-reported adherence measures 
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concluded that “those involved in the care of patients with cystic fibrosis were able to predict 
patient compliance”.[188] Studies using more reliable measures e.g. electronic data capture (EDC) 
or pharmacy refill have shown that clinicians’ “predicted” adherence levels are actually 
unreliable.[4, 161] 
 
All citations (title and abstract) were screened for eligibility and the following information was 
extracted from the texts of all eligible literature: 
1. Authors and year of publication 
2. Study design 
3. Study population 
4. Method for capturing adherence data 
5. Timing and duration of adherence data capture 
6. Nebuliser adherence level 
7. Associations between adherence and clinical factors  
8. Associations between adherence and psychological factors  
9. Other relevant findings regarding efforts to support adherence 
 
Studies included in this review are either epidemiological observational studies or analysis of data 
from clinical trials. Given the observational nature of these studies, the methodological quality was 
assessed using the STROBE statement,[189] with the AHRQ framework used to assess the risk of 
confounding and bias of the studies.[190] The AHRQ framework consists of 13 questions to assess 
the risk of confounding, selection bias, performance bias, detection bias, attrition bias and selective 
outcome reporting.[190] The reliability of the adherence-related results depended not just on the 
methodology quality of the studies, but also on the methods used to measure adherence. This was 
evaluated by comparing the different measurement methods used in the studies and taking into 
account expert opinion from relevant reviews.[184, 191] 
 
The data extracted from the studies have both qualitative (information about study methodology 
and methods used to measure adherence) and quantitative (adherence levels and association 
between adherence with clinical / psychological factors) components. Due to the heterogeneous 
nature of the methods used to measure adherence and relative diversity of the patient population 
and drugs involved, a meta-analysis of the adherence results was not possible. Therefore, a 
qualitative synthesis of the relevant data was performed using an approach that mirrors the ESRC 
methods.[192] The data from individual studies was initially tabulated for preliminary synthesis of 
findings. Studies were then grouped together based on adherence measurement methods, in order 
to explore the relationships within the data. A qualitative case description was used to summarise 
the findings. This narrative analysis of the included studies is similar to the approach used in the 




3.2.3 Results of the literature review 
 
Figure 3.1 shows the flow from electronic database search and other ‘snow-balling’ strategies to 
study inclusion. In total, 18 studies were included in the review, including 16 journal papers and 
two conference abstracts.  
 





























The most common method to measure adherence was using pharmacy refill, which was employed 
in eight studies. Only six studies have objective adherence measure via electronic data capture 
(EDC). All studies were conducted at high-income, developed countries (UK, US, Canada, 
Australia, New Zealand). One study was an RCT comparing two different breathing modes of I-
neb® (a third generation adaptive aerosol dispenser). Two studies were open label drug studies, 
whilst the remaining observational studies were either prospective studies (N = 8), retrospective 
studies (N = 3) or commercial insurance database analysis (N = 4). Table 3.1 summarises the 
findings for each individual study. Table 3.2 summarises the overall findings of this review. 
Electronic database search 
 
Databases: Embase, Medline 
Hits: n = 49 
Other sources (after screening titles and 
abstracts) 
 
Hand-searching journals, n = 4 
Hand-searching ‘unpublished’ work, n = 10 
Citation and reference tracking, n = 14 
Excluded after 
screening titles and 
abstracts 
 
n = 38 
Full texts and conference abstracts obtained and screened for inclusion (n = 39) 
 
Electronic database: n = 11   Other sources: n = 28 
 
*Two conference abstracts presented   *Two conference abstracts presented 
adherence data from the same source.  adherence data from the same source. 
These two abstract were thus ‘combined’,  These two abstract were thus ‘combined’, 
i.e. n = 10     i.e. n = 27 
Exclusion: (n = 19) 
 
Reasons: 
• No adherence data presented (n = 4) 
• Only composite adherence results presented which included non-
inhaled therapies (n = 2) 
• Insufficient information described for the adherence measure (n = 3) 
• Only self-reported adherence data presented (n = 2) 
• Clinical and psychological factors related to adherence were not 
evaluated (n = 8) 
Included studies in the review (n = 18) 
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Young adults with CF 
transitioning from 
children to adult services 
already on I-neb® 
 
N = 8 (19 eligible) 
Electronic data capture 
(EDC) via I-neb®; for 1 
year pre-transition and 1 
year post-transition 
Adherence 6-month pre-transition (mean 
57%, SD 38) is higher than 6-month post 
transition (mean 28%, SD 23), p-value 
0.011. 
 
“Similar trend” with 12-month pre- and 








transition =  57% 
6 months post-
transition  
= 28% a,b 
1 Only 8 participants 
 
2 Adherence 12 months pre- 
and post transition were not 
reported 
McNamara PS, 





Children with CF aged 2-
15 years established on 
I-neb® 
 
N = 28 (48 eligible) 
Electronic data capture 
(EDC) via I-neb®; for 1 
year 
Similar adherence between Dornase alfa + 
colistin (mean 67% ± 35%) vs colistin only 
(mean 64% ± 35) 
 
Adherence was better in the evening 
(mean 75% ± 37%) vs morning (mean 
58% ± 34%). 
 
N/A 
Change in colistin 
twice daily to 2 dose 
once daily improved 
adherence at month 1 
post change, but not 




= 60-70% a,b 
1 Only 28 participants 
 
3 Dornase alfa + colistin may 
only be prescribed for those 
who can adhere to both 
treatments 






Children with CF aged 
11-17 years established 
on I-neb® 
 
N = 24 (“everyone 
eligible” is in the study) 
Electronic data capture 
(EDC) via I-neb®; for 1 
year 
21/24 have better weekday adherence 
(than weekend) 
20/24 have better term time adherence 
(than during holidays) 
 
Mean number of nebuliser used was 
similar for those on 2/day and 3/day at 1.4 









= 65% a,b 
1 Only 24 participants 
 
3 It may be that 3 nebulisers 
per day (instead of 2/day) were 
only prescribed for those 
whom clinicians believe are 
able to cope with such 
treatments 
McCormack P, 




TIM vs TBM 
after a baseline 
period of TBM, 
UK 
Children with CF aged 5-
16 years established on 
long-term antibiotics via 
I-neb® (>3 months) in 
TBM mode for chronic P. 
aeruginosa infection 
 
N = 20 (“everyone 
eligible” is in the study) 
Electronic data capture 
(EDC) via I-neb®  
 
I-neb® downloaded after 
4-6 weeks of baseline 
(participants randomised 
to TIM or stay at TBM at 





At baseline, there was no statistically 
significant difference between TIM (mean 
86%, SD 11) and TBM (mean 72%, SD 
30) 
 
Adherence at the end of study shows TIM 
maintained adherence (mean 89%, SD 
8%) but adherence declined in TBM 
(mean 65%, SD 33). Nebulisation time 
reduced from 6.9 minutes (SD 2.9) to 
mean 3.7 minutes (SD 2.3) following 







(EDC) = 72% for 
TBM, 86% for 
TIM 
 
End of study, 
mean adherence 
(EDC) = 65% a,b 
for TBM, 89% 
for TIM 
1 Only 20 participants 
 
4 The random allocation 
method (using opaque 










Children with CF and 
first / new growth of P. 
aeruginosa under-going 
eradication therapy with 
nebulised colistin via I-
neb® 
 
N = 35 episodes in 33 
children (each episode is 
a unit of analysis) 
Electronic data capture 
(EDC) via I-neb®; for 3 
months (which is the 
duration of eradication 
period with nebulised 
colistin). 
Adherence better in the evening vs 








(EDC) ≈ 80% a,b 
1 Only 33 participants (although 
statistically significant  
difference in adherence 
between evening and morning 
sessions were detected) 
 
2 Confidence intervals not 
reported. 
 
† = conference abstract   
¶ These adherence levels may over-estimate the real world adherence among adults with CF because:     a likely selection bias     b only children included     c adherence not measured in a real-world setting 
Ω Limitations of the study include:    1 small number of participants limit the precision of results +/- power to detect between group differences     2 selective reporting     3 selection bias     4 others 













Methods and  



































Adults with CF aged 
≥ 18 years only on 
long-term nebulised 
colistin via Pro-dose 
 
N = 38 (47 invited) 
Electronic data 
capture (EDC) via 




data for colistin is 
captured 
Higher adherence associated with increasing age (r = 0.348, p-









(EDC) ≈ 47% a 
1 Only 38 participants 
 
2 Only correlation coefficients 
for age were reported (no 
confidence intervals). Other 
correlation coefficients were 
not reported.  
 
3 Only adherence to a single 
drug (colistin) is being 
considered 
Shakkottai A, 







Children with CF 
aged 0-21 years 
prescribed at least 3 
months of 
hypertonic saline / 
dornase alfa / 
tobramycin / 
enzyme / vitamins 
 
N = 204 (300 
eligible) 
Pharmacy refill 






‘Modified MPR’ = 
annual MPR 
instead of MPR 
over 5 years 
Adherence declined with age. 
 
Adherence for 0-5yo, median (range): 
HS (n=37) 80% (12.8-100%) 
Dornase alfa (n=31) 83.3% (15.4-100%) 
TSI (n=12) 85.7% (47.1-100%) 
 
Adherence for 6-12yo, median (range): 
HS (n=61) 66.7% (16.4-100%) 
Dornase alfa (n=37) 72.9% (20.0-100%) 
TSI (n=19) 66.7% (20.0-100%) 
 
Adherence for 13-21yo, median (range): 
HS (n=49) 54.5% (12.5-100%) 
Dornase alfa (n=23) 64.7% (14.7-100%) 


















(MPR) ≈ 65% a,b 
4 Relatively stable overall 
modified MPR may mask 
variability within specific 
drugs and within individuals 
 
Quittner AL, 















2005 to June 2011) 
 
CF diagnosis in ≥2 
visits, ≥1 




enrolment for ≥180 
days 
 
N = 3287 
Pharmacy refill 








as the mean of 
drug-specific MPR 
(i.e. azithromycin 
MPR may be 
included) 
Adherence differed from medication to medication: 
Dornase alfa mean MPR 57% (n = 2081) 
TSI mean MPR 51% (n = 1223) 
AZLI mean MPR 47% (n = 65) 
Colistin mean MPR 42% (n = 166) 
HS mean MPR 40% (n = 785) 
 
There was a U-shaped relationship between adherence and age, 
with highest adherence in people aged 6-10 years (median cMPR 
63%) and lowest in people aged 26-35 years (median cMPR 42%). 
There was also consistent increase in cMPR with increasing 
numbers of prescribed medications (median 35% for 1 medication, 
n = 1513; median 62% for 5 medications, n = 26). The cMPR 
included MPR of azithromycin, which is an oral therapy. However, 
this pattern was consistent for all five types of inhaled therapy. 
 
On the other hand, a gender difference in adherence was only 
observed for azithromycin (male mean 54% ± 34%, female mean 








TSI = 51% a 
 
AZLI = 47% 
 
Colistin = 42% 
 
Dornase alfa = 
57% 
 
HS = 40% 
3 People prescribed 
pulmonary medications but 
not picked up any will not be 
included in the study 
 
3 It may be that higher 
number of prescriptions were 
only prescribed for those 
whom clinicians believe are 




¶ These adherence levels may over-estimate the real world adherence among adults with CF because:     a likely selection bias     b only children included     c adherence not measured in a real-world setting 
Ω Limitations of the study include:    1 small number of participants limit the precision of results +/- power to detect between group differences     2 selective reporting     3 selection bias     4 others 
Abbreviations: Pro-dose = 2nd generation adaptive aerosol dispenser (I-neb® is a 3rd generation adaptive aerosol dispenser); TSI = tobramycin solution for inhalation; AZLI = aztreonam solution for inhalation; 




















Association between adherence  
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The Thomson Reuters 
MarketScan Commercial 
Claims and Encounters 
Database (1 Sept 2006 to 
31 Aug 2008) 
 
≥4yo with ≥1 claim with CF 
code and ≥1 claim for 
dornase alfa continuously 
enrolled for 12 months pre-
index date and 13 months 
post index 
 
N = 907 (1317 excluded as 



















New users (n = 238) have lower adherence compared to continuing 
users (n = 669), mean 39%, SD 26%, median 32% vs mean 66%, 
SD 29%, median 70%, p-value < 0.001 
 
U-shaped relationship with age; mean MPR ± SD: 
Overall = %59 ± 30% 
5-12 years = 66% ± 29% 
13-20 years = 57% ± 29% 
21-30 years = 54% ± 30% 
31+ years = 56% ± 31% 
(p value < 0.001) 
 
Seasonal adherence in mean MPR ± SD:  
Spring = 59% ± 36% 
Summer = 56% ± 37% 
Autumn = 61% ± 35% 
Winter = 61% ± 34%                  (p value < 0.001) 
 






to regions:  
 
MPR for North 




Northeast 55% ± 
31%  
 
MPR for South 
58% ± 30% 
 
MPR for West 






Mean = 0.59 a 
 
Median = 0.60 
3 People prescribed 
dornase alfa but not 
picked up any will not 
be included in the 
study 
 
3 Only adherence to a 
single drug (dornase 
alfa) is being 
considered  
 
4 Analysis for regional 
differences in 
adherence did not 
account for possible 
influence of case-mix 
Briesacher 











The  Medstat MarketScan 
Commercial Claims and 




≥2 inpatient / outpatient 
claims with a diagnosis of 
CF and were continuously 
enrolled in health insurance 
with drug coverage for at 
least 1 year 
 
N = 804 (1691 excluded as 
not on TSI) 
Pharmacy 
refill over 












Although TSI is commonly used as treatment among people with P. 
aeruginosa infection, 352/804 (43.8%) of the study subjects have no 
coded diagnosis of P. aeruginosa infection. 
 
Adherence magnitude was similar among whose with P. aeruginosa 
infection (6% high, 22% medium, 72% low*) and without P. 
aeruginosa infection (7% high, 23% medium, 70% low*). 
 
* ‘High’ = ≥4 cycles (i.e. adherence ≥67%) 
* ‘Medium = >2 to <4 cycles (i.e. adherence >33% to <67%) 












Low utilisation = 570 
(71%) 
 
Medium utilisation = 
180 (22%) 
 
High utilisation = 54 
(7%) 
3 People prescribed 
TSI but not picked up 
any will not be 
included in the study 
 
 
Wertz DA, et 











Research Database (HIRD) 
(01 Jan 04 to 31 Mar 09) 
 
Aged 0–64 years with ≥2 
medical claims for CF and 
≥15 months of  continuous 
enrolment (3 months pre-
index, 12 months post 
index) 
 
N = 388 TSI users (594 did 
not fulfil continuity criteria); 
444 non users (1114 did 










Adherence varied according to age ranges: 
<6 years – 25% high, 42% medium, 32% low * 
6-17 years – 35% high,33% medium, 32% low * 
18-40 years – 23% high, 33% medium, 44% low * 
≥41 years – 34% high, 37% medium, 29% low * 
 
Adherence in females slightly lower than males: 
Females – 28% high, 35% medium, 37% low * 
Males – 31% high, 34% medium, 34% low * 
 
* ‘High’ = ≥4 cycles (i.e. adherence ≥67%) 
* ‘Medium = 2-3 fills (i.e. adherence 33-50%) 





Mean number of fills 







Low n = 139 (35.8%) 
 
Medium n = 134 
(34.5%) 
 
High n = 115 
(29.6%) 
2 The age range used 
(especially the wide 
age range covering 
younger and older 
adults from 18-40 
years) is less helpful 
to study the 
relationship between 
adherence and age  
 
3 People prescribed 
TSI but not picked up 
any will not be 
included in the study 
 
¶ These adherence levels may over-estimate the real world adherence among adults with CF because:     a likely selection bias     b only children included     c adherence not measured in a real-world setting 
Ω Limitations of the study include:    1 small number of participants limit the precision of results +/- power to detect between group differences     2 selective reporting     3 selection bias     4 others 









Methods and  
duration of  
adherence data capture 
 
Association between adherence  
























Adults with CF 




N = 77 (115 
patients in 
clinic) 
Pharmacy refill over 1 year 
 
This was compared 
against clinician estimation 
and self-report  
 
Only Dornase alfa 





“There was no difference 
between reported 
effectiveness ratings for 
patients with good, 





(MPR) = 54% a 
2 Adherence levels 
according to perceived 
effectiveness of treatment 
were not presented. 
 
3 Only adherence to a 
single drug (dornase alfa) 
is being considered 








People with CF 
aged ≥6 years 
prescribed with 






N = 95 (107 
consented to be 
in the study) 
Pharmacy refill over 1 year 
– medication possession 
ratio (MPR) was 
calculated 
 
Cumulative MPR (cMPR) 
calculated as the mean of 
drug-specific MPR (i.e. 
azithromycin MPR may be 
included) 
Different levels of adherence for different 
medications: 
HS MPR (n=25) median 49% (IQR 0-
85%) 
Dornase alfa MPR (n = 90) median 
~70% 
TSI MPR (n = 65) median ~68% 
 
U-shaped relationship with age; median  
cMPR *: 
6-12 years ≈ 80% 
13-18 years ≈ 72% 
19-25 years ≈ 50% 
26-34 years ≈ 54% 
≥35 years ≈ 74% 
* Adherence according to age was only 






median = 63% a 
1 Statistical significance 
was not obtained for the 
comparisons between 
different medications and 
for the different age 
ranges. This might be due 
to the relatively small 
sample size (N = 95) rather 
than a genuine lack of 
difference 
 









CF aged 6-13 










only 21 were on 
nebulised 
treatment) 
1. Parent estimation (3 
months) 
2. Self-report (3 months) 
3. Pharmacy refill over 3 
months (medication 
possession ratio, MPR 
is calculated) 
4. Daily phone diary (DPD) 
with primary carer – 
done twice (1 weekday, 
1 weekend), covering all 
the events 24 hours 
prior to the DPD 
Different levels of adherence for different 
medications: 
 
Combined nebulised medications MPR 
(i.e. dornase alfa, TSI and albuterol) = 
68.3% ± 40.7%  
 









(MPR) = 68.3% a,b 
1 Only 21 participants 
 
2 Only a small proportion of 
people approached 
participated in the study, 
and MPR data for 
nebulised medication only 
available for 11/21 
participants. MPR data for 
inhaled tobramycin was not 
reported. 
 
¶ These adherence levels may over-estimate the real world adherence among adults with CF because:     a likely selection bias     b only children included     c adherence not measured in a real-world setting 
Ω Limitations of the study include:    1 small number of participants limit the precision of results +/- power to detect between group differences     2 selective reporting     3 selection bias     4 others 










Methods and  
duration of  
adherence data capture 
 
Association between adherence  





















Parents of children 
with CF aged ≤13yo. 
 
N = 87 (142 
participated out of 
227 approached but 
only 87 were on 
nebulised treatment) 
Daily phone diary (DPD) 
with parents – done 
thrice within 3 weeks (2 
weekdays and 1 
weekend) covering all 
events 24 hours prior to 
the DPD 
Neither parental age nor parental 
education level were predictors for 
nebuliser adherence (although both 
factors were predictors for airway 
clearance adherence) 
 
* Low adherers = median 40%  
* High adherers = median 80%  
* Super adherers = median 120% 
Compared to 
parents of super 
adherers* (n = 21), 
parents of low 
adherers* (n = 32) 
reported lower self-
efficacy scores 
(median 1080 vs 
1096) but similar 
intention (median 21 
vs 21).  
Compared to parents 
of super adherers*, 
parents of low 
adherers* reported 
increased use of 
negative religious 
coping (median 4.5 vs 
0.0) and lower body 
sanctification (median 
55.5 vs 62.0) 
compared to parents 
of super adherers 
Overall mean 
nebuliser 
adherence (DPD)  





‘Low’ = 32 (36.8%) 
 
‘High’ = 34 
(39.1%) 
 
‘Super’ = 21 
(24.1%) 
3 Only a small 
proportion of people 
approached 
participated in the 
study 
 
Rosenfeld M, et 





HS, US & 
Canada 
Infants with CF, 
aged 12-30 months 
 
N = 20 (22 infants 
screened) 
Counting of returned 
medication vials and 
daily diary (electronic / 
paper) with parents; for 
2 weeks 
Based on daily diary, similar 
adherence rates recorded were in the 
morning (median 100%) compared to 








= 96.1% a,b 
1 Only 20 participants 
 
3 High adherence rates 
may be due to short 
study duration, close 
observation of 
participants and 
selection of highly 
motivated parents 
Zindani GN, et 





Children with CF on 
both vitamins and 
dornase alfa. 
 
N = 28 (80 eligible) 
Counting of empty 
medication vials; for 3 
months 
Dornase alfa adherence: 
<12yo (n = 14), mean 62.9% (SD 35.4) 
and median 79.1% (IQR 17.6-100%) 
≥ 12yo (n = 14), mean 70.0% (SD 




In the discussion, the 
authors suggested 
that disease severity 







= 66.5% a,b 
 
1 Only 28 participants 
 
3 Only a small 
proportion of people 
approached 




et al; 2010 [116] 
 
Multi-centre 
open label trial 
comparing x2 
AZLI doses, US, 
Canada, 
Australia & New 
Zealand 
People with CF 
aged ≥ 6yo and 
FEV1 25-75% 
 
N = 274 (616 people 
initially screened, 
297 people 
completed the initial 
phase II trials) 
Counting of empty 
medication vials; for 18 
months i.e. the trial 
period 
Similar adherence levels among 
people in the AZLI twice daily arm 








(medication count)  
89.2% a,c 
 




3 Only a small 
proportion of people 
originally screened 
remained in this study. 
People with lower 
adherence may have 
dropped out of the 
study 
 
¶ These adherence levels may over-estimate the real world adherence among adults with CF because:     a likely selection bias     b only children included     c adherence not measured in a real-world setting 
Ω Limitations of the study include:    1 small number of participants limit the precision of results +/- power to detect between group differences     2 selective reporting     3 selection bias     4 others 
Abbreviations: HS = hypertonic saline; AZLI = aztreonam for inhalation solution 
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Table 3.2: Summary of the narrative synthesis 
 





Methodological qualities of 
the included studies 
 
• Nine of the studies are small (<40 participants) and lack the power to detect 
genuine relationships between adherence and clinical / psychological factors. Four 
of the larger studies are retrospective analysis of commercial insurance 
databases, which lack prescription data and may over-estimate adherence. 
• All 18 studies are susceptible to selection bias since no studies have 
systematically included the entire cohort within a centre or all participating centres.  
• Impact of these limitations on the results include: 
i. It is difficult to reliably determine the relationships between adherence and 
clinical / psychological factors – true relationships may be obscured yet any 
observed relationships may be spurious 
ii. Observed adherence levels may be over-estimated 
   
 
Association between 


















5. Different inhalation 
modes of nebuliser 
 
















A consistent relationship was observed in multiple different studies using different 
adherence data capture methods – there is a U-shaped relationship between 
adherence and age, with lowest adherence among younger adults aged 19-25 years 
(adherence 42-54%) and highest adherence among children aged up to 12 years 
(adherence 63-80%)  
 
Inconsistent relationship observed in different studies 
 
Inconsistent relationship observed in different studies 
 
Registry analyses have demonstrated that people from more deprived areas in the 
UK and uninsured people in the US were less likely to be prescribed preventative 
inhaled therapies. However, there are no studies looking at whether adherence to 
prescribed therapies differed according to socioeconomic status. 
 
A small RCT (20 participants) found that Target Inhalation Mode (TIM) may better 
sustain adherence compared to Tidal Breathing Mode (TBM) 
 
Two studies using electronic data capture (EDC) among children with CF found 
higher adherence levels in the evening. Another study using EDC among children 
with CF found higher adherence during weekdays (vs weekends) and term-time (vs 
holidays). A study using pharmacy refill found lower adherence in the summer 
compared to other seasons. 
 
A study found differences in adherence according to geographic locations but this 
evidence is inconclusive since potential differences in case-mix were not accounted 
for in the analysis. 
 
Within a cohort, there is a varying degree of adherence to different inhaled 
therapies. Heterogeneity between studies meant it is not possible to draw a 
conclusion regarding the overall adherence level to any specific treatment.  
Three studies found that adherence did not decrease as the number of prescribed 
medications increased, but two of these studies are observational and may be 
confounded by indication bias (more treatments may only be prescribed for those 








Only two studies evaluated the potential influence of psychological factors: 
1. One study (using pharmacy refill) found no association between perceived 
effectiveness of the treatment and adherence. 
2. One study (using daily phone diary) found similar intention regardless of 
adherence, but lower self-efficacy was associated with lower adherence. 
 
 
Adherence levels among 
adults with CF 
 
 
Seven studies evaluated adherence among adults with CF (one with EDC, the 
remaining six studies with pharmacy refill) found median adherence levels of 30-
50% in real-world settings.  
This contrasted with mean adherence level of 89% (measured by counting empty 





3.2.3.1 Methodological limitations of reviewed studies 
Nine studies recruited fewer than 40 participants from a single centre (or two centres), hence those 
studies have limited precision in detecting relationships between adherence and clinical / 
psychological factors. Four of the larger studies (with 388 to 3287 participants each) are 
retrospective analysis of commercial insurance databases in the US. It is impossible to determine 
the exact prescription of the participants in those studies,[5, 197-199] hence people with CF on 
nebulised medications who do not collect any of their medications (i.e. adherence = 0) were not 
included. This may reduce the power to detect association between adherence and clinical / 
psychological factors; and also over-estimate nebuliser adherence levels. 
None of the 18 studies has systematically included the entire cohort within a centre or all 
participating centres. Therefore, these studies are susceptible to selection bias, whereby people 
with poor adherence and poor engagement with the clinical team are less likely to be recruited, 
hence over-estimating the actual real-world adherence levels. The selection bias (or lack of 
genuine representativeness) may also impact on the observed relationship between adherence 
and clinical / psychological factors.[204] For example, if most people with high levels of depression 
were not included in a study, the study may well be under-powered to detect the relationship 
between adherence and depression even if large numbers of participants were recruited. 
The heterogeneity of the methods to capture adherence data, duration of data capture and 
methods of calculating adherence is another important limitation. The heterogeneity of measured 
adherence and different factors influencing adherence that were investigated meant it was not 
possible to pool different studies in a meta-analysis. The lack of standardisation in the methods to 
calculate adherence also meant that differences in adherence level between studies could simply 
be due to data issue rather than genuine differences in adherence between different populations. 
Results from different studies were interpreted in the context of these limitations, and adherence 
levels between different populations (e.g. the UK vs the US) were therefore not directly compared. 
 
3.2.3.2 How is adherence related to age? 
Eight studies looked at the influence of age on adherence. In general, children have higher 
adherence levels compared to adults, and younger adults tended to have the lowest adherence 
levels. 
Four studies included people with CF with a wide age range (both children and adults).[5, 197, 
199, 200] All four studies used medication possession ratio (MPR) as the adherence measure and 
found a U-shaped relationship between adherence and age, with lowest adherence among 
younger adults (aged 19-25 years; adherence 42-54%) and highest adherence among younger 
children (aged up to 12 years; adherence 63-80%). 
A study among adults with CF used electronic data capture (EDC) as the adherence measure and 
found increasing adherence with age (adherence ~47% for everyone in that study).[178] The other 
study which used EDC followed up adolescents who transitioned from children to adult services 
and found a decline in adherence from a mean of 57% pre-transition to 28% post-transition.[194] A 
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study among children which measured adherence using MPR found lower adherence among older 
children (median adherence ~83% among children aged 0–5 years; median adherence ~60% 
among children / adolescents aged 13 to 21 years).[177] Another study measured adherence by 
counting empty medication vials over a 3-month period and found similar dornase alfa adherence 
among children aged ≥12 years (median adherence 78.4%) and <12 years (median adherence 
79.1%).[203]  
 
3.2.3.3 What is the impact of disease severity? 
The authors of the study which found similar dornase alfa adherence among children aged ≥12 
and <12 years speculated that older children might have higher adherence due to more severe 
lung disease.[203] However, none of the 18 studies that were included in this review evaluated the 
relation between adherence and %FEV1 (which is generally accepted as the most important 
marker for the severity of lung disease in CF [205-208]). Another study found no differences in 
MPR for nebulised tobramycin among people with P. aeruginosa infection (who typically have more 
severe lung disease) vs people without P. aeruginosa infection. 
 
3.2.3.4 Is there a gender difference in adherence? 
Potential gender differences in adherence are of interest because a study using self-reported 
adherence measure found lower adherence among adolescent females with CF, and that CF had a 
greater emotional impact on adolescent females compared to adolescent males.[209]  
Three studies using MPR as the adherence measure evaluated the relationship between gender 
and nebuliser adherence. A study found slightly lower adherence among females (28% with 
adherence ≥67% compared to 31% among males),[199] whilst two other studies found no gender 
difference in adherence for nebulised medications.[5, 197] Another study using EDC as the 
adherence measure also found no gender difference in adherence.[178] 
Therefore, studies using more reliable adherence measures do not provide any compelling 
evidence of a gender difference in adherence, but numbers are small and study quality is low. 
Thus there is an absence of evidence, rather than evidence of absent gender difference. 
 
3.2.3.5 Is there evidence that socioeconomic status influence nebuliser adherence? 
A UK CF registry analysis found that people from more deprived areas were less likely to be 
prescribed preventative inhaled therapies,[150] and this is mirrored by a recent US CF Foundation 
Patient Registry analysis which found that uninsured adults with CF were less likely to receive 
preventative inhaled therapies.[151] 
However, the direct impact of socioeconomic status (or insurance status in the US) on medication 
adherence has not been directly evaluated. A study using daily phone diary as the adherence 
measure among 87 children with CF found that neither parental age nor education level influenced 
nebuliser adherence.[201] However, both these factors were associated with adherence to chest 
physiotherapy in that study.[201] Thus the evidence is inadequate to draw firm conclusions about 
the relationship between socioeconomic status and nebuliser adherence.  
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3.2.3.6 What is the impact of different inhalation modes?  
I-neb® was designed to deliver aerosol with two different breathing pattern algorithms: (1) Tidal 
Breathing Mode (TBM) in which users inhale spontaneously throughout tidal breathing with pulsing 
of aerosol depending on flow rate and volume of the breathing pattern; (2) Target Inhalation Mode 
(TIM) in which user is guided into a slow and deep inhalation to reduce treatment times and 
optimise lung deposition.[210] A randomised clinical study among 20 children found that children in 
the TIM arm maintained their adherence (mean 86% at baseline, mean 89% at four weeks post 
randomisation) while children in the TBM arm showed a decline in adherence (mean 72% at 
baseline, mean 65% at four weeks post randomisation).[175] 
 
3.2.3.7 What is the temporal variation in adherence? – time of day, weekdays vs weekends, 
holidays / seasonal effects 
Data-logging nebulisers such as the I-neb® also allowed the detailed study of variation in 
adherence. Two studies using EDC among children with CF found higher adherence levels in the 
evening (mean 75% and 84%) compared to the morning (mean 58% and 74%).[176, 195] Another 
study using EDC among children found that most children (21/24, 87.5%) have better adherence 
during the weekdays compared to weekends, and most children (20/24, 83.3%) have better 
adherence during term time compared to holidays.[171] 
Alternative adherence measures are more limited in terms of studying variation in adherence (see 
Section 3.3). A study among infants with CF using parent self-reported adherence captured by 
daily diary found a recorded (by parents) median adherence of 100% for both morning and the 
evening sessions.[202] A large study using MPR did find seasonal effects in adherence, with 
slightly lower adherence in the summer (mean 0.56) compared to other seasons (mean 0.59 – 
0.61) which the authors attributed to summer holidays.[197] 
 
3.2.3.8 Is there geographical variation in adherence? 
As mentioned in Section 3.2.3.1, retrospective analysis of commercial insurance databases 
allowed adherence to be studied among larger groups of people with CF. One such study found 
greater differences in adherence according to geographic locations (e.g. mean MPR for West 
region was 0.62 whereas mean MPR for North East region was only 0.55) compared to the 
seasonal difference described in Section 3.2.3.7.[197] This suggests that perhaps adherence to 
preventative inhaled therapies differed according to specialist CF centres, although it should be 
noted that the regional analysis did not account for potential differences in case-mix. 
 
3.2.3.9 What is the influence of prescription on adherence? 
Studies using MPR as the adherence measure were able to describe adherence levels for different 
preventative inhaled therapies.[5, 162, 177, 200] Within a cohort, adherence differed according to 
the type of inhaled therapies. However, there were no consistent patterns between different 
cohorts of study subjects. For example, three studies found highest levels of adherence with 
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dornase alfa [5, 162, 200] but another study found higher adherence levels to nebulised 
tobramycin compared to dornase alfa (median ~75% vs median ~70%).[177]  
However, perhaps surprisingly, different studies using different adherence measures consistently 
found no evidence of lower adherence with increased number of medications or doses prescribed. 
An open label drug trial found similar adherence levels among people on twice daily (mean 92%) 
and thrice daily (mean 88%) Aztreonam for inhalation solution by counting empty medication 
vials.[116] A large study even found a consistent increase in MPR with increasing numbers of 
prescribed medications, e.g. median MPR of 35% for people prescribed x1 type of pulmonary 
therapies and median MPR of 62% for people prescribed x5 types of pulmonary therapies).[5] A 
study using EDC also found similar adherence among children prescribed 3 doses of inhaled 
medications per day i.e. colistin twice daily and dornase alfa once daily (mean 67%) and 2 doses 
of inhaled medications per day i.e. colistin twice daily only (mean 64%).[176] When colistin 
prescription was changed from one dose twice daily to two doses once daily, adherence improved 
at Month 1 but improvement was not sustained at Month 3.[176] 
 
3.2.3.10 What psychological factors are associated with nebuliser adherence? 
Only two out of the 18 studies evaluated the potential influence of psychological factors. One study 
using MPR as the adherence measure among 77 adults with CF reported that there was no 
association between perceived effectiveness of dornase alfa and adherence.[161] Another study 
using daily phone diary as the adherence measure among 87 children with CF aged ≤13 years 
found that parents reported similar intention (i.e. the motive of performing a behaviour) regardless 
of adherence, but lower self-efficacy (i.e. belief in one's ability to perform a behaviour) scores were 




This literature review has four main findings.  
 
First, among the several clinical (i.e. demographic / treatment) factors potentially influencing 
nebuliser adherence that were explored, only age has a consistent relationship with adherence. 
Adolescents and young adults tended to have the lowest adherence levels. Increasing adherence 
levels among older adults [5, 178, 199, 200] may be a function of age (e.g. increased maturity 
[211]) but may also reflect survival bias (if people with higher adherence levels also live longer).  
 
Second, current evidence, albeit not extensive, suggests that “treatment burden” (which is often 
operationalised as the duration, frequency and complexity of treatment regimens) does not offer a 
sufficient explanation for low adherence among people with CF. Similar adherence levels were 
observed with different number of types or doses of inhaled medications. One study even found a 
consistently increasing levels of adherence with increasing numbers of prescribed pulmonary 
medications,[5] although it may be that people with higher adherence were being prescribed more
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treatments as they are perceived as being able to take them.[212] Older adults tended to have 
more complex treatment regimens compared to younger adults,[213] but older adults also have 
higher adherence levels. Simplifying treatment regimen by altering twice daily colistin to two doses 
once daily did not result in sustained adherence improvement.[176] Another study found that 
adolescents with CF were most adherent during term-time and weekdays when they are likely to 
be busiest (thus most susceptible to lapse due to “treatment burden”).[171] A potential explanation 
for this observation is that routine is more regimented during school days and more lax during 
weekends or holidays. 
 
Third, real world nebuliser adherence among adults with CF is lower than adherence observed in 
controlled clinical trials. Various controlled clinical trials in CF reported nebuliser adherence levels 
of 80-100%.[116, 214-216] This review found a real world nebuliser adherence level of around 35-
75% among people with CF. Among adults, median adherence is only around 30-50%. The real-
world nebuliser adherence figures in this literature review are mostly derived from larger studies 
based on pharmacy refill data collected in commercial insurance databases.[5, 197-199] It has 
been estimated that administrative databases could over-estimate adherence by 25% because 
prescription data are unavailable, hence administrative databases fail to capture people who did 
not even fill the first prescription (i.e. adherence = 0%).[217] MPR data have also been shown to 
over-estimate adherence when compared against EDC data in other CF treatments.[167] 
Adherence figures from the US may be perceived as less reliable because copayment is thought to 
discourage adults with CF from collecting prescribed medications. However, a recent large study 
(10,563 study subjects) on cost sharing among patients with acute coronary syndrome found no 
improvement in adherence rates.[218] Indeed, pharmacy refill data among adults with CF in 
Australia [161] and a recent study among 106 adults in the UK (where prescription cost is not an 
issue) [219] also found adherence levels of only 50-60%. Given that preventative inhaled therapy 
would only work if they are used appropriately, this level of adherence would imply that the CF 
population is not deriving the optimal health benefits observed in controlled clinical trials. Two 
recent UK CF registry analyses (undertaken as part of the PhD research) highlighted the real-world 
consequences of low adherence among adults with CF. The first analysis identified a group of 
adults with high year-on-year intravenous antibiotics use, even among those with FEV1 ≥70%, 
which suggests a reliance on rescue therapies to compensate for low adherence with preventative 
inhaled therapies.[220] The second analysis demonstrated that adult CF centres are still 
dependent on higher intravenous antibiotics use to achieve better FEV1, despite the increasing 
availability and prescription of preventative inhaled therapies.[79] Of note, low levels of adherence 
are also pervasive in other long-term conditions. It is estimated that only around 50% of all 
medications are taken as recommended, leading to increased morbidity and excess mortality 
which is estimated to cost around US$100 billion per year.[221-228] 
 
Fourth, the reviewed studies looking at adherence interventions [175, 176] have not demonstrated 
clear evidence of improving adherence. In other long-term conditions, there is meta-analysis
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evidence that feedback of objective adherence data is associated with improved adherence.[229] 
This literature search found only one published study which evaluated feedback of objective 
adherence data (captured via I-neb®), which is a before and after study among 28 children with 
CF.[230] Children who independently uploaded data maintained median adherence of 100% over 
two months (N = 3). Children who uploaded data with prompting showed a relative increase in 
adherence of 111% (baseline median adherence of 38%; N = 10). Children with no data upload 
showed a relative increase in adherence of only 7% (baseline median adherence of 71%; N = 15). 
However, these differences may be the result of people with improving adherence being more 
willing to upload and share their data, instead of feedback improving adherence. Another 
‘intervention’ which is expected to increase adherence would be a period of hospitalisation to 
concentrate on adherence, since a hospitalised person with CF should receive more attention from 
clinical staff and should have fewer distractions. However, adherence levels during hospitalisations 
are surprisingly low. A study which evaluated I-neb® adherence among 12 children with CF during 
their hospitalisations found a median adherence of only 51%.[231] This adherence level is lower 
compared to adherence levels among children with CF in general, perhaps suggesting that 
children that required hospitalisation have lower adherence levels. It is nonetheless important to 
note that hospitalisation alone does not guarantee the use of nebulisers. In hospitals, even a nurse 
handing a medication to patients does not necessarily equate to the medication being used – 
another recent study using I-neb® also found unexpectedly low levels of adherence (mean 62%) 
among hospitalised children with CF even though the prescription charts recorded 100% of 
nebulised medications as being administered.[166]  
 
This literature review has several limitations. Only studies published in the English language were 
included. Generalisability of the findings in non-developed countries is uncertain, since all included 
studies were conducted at developed countries. Authors of relevant abstracts were not emailed to 
obtain further data and the search for unpublished studies was not comprehensive. Possible 
publication bias meant that any observed associations may be spurious or exaggerated;[232, 233] 
though the literature review did identify studies with conflicting results which suggests that 
manuscripts highlighting a lack of association were still being submitted and published. Literature 
search and review were only performed by a single person; hence several studies may be missed 
or inadvertently excluded. The electronic databases search were limited by the use of mainly 
MeSH terms, hence more studies were found with ‘snow-balling’ strategies compared to databases 
search. In addition, three large RCTs evaluating adherence interventions have recently been 
completed but full results are yet to be published (see summary of these studies in Table 3.3).[234-
236] Consequently, these studies were not included in this review. None of the studies used EDC 
to capture adherence data and their results are unlikely to invalidate the main conclusions of this 
review. A meta-analysis could not be performed due to the heterogeneity of the included studies, 




Table 3.3: Summary of three large RCTs evaluating adherence interventions among people with 
CF that have been completed but full results are yet to be published 
 
 
I Change Adherence and Raise Expectations (iCARE) Study [234] 
Design: Cluster RCT, 2-arm, 18 centres across the US  
Participants: Adolescents with CF aged 11-20 years on ≥1 type of respiratory therapy, N = 607 
Intervention: Comprehensive adherence programme (CAP) – education + problem solving 
Comparator: Usual care 
Outcomes: Primary – composite adherence to chronic pulmonary medications (nebulisers + azithromycin), measured as MPR†  
                 Secondary – %FEV1, pulmonary exacerbations, quality of life 
Interim results: Adherence (MPR†) at 12 months – Intervention group, i.e. CAP (N = 154), median 54% (IQR 28 – 72%) 
                                                                                         Comparator group, i.e. usual care (N = 140), median 52% (IQR 28 – 71%)  
 
  
Cell phone intervention to improve adherence (CFfone) [235] 
Design: 2-arm parallel RCT, multi centre  
Participants: Adolescents with CF aged 11-20 years and have regular internet access, N = 95 
Intervention: CF Fone – secure website providing behavioural & medical information with social networking features  
Comparator: website with CF information 
Outcomes: Primary – CF knowledge  
                  Secondary – adherence (measured as MPR†); quality of life 
Interim results: Adherence levels not yet reported; quality of life similar for both arms  
 
 
Building Adherence to Live With And Navigate my CF Experience (BALANCE) [236] 
Design: 2-arm parallel RCT (comparing x2 types of adherence interventions), single centre  
Participants: Adults with CF aged ≥16 years on chronic respiratory therapy, N = 128 
Intervention 1: Motivational interviewing (MI) 
Intervention 2: Education + problem solving (EPS) 
Outcomes: Primary – composite adherence to chronic pulmonary medications (nebulisers + azithromycin), measured as MPR† 
                  Secondary – change in %FEV1 
Interim results: Adherence (MPR†) at 12 months – Intervention 1 group, i.e. MI (N = 44), median 54% (IQR 37 – 73%) 




† MPR = medication possession ratio. Composite MPR was calculated by averaging MPR of all individual chronic pulmonary medications. 
 
 
Nonetheless, this review has identified several notable gaps in the current evidence base; not least 
of which is an absence of adequately powered prospective studies explicitly designed to objectively 
explore adherence using EDC data. EDC is generally considered the ‘gold standard’ measure to 
capture adherence data,[168] but clinical (i.e. demographic / treatment) factors that may influence 
adherence have not been systematically explored using EDC adherence data. For example, there 
has been no study using EDC to explore the impact of socioeconomic status on adherence. 
“Treatment burden” is the focus of many CF-related studies,[213, 237-244] yet the impact of 
continuous vs alternating inhaled antibiotics regimen (which is an important factor that influences 
complexity of treatment regimen [245, 246]) on adherence also has not been explored.  
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Only two studies have evaluated a limited range of potential psychological factors that may 
influence adherence using (relatively) accurate adherence measures,[161, 201] even though 
psychological factors are likely to be more proximal determinants of adherence compared to 
clinical factors.[247] As described in Section 3.1.2, studying adherence using self-reported data 
may result in misleading conclusions because self-report is so unreliable. A recent study identified 
different predictors of medication adherence by using different adherence measures (self-report vs 
EDC).[248] This study was a secondary analysis using data from two randomised control trial of 
adherence interventions among patients with Type II diabetes and rheumatoid arthritis. Age was 
found to be the only predictor of adherence using the Morisky Self-Report Scale (increasing age 
was associated with higher adherence); but gender and income were the only predictors of 
adherence using the Aardex Medication Event Monitor, which is a form of EDC (female tended to 
have higher adherence and annual income <$10k was associated with the lowest adherence). This 
finding highlights the need for more studies exploring the relationship between adherence 
determinants and adherence using accurate EDC data. 
 
Due to the paucity of existing literature which relates objective adherence data to psychological 
determinants, relevant qualitative literature or studies that explored determinants of adherence 
using self-reported adherence are summarised in the next section of this chapter (Section 3.3). 
Another evidence gap is the lack of studies evaluating the relevance of ‘habit’ (i.e. automatically 
experiencing an urge to perform a behaviour in certain settings) in sustaining medication 
adherence among people with CF.  In other long-term conditions, habit has been shown to better 
predict medication adherence compared to conscious motivational factors e.g. treatment beliefs,[7-
11] albeit these are studies using self-reported adherence. A recent meta-analysis of 771 
medication adherence intervention studies also identified habit as a promising target for 
intervention.[249] Therefore, Section 3.4. discusses the potential role of habit in nebuliser 
adherence and considers how habit can be measured, by drawing heavily on a recent habit 
scoping review.[250] Finally, the evidence gaps are summarised and the steps taken to address 
these gaps in the subsequent chapters are outlined in Section 3.5. 
 
 
Chapter 3, Section 3: A review of other factors that may influence nebuliser adherence 
 
Studies not grounded on reliable adherence data or studies not related to nebuliser use were 
excluded from the literature review in Section 3.2 to avoid conflating studies with different 
methodological robustness. Misleading conclusions can be reached by using inaccurate data e.g. 
self-reported adherence data. For example, a recent study identified different predictors of 
medication adherence by using different adherence measures (self-report vs EDC).[248] It is likely 
that simply ascertaining a list of barriers or facilitators without triangulation with accurate 




However, the strict exclusion criteria for the literature review in Section 3.2 meant that only two 
studies evaluating potentially relevant psychological factors were included. To obtain a broader 
overview of the current CF literature, this section summarises qualitative literature or studies that 
explored determinants of adherence using self-reported adherence. In this section, relevant studies 




“Forgetting” has been identified as a significant barrier to using nebuliser among people with CF in 
two qualitative [251, 252] and three quantitative studies.[245, 253, 254] Both intentional and 
unintentional forgetting were identified in a qualitative study.[251]   
 
Studies in other long-term conditions have demonstrated that “forgetting” is rarely a random event; 
instead it may be under-pinned by other factors e.g. treatment beliefs.[255, 256] Within a 
comprehensive behavioural framework e.g. the COM-B model (Capability, Opportunity, Motivation 
and Behaviour), “forgetting” may be the outcome of impaired cognition (psychological capability), 
change to daily lifestyle (physical capability) or absence of cue for action (automatic 
motivation).[257] Thus, the term “forgetting” is essentially a reiteration of the problem and holds no 
explanatory value. Simply identifying “forgetting” as a barrier without delving deeper into the actual 
cause of forgetting is unhelpful in understanding adherence or to develop an effective adherence 
intervention. 
 
3.3.2 “Treatment burden” 
 
A recent James Lind Alliance Priority Setting Partnership has identified “effective ways of 
simplifying treatment burden” as one of the top 10 research priorities in CF.[258] “Treatment 
burden”, often operationalised as the duration, frequency and complexity of treatment regimens, 
has been identified by various qualitative and quantitative studies as being particularly problematic 
for nebuliser use.[245, 251-253, 259] The treatment demands placed upon people with CF has 
been described as “extraordinary when compared with most other chronic illnesses”.[260] People 
with CF reported spending 2-3 hours daily preparing and using treatments, with airway clearance 
and inhaled therapies particularly time-consuming.[239, 243]  
 
Various competing social and work demands were reported, and time pressures were identified in 
various qualitative and quantitative studies.[245, 251-254, 259] Managing competing priorities is a 
challenge [251, 252] and the trade-off may be to miss medications every few days or when 
busy.[245] Adding to treatment burden is the potential inconvenience associated with access to 
medications, such as the cost of medications and the need to obtain some medications from 




3.3.3 Are dry powder inhalers the solution to CF adherence? 
 
Dry powder inhalers e.g. mannitol, colistin dry powder and tobramycin dry powder are specifically 
marketed around their ability to alleviate “treatment burden” due to shorter inhalation duration and 
these inhalers do not require cleaning.[261-264] A discrete choice experiment suggested that an 
“average” adult with CF considered reduced time burden to be twice as important as side-effects 
from using treatments e.g. dry cough.[240] A time trade-off survey suggested that an “average” 
adult with CF would be willing to give up 5.3 years of life (out of 40 years) just to use dry powder 
inhalers.[244] 
 
Short-term adherence to tobramycin dry powder inhalers among 78 adults at the Cork Adult CF 
Centre may seem promising but it is important to recognise that the adherence was estimated via 
self-report. The number of adults approached to try dry powder inhalers was not presented in the 
paper, but around 140-150 adults with CF received care at Cork.[265, 266] Among participants 
previously using nebulised tobramycin (TIS) who were switched to use dry powder tobramycin 
(TIP) for 12 months, TIP adherence at month 12 (31/40, 77.5% self-reported adherence ≥80% with 
TIP) was significantly higher compared to baseline TIS adherence (22/49, 44.9% self-reported 
adherence ≥80% with TIS). 
 
However, longer-term data are not promising. Data from Cardiff showed that around 50% of adults 
who trialled dry powder inhalers discontinued after 4-5 months due to intolerance.[267] Data from 
Birmingham showed that only 58/130 (45%) of the adults initially prescribed TIP remained on TIP 
after 29 months, with most common causes of discontinuation being side-effects e.g. cough or 
chest discomfort.[268] MPR among those still on TIP was only around 65%.[268] Recent data from 
Leeds showed that MPR was somewhat higher for nebulised antibiotics (mean ~65%) compared to 
dry powder antibiotics (mean ~62%).[219] A recent analysis of national commercial self-insurance 
claims database in the US found no differences in adherence (as a continuous variable) between 
TIP and TIS even after various adjustments (mean numbers of medication cycles collected over 1-
year were 3.85 vs 3.65, which roughly equate to MPR of 64.2% vs 60.8% since each adult would 
be using 6 cycles of tobramycin per year with an alternating regimen).[269] 
 
It has been argued that people with CF would only recognise that a particular treatment is quick 
and easy if they had used a previous version that was slower and harder, thus provision of quick 
easy treatment as first line would result in the same adherence levels as older harder 
treatments.[270] A more pertinent point is that “treatment burden” cannot solely be a function of the 
treatment. Perceived burden would involve interaction between the treatment and the person using 
the treatment. A person prescribed only one pulmonary medication may still find the treatment 
burdensome and achieve an adherence level of 35% whilst another person prescribed five 
pulmonary medications may not find managing those treatments burdensome and achieve an 
adherence level of 62%. Indeed, a large study found a consistent increase in MPR with increasing 
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numbers of prescribed medications, e.g. median MPR of 35% for people prescribed x1 type of 
pulmonary therapies and median MPR of 62% for people prescribed x5 types of pulmonary 
therapies.[5] 
 
As discussed in Section 3.2.4, it is unlikely that “treatment burden” offers a sufficient explanation 
for low adherence among people with CF. Ivacaftor (which only involves swallowing tablets twice 
daily) is far “less burdensome” than dry powder inhalers but EDC data showed an ivacaftor 
adherence level of ~60%.[167] Dry powder inhalers have not solved the adherence problem in 
asthma (whereby EDC data also show adherence levels of 50-60% [271, 272]) and it seems 
unlikely that they will be the magic bullet solution for low adherence among people with CF. 
 
3.3.4 Organisation / structure / routine 
 
People with CF have reported that being organised and establishing a structure (e.g. having a 
regular and predictable schedule) and having a routine (i.e. fostering contextually stable 
behaviours and persistent behavioural pattern) facilitate the use of medications.[251, 252, 259] 
People have also described finding treatments “a lot easier” when they have a routine.[251] This 
raises the possibility that developing a routine may help to moderate the perceived difficulty or 
“burden” of using preventative inhaled therapies.  
 
3.3.5 Disease severity 
 
People with CF tend to be more symptomatic (e.g. have frequent cough productive of sputum and 
shortness of breath) with increasing lung disease severity. Presence of symptoms could motivate 
people to use their treatments [251, 252] whilst the absence of symptoms could potentially 
discourage people from using their treatments regularly.[245, 251] However, increasing disease 
severity also meant more fatigue, and this can result in treatments being omitted.[251, 259] 
 
Quantitative studies evaluating severity of disease as a predictor for adherence have found 
conflicting results.[188, 273] 
 
3.3.6 Perception of illness and treatment effects 
 
The conflicting results for disease severity as a predictor of adherence may be in part due to 
people under-estimating the severity of their illness.[66] Thus, perception of illness may be more 
relevant than the actual severity of disease in terms of influencing adherence.  
 
A quantitative study among children with CF found that perception of more severe disease or 
increased susceptibility to recurrent infection was strongly correlated with higher self-reported 
adherence to inhaled therapies.[274] Among adults with CF, the results are less convincing. A 
quantitative study found that no relationship between perception of disease severity and reported 
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adherence to pancreatic enzyme replacement therapy or exercise (adherence to inhaled therapies 
was not evaluated);[275] although another study found those who perceived their illness to be less 
severe reported slightly lower levels of adherence.[276]  
 
A qualitative study suggested that people may also be discouraged from using their medications if 
they perceive it as futile and expressed preference to pursue other activities if life may be 
limited.[252] Other qualitative studies found stronger desire to use treatments among people who 
experienced benefit from the treatment (e.g. if regular use of medications kept them out of hospital 
[259]), or if non-adherence resulted in worsening of symptoms.[251] Participants in a qualitative 
study reported that side-effects were not an important barrier to using treatments, although side-
effects may result in missed doses.[259] However data are not consistent and some empirical data 
suggest that side-effects may be an important cause of treatment discontinuation (see Section 
8.1.3.3).[267, 268] 
 
3.3.7 Beliefs about treatments 
 
The Beliefs about Medication Questionnaire (BMQ) has been used among adolescents with CF to 
evaluate their beliefs about the necessity of treatments and their concerns about potential adverse 
effects.[277] This study found that low self-reported adherence levels to inhaled antibiotics were 
associated with lower necessity scores and believing that CF is not amenable to treatment.[277]  
Another study used BMQ among parents of children with CF, and found that adherence to 
pancreatic enzyme replacement therapy and chest physiotherapy (adherence to inhaled therapies 
was not evaluated) was also related to parental necessity beliefs (rather than concerns about 
potential adverse effects).[278] 
 
A qualitative study found that lack of immediate impact from treatments or feeling well may reduce 
the belief that treatments are necessary.[252] Qualitative studies also found that not everyone 
views preventative inhaled therapies as important.[252, 259] Another study reported that “guilt” 
from non-adherence, even if there was no immediate impact on symptoms, might encourage the 
use of treatments.[251] 
 
3.3.8 Knowledge of disease and treatment 
 
Education-based counselling or information provision is often used as an adherence intervention in 
CF [15, 279] because previous studies have identified gaps in knowledge.[280] A recent 
quantitative study among adolescents with CF found that disease knowledge was only correlated 
with MPR to nebulised hypertonic saline but not with MPR to nebulised dornase alfa.[281] Another 
recent quantitative study among adults with CF found no correlation between disease- or 






A recent large epidemiological study (6088 people with CF and 4102 parents) found higher levels 
of depressive symptoms (10% of adolescents, 19% of adults) and anxiety (22% of adolescents, 
32% of adults) among people with CF compared to the general population.[283] However, another 
recent large epidemiological study in the UK (2065 people with CF) found similar levels of 
depressive symptoms (~3% of adolescents, ~12% of adults) and anxiety (~20% of adolescents, 
~33% of adults) among people with CF compared to the general population.[284] 
 
A study has found that children and parents with depression had lower adherence to chest 
physiotherapy [285] although another study failed to demonstrate this association.[278] Studies 
evaluating the impact of depression or anxiety on adherence to inhaled therapies were also 
inconclusive, in part because studies were small and adherence were measured using self-report. 
A study among 52 people with CF found that children and adolescents with anxiety disorders 
(diagnosed with DSM-based interviews) actually had higher levels of reported adherence.[286] A 
recent study among 67 people with CF found that adults with depressive symptoms (measured 
with Major Depression Inventory, MDI [287]) had lower levels of reported adherence.[288] Another 
study found that participants with depressive symptoms (measured with Center for Epidemiologic 
Studies Depression scale, CES-D [289]) reported lower medications beliefs and has lower 




3.3.10 Other psychological factors  
 
The study that evaluated the relationship between depressive symptoms, adherence and treatment 
beliefs used a measure of ‘medication beliefs’ that included measures for self-efficacy, motivation, 
perceived importance and outcome expectancies from taking the medication.[290] Among these 
four measures, self-efficacy was most strongly associated with medication adherence.[290] 
Structural equation modelling found that the impact of depressive symptoms on medication was 
mediated by medication beliefs in that depressive symptoms was associated with less positive 
medication beliefs but did not directly reduce medication adherence.[290] 
 
However, the relevance of self-efficacy as a determinant of nebuliser adherence remains 
uncertain. A recent quantitative study among adolescents with CF found no association between 
self-efficacy and adherence to inhaled therapies (as measured by MPR).[281] 
 
3.3.11 Ways of coping with CF  
 
A study found that people with CF who reported high external control (that is attributing success to 
luck or fate, or efforts of others, i.e. little personal control over the course of CF) also reported 
higher levels of overall treatment adherence.[291] Perception about locus of control may relate to 
people’s coping mechanisms. 
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A study found that people who scored highly on the optimistic acceptance and hopefulness scales 
also reported higher levels of adherence with pancreatic enzyme replacement therapy and chest 
physiotherapy (adherence to inhaled therapies was not evaluated).[292] On the other hand, 
avoidance strategies (e.g. denial) were associated with lower levels of self-reported 
adherence.[292] Since self-report is poorly calibrated to the actual adherence levels,[4] it is 
possible that a person’s coping characteristics influenced the reporting of adherence rather than 
actually reflecting objective adherence. 
 
3.3.12 Family relationship  
 
Family dynamics and relationships are likely to be an important determinant of adherence, 
especially among children with CF who rely on parents to deliver treatments. Two quantitative 
studies found that better observed family functioning were associated with higher reported 
adherence among children with CF.[293, 294] 
 
Parental supervision tended to decline from early to late adolescence, which may contribute to 
lower medication adherence.[295] However, a qualitative study focussing on adolescents with CF 
suggests that early development of self-care skills in children, then a gradual shifting of 
responsibility for treatments to adolescents can facilitate adherence.[252] Parents who were able 
to engage in open conversations about adherence with their children may better support 
adherence, compared to parents who were unwilling to cede control.[252] There was also a 
suggestion that allowing adolescents to experience negative health consequences of non-
adherence may increase likelihood of future treatments.[252] 
 
Supports and reminders from parents are considered important,[251] even among adults with 
CF.[259] 
 
3.3.13 Other social relationships and the stigma using treatments  
 
A quantitative study found that both friendships with positive traits (e.g. companionship, support) 
and negative traits (e.g. criticism, conflict) among adolescents with CF were negatively correlated 
with parent reported medication adherence.[296] Compared to non-CF peers, friendship with CF 
peers were less common and of lower quality,[296] which may be due to strict infection control and 
clinical segregation policies [124] discouraging in-person contact among people with CF. 
 
Qualitative studies among adolescents and younger adults with CF found a strong sense of stigma 
or embarrassment with using treatments in the presence of peers.[251, 252] The desire to be seen 
as healthy or “normal” meant that adolescents with CF were reluctant to bring treatments to friends’ 





3.3.14 Relationships with the CF care team  
 
Healthcare for people with CF are almost exclusively delivered by multidisciplinary teams (MDT) 
through specialist CF centres,[124] which meant that the MDT is a core element that plays an 
important role in the lives of people with CF. A small study among 27 adults with CF failed to detect 
an association between relationship with the care team and self-reported medication adherence, 
although it did find that better relationship with care team was associated with better social 
adjustment.[276] 
 
Qualitative studies have emphasised the importance of CF care teams. Developing a trusting 
relationship with the team and CF physicians discussing adherence frankly are considered to be 
important facilitators of adherence for adolescents with CF.[252] CF care teams should also 
provide “tools” to support adherence, and be creative in identifying and solving potential barriers to 
adherence.[252] Adults with CF felt that support from care teams are “essential for adherence to 
therapy”,[259] and that attending CF clinic is an motivator to increase treatment adherence.[251] 
 
As such, CF clinic may provide a structure to systematically evaluate and support adherence with 
preventative inhaled therapies. A survey in 2008 among specialist CF centres in the US found that 
64% of the CF centres reported discussing adherence at every clinic visit, but only 8% of the 
centres have access to MPR adherence data (EDC was not routinely available in the US during 
that period).[297] Some centres were concerned that objective adherence data would be used 
punitively to “catch” people with CF lying about their adherence.[297] Around 20% of the centres 
felt that adherence would only be a concern if lung function was unstable or if a person with CF 
was unwell.[297] This emphasises the importance of changing the care team in order to facilitate 
better treatment adherence among people with CF.[298]  
 
Ten specialist CF centres in the US participated in a quality improvement initiative to regularly 
assess and address adherence issues in clinics.[299] At the end of the 1-year period, 72% of care 
staff at those CF centres reported that adherence was being asked during every visit and 100% of 
staff reported that adherence is important for all patients; which improved from figures of 61% and 
89% respectively at the start of the initiative.[299] However, no adherence data (or even outcome 
data) was systematically collected.[299] Therefore it is uncertain whether this initiative actually 
improves the adherence levels of people with CF.  
 
3.3.15 Conclusions  
 
Factors that mediate nebuliser adherence among adults with CF are poorly understood. Most 
studies of adherence determinants among people with CF have eschewed explicit psychological 
theory, focusing instead on the practical barriers and facilitators to adherence. While these factors 
may have some explanatory value for low adherence, most of the effects were small and a 
significant amount of variance in adherence remained unexplained. Many quantitative studies also 
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found conflicting results, perhaps due to differences in study designs and adherence was 
measured with error either by self-report or MPR (gold standard EDC adherence data were rarely 
used). For example, a quantitative study using MPR data found that adherence was negatively 
correlated with the number of reported barriers,[254] but another quantitative study found that 
younger adults with CF who reported higher adherence also reported more barriers (perhaps due 
to people being more aware of the barriers they faced if they persisted with using 
medications).[253]  
 
A study found that treatment beliefs mediate the relationship between depressive symptoms and 
treatment adherence,[290] which highlights the importance of studying the role of psychological 
factors as adherence determinants. Where explicit psychological theory was used in previous 
studies of potential adherence determinants in CF, only relatively ‘narrow’ theories have been 
applied, e.g. the Health Belief Model (which posits that perceived susceptibility to recurrent ill 
health would be associated with taking the recommended health actions to reduce that 
susceptibility, e.g. by increasing medication adherence [300]) [274, 275] or the Necessity-Concerns 
Framework (which posits that patients implicitly weigh the advantages and disadvantages of using 
treatment uses against the disadvantages when deciding whether or not to adhere to treatments 
[301]).[259, 277, 278] These theories assume that adherence or non-adherence arises only from 
rational deliberation. 
 
Yet, dual process theories propose that behaviour may be directed either via conscious reflective 
deliberation, or through more rapid automatic processing.[302-304] The Capability, Opportunity 
and Motivation (COM-B) model, which incorporates all potential determinants of action,[305] posits 
three factors necessary for any behaviour to occur: perceptions of capability, opportunity and 
motivation. Each of these may be subdivided: capability may be psychological (e.g. knowledge) or 
physical (e.g. dexterity); opportunity may be social (e.g. permission to use nebulisers at the 
workplace) or physical (e.g. availability of medication) and motivation may be reflective and 
deliberative (e.g. necessity, concerns) or non-reflective, drawing on automatic processes (e.g. 
habit associations).  
 
The COM-B model demands explanations for low adherence over and above treatment or health 
beliefs, which are one component of reflective motivation. Recent work in other subject areas has 
highlighted the importance of targeting automatic processes (e.g. habit) for behaviour change in 
general [306, 307] and to improve medication adherence in other long-term conditions.[7-11, 249] 
Habit may well be important in sustaining medication adherence among adults with CF, but the 
literature search found no studies looking at habit in the context of CF medication adherence. As 
the first step to explore the potential role of habit in nebuliser adherence among adults with CF, the 





Chapter 3, Section 4: The concept of ‘habit’ and methods to measure ‘habit’ 
 
For some health behaviours, a single action may be adequate to attain desired health outcomes, 
e.g. a single vaccination.[308] For many other health behaviours, behaviour change must be 
lasting for health benefits to be realised e.g. the use of CF preventative inhaled therapies – using a 
single dose of dornase alfa, for example, has negligible health impact.[309]  
 
Various systematic reviews have highlighted the difficulty of changing behaviour, but maintaining 
behaviour change is even more difficult.[193, 249, 310, 311] A potential mechanism for sustaining 
behaviour change is habit formation. Drawing heavily on a recent habit scoping review,[250] this 
section focuses on the concept of habit to understand its role in influencing health-related 
behaviours and methods to measure habit. 
 
3.4.1 The concept of ‘habit’ 
 
3.4.1.1 What is ‘habit’? 
Various definitions of ‘habit’ have been used. A definition of ‘habit’ which is coherent and provides 
evidence-based explanatory mechanism for habitual (health) behaviours is “a process by which a 
stimulus automatically generates an impulse towards enacting a behaviour”.[250]  
This definition distinguishes between habit as a process, and habitual behaviour as a manifestation 
of that process. This definition also incorporates all the characteristics of habit as described in 
Sections 3.4.1.2 and 3.4.1.3 which distinguishes habitual behaviour from other forms of automatic 
behaviour. By clarifying that habit activates an impulse towards behaviour instead of activating a 
behaviour, this definition allows for the possibility that a habit impulse may not always be enacted 
as a behaviour (see Section 3.4.1.6). 
 
 3.4.1.2 Habit is automatic and cue-contingent 
Habit is a non-conscious (i.e. automatic) process by which behaviour is contextually cued. For 
example, an adult with CF may automatically use his nebuliser (behaviour) after walking his dog 
every morning (contextual cue).[16]  
It follows that if the cue is rarely encountered, it is possible for a “strongly habitual” behaviour to be 
infrequent.[250] For example, if an adult with CF who automatically uses his nebuliser after walking 
his dog only walks his dog once a week, the adult with CF may also only activate his habit impulse 
for using nebulisers once a week. 
Discontinuation of cue exposure may disrupt habitual behaviour.[312, 313] However, sustained 
behaviour change may not be achieved just with discontinuation of cue exposure if a return to the 
‘previous context’ spontaneously activates unwanted ‘implicit habit’.[250] For example, a person 
with CF may consistently use his nebuliser after his evening meals whilst in hospital. However, 
when he returned to his home environment, he might also return to his previous behaviour of 
spending most of his time after his evening meals playing games on his Xbox console instead. 
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‘Implicit habit’ i.e. stored cue-behaviour association may explain why behaviour change 
interventions typically only have short-term effects [193, 310] in that old behaviours re-emerge after 
the active intervention period.[250]  
 
3.4.1.3 Habit is acquired by context-dependent repetition 
Habit forms through associative learning when a specific behaviour is consistently repeated in a 
specific setting.[250] This context-dependent repetition gradually shifts the cognitive control of a 
behaviour from reflective to automatic processes, such that encountering a context is sufficient to 
elicit the associated behaviour.[250]  
A behaviour can also be repeated in different settings (e.g. using nebulisers at different times of 
the day instead of always after the evening meals). This may help to stave off boredom but in 
theory, will not contribute to strengthening of habit.[314] 
 
 3.4.1.4 Habit determines behaviour frequency – how habit maintains a focal behaviour 
The gradual shifting of a behaviour’s cognitive control from reflective to automatic processes 
means that as habit develops, it can cue further context-dependent repetitions which in turn further 
strengthens the habit.[250] This positive feedback loop means that enacting the behaviour gets 
progressively easier, even though the initial process of habit formation is effortful.[314] 
Automatic control of habitual behaviours reduces the dependence of habitual behaviour on 
conscious attention or deliberative processes.[250] Habitual behaviour should therefore persist 
even if attention or conscious motivation wane i.e. habit can shield new behaviours from 
relapse.[314] In contrast, behaviour which relies on effortful self-regulation (which is a limited 
mental resource [315-317]) would be susceptible to disruption when self-regulation is reduced 
during times of stress, or if there is a need to devote resources to other cognitively effortful 
tasks.[250]  
Habit should over-ride intention where opposing habits and intentions (i.e. motives) are 
present.[250] This is because the impulsive pathway should generate a response more 
instantaneously than the deliberative pathway. Various moderation tests have demonstrated that 
intention becomes less predictive of a behaviour as habit strength increases.[250] That means if a 
person intended to use his nebuliser after his evening meals but he also has a very strong habit of 
playing games on his Xbox console after his evening meals, it is more likely that the person ended 
up playing games on his Xbox console. However, findings of moderation tests were not always 
consistent, e.g. some studies found no interaction [318] whilst other studies even found that 
intention were more predictive of behaviour with stronger habits.[319] The inconsistent findings 
may be related to differences in study designs and habit measures rather than a genuine lack of 
moderating impact of habit on the intention-behaviour relationship.[250, 320]  
Habit may also narrow people’s attention towards the habitual option and reduce accessibility to 
alternative options. A study found that people with strong habit towards choosing a particular travel 
mode showed a lack of interest in acquiring new information for other travel options and used less 
45 
 
information in their decision-making.[321] Another study found that people with strong routines 
tended to use information in a way that is biased towards maintaining their routines.[322] For 
example, people with strong routines were more likely to be only searching for confirmatory 
information and preferred to maintain a routine even when presented with contradicting evidence, 
compared to people with weaker routines.[322] 
 
 3.4.1.5 Other potential cognitive benefits of habit  
As a behaviour becomes cognitively efficient, self-regulatory resources can be freed up for other 
tasks. A study asking participants to provide hourly reports of their on-going experience found that 
people tend to be able to think about things other than the focal behaviour when they are 
performing that focal behaviour habitually.[323]  
Another study used multiple-step mediation analyses to investigate the inter-relation between 
exercise and healthy nutrition.[324] This study demonstrated that high behaviour-specific (regular 
exercise) habit strength may facilitate the regulation of another related behaviour (healthy nutrition) 
with two different ‘mechanisms’.[324] First, as enacting a behaviour becomes more automatic, 
efficient and effortless with increasing habit strength, previous self-regulatory resources occupied 
by exercise-specific demand could be invested in the planning of one’s diet.[324] Second, the 
psychological resources used to master a behaviour can also be ‘transferred’ to facilitate the 
mastery of another related behaviour, i.e. cognitive transfer.[324]  
The potential for habit formation in a single behaviour to facilitate engagement in another health 
behaviour is particularly pertinent in CF because CF is a multi-system condition requiring multiple 
treatment types (see Section 2.3). 
 
3.4.1.6 Habit impulse can be inhibited  
As discussed in Section 3.4.1.4, habit strength should correlate with likelihood of behavioural 
enactment. However, habitual behaviour is not an automatic consequence of encountering relevant 
cues.[250] There is empirical evidence that contextually cued automatic behaviours can be 
consciously inhibited with sufficient will-power and self-regulatory resources e.g. through vigilant 
monitoring of cues and behaviour, or planning alternative responses to cues.[250] A study using 
episode-sampling diaries found a modest level of level of success (self-reported mean success 
score of 3.57 on a 7-point scale) at inhibiting unwanted habitual behaviour by vigilantly monitoring 
for a response to cues and inhibiting its performance.[325] Other strategies e.g. distraction or cue 
avoidance were unsuccessful in that study.[325]  
Nonetheless, strategies to tackle unwanted habitual behaviours can be divided into two broad (but 
potentially overlapping) categories: (1) altering the environment to constrain the behaviour and 
discontinue cue exposure (since habit is cue-contingent; see Section 3.4.1.2) (2) disrupt the cue-





3.4.1.7 Habitual behaviours may be habitually instigated or habitually executed  
Questions have been raised as to whether complex health behaviours can be habitual, since it 
unlikely for complex behaviours to be completely undertaken without conscious mediation.[326] 
Some of the most compelling studies on ‘habit’ are based on automation of simple actions e.g. 
pulling levers, with the assumption that these simple actions transpose to more complex 
behaviours (i.e. complex habitual actions are viewed as concatenated sequences of simpler and 
lower-order habitual actions).[250] There is no empirical data supporting this assumption [250] and 
recent experimental work also highlighted the difficulty of inducing inflexible habits in human 
subjects.[327] 
Action-phase models deconstruct a higher-order behaviour into sequential subcomponents starting 
prior to action selection and concluding in action completion, e.g. a ‘bicycle commute’ can be 
broken down into ‘retrieving the bicycle from the garage, ‘putting on cycle helmet’, ‘pedalling’, 
‘navigating the traffic’ etc. Conceptualising all habitual behaviours as being automatically selected 
(i.e. the decision to act in action-phase terminology) and automatically performed (involving the 
completion and termination of action) restricts the explanatory value of habit for complex 
behaviours. A better theoretical understanding of complex habitual health behaviours is obtained 
by distinguishing habitual behaviours into two types i.e. habitually instigated sequences (action 
sequence automatically initiated without deliberation) and habitually executed actions (action 
performed to completion without conscious input); and recognising that habitual instigation does 
not necessitate habitual execution and vice versa. Habitual instigation would better match 
everyday experiences of complex behaviour whereas habitual execution would fit with historical 
perspective of ‘habitual behaviours’ as chunked automated sequences of lower-order actions.  
This distinction is less meaningful for simple behaviours in which the instigation and execution 
cannot be easily separated e.g. drinking water. However, this distinction has practical implications 
for complex health behaviours e.g. using nebuliser. If nebuliser use episodes are habitually 
instigated (e.g. triggered at the same time of day) but non-habitually performed (e.g. executed 
mindfully in a varying sequence), habit formation should target the automatic selection of the 
behaviour (i.e. target the “decision process”). If nebuliser use episodes are consciously instigated 
(e.g. mindfully triggered) but habitually performed (e.g. performed in an automated and unvarying 
sequence), then habit formation should aim to automate sequential activation of multiple sub-
behaviours (i.e. target the “execution process”).  
There is also emerging empirical evidence to suggest that instigation, rather than execution habits, 
are more likely to predict the frequency of health behaviours.[328, 329] Given that a hallmark of 
habit is that habit should predict the enactment of future behaviour,[250] this evidence suggests 
that distinguishing between instigation and execution habits is likely to be relevant for 





3.4.2 Methods of measuring ‘habit’ 
 
The recent scoping review on ‘habit’ [250] identified four types of habit measures. This section 
summarises those four habit measures, highlights a measure for habit impulse described in a 
commentary to the scoping review,[330] and discusses the general strengths and limitations of 
different habit measures. Finally, the characteristics of an adequate method to measure the habit 
of using nebuliser among adults with CF are considered.  
 
3.4.2.1 Habit measure 1 – frequency in context 
The ‘Behaviour Frequency × Context Stability’ (BFCS) is the most commonly used frequency in 
context measure and can be adapted for a range of habitual behaviours. It is the multiplicative 
product of self-reported behaviour frequency (e.g. ‘how often do you do X?’) and variation in 
contextual cues (e.g. ‘when you do X, how often is it performed at the same place?’).[331] This is 
based on the assumption that ‘strong habits’ have been frequently performed in stable contexts, 
whereas ‘weak habits’ have been performed in unstable contexts or performed less 
frequently.[320] However, it is uncertain whether the implied compensatory relationship between 
behaviour frequency and context stability (i.e. frequent behaviour in varying settings is expected to 
have the same influence on habit strength as infrequent behaviour in unvarying setting) 
exists.[332]  
BFCS typically relies on researcher-generated cues (e.g. location in the example above) to infer 
context stability, yet any environmental features can cue habit and contextual cues will differ 
between individuals.[250] A limitation of BFCS that relies on researcher-generated cues is that it 
only truly “measure habit” if idiosyncratic contextual cues for a person are correctly identified.[250] 
BFCS could also be based on cues elicited from participants or could even use a general context 
instead of specific cues (see example in reference [320]). However, the focus on cue (or context) 
stability meant that BFCS may be assessing the likelihood habit has formed rather than the 
automaticity with which habitual impulses are being generated.[250] 
 
3.4.2.2 Habit measure 2 – Self-Report Habit Index (SRHI) 
SRHI is a self-report scale designed to assess the experience of habit and the strength of 
underlying cognitive association.[332] It consists of 12 items reflecting on automaticity, behaviour 
frequency (to capture the experience of repetition) and self-identity.[332, 333] 
The SRHI assumes that people can accurately infer that they are unaware of initiating an action by 
reflecting on the consequences of the action (i.e. the “symptoms” of habit).[332] It does not require 
an insight into the habit process itself.[332] However, it is argued that people’s recollection of 
behaviour and experience is unreliable.[334] Studies have suggested that executive processes 
leading to habitual actions are inaccessible to conscious awareness, hence people may not be 
able to distinguish between automatic and non-automatic actions.[334] Not all automatic processes 
are habits, and people may also not be able to distinguish between actions that are habitual and 
automatic, or non-habitual and automatic (e.g. non learned forms of automaticity).[334] As a result, 
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people may misattribute a frequent behaviour as “habit” or “automatic”, when in reality the 
behavioural response actually requires considerable deliberative planning or cognitive effort.[334]  
Generic SRHI items (e.g. ‘Behaviour X is something I do without thinking’) neglect cue or context, 
but references to specific cues or contexts can be easily accommodated within the item (e.g. 
‘Behaviour X in Context Y is something I do without thinking’).[332] However, a study that collected 
both generic and context-specific SRHI scores found similar results with both context-free and 
context-specific items.[335]  
The parsimony and conceptual basis of SRHI have also been questioned.[250, 336] Behaviour 
frequency SRHI items are likely to illicit responses that covary closely with performance frequency 
but ignore frequency with which cues are being encountered.[250] The self-identify items are 
perhaps redundant, since self-identity is not considered a defining feature of habit.[250]  
 
3.4.2.3 Habit measure 3 – Self-Report Behavioural Automaticity Index (SRBAI) 
SRBAI is an automaticity subscale of the SRHI and consists of four items.[336] Limitations of 
SRHI, e.g. the potential lack of reliability in reflecting on non-conscious processes, also apply to 
SRBAI. Being more parsimonious, SRBAI is a likely to be a more practical tool than SRHI in 
collecting data for multiple behaviours and/or multiple time points.[336]  
However, the reduction in the number of items may reduce the reliability of SRBAI compared to 
SRHI.[332] The validation datasets for SRBAI showed stronger correlation between behaviour and 
SRHI compared to SRBAI,[336] suggesting that an assessment of behaviour frequency and/or 
experience of repetition may be crucial to measure habit.[320] For example, experience of 
repetition may help in discerning habitual from non-habitual forms of automaticity.[250] 
 
3.4.2.4 Habit measure 4 – Association tests 
Association tests are designed to directly assess the strength of cue-behaviour associations. 
Examples include the Implicit Association Test (IAT) and Go / No-go Association Task 
(GNAT).[337] These tests operate on the basis that habitual responses should be more quickly and 
frequently recognised in the presence of cues (since the impulsive pathway should generate a 
response more instantaneously than the deliberative pathway).[250] Association tests are usually 
administered in a controlled environment (e.g. a quiet room or separate cubicle) using a computer 
with webpage application or an appropriate software.[338] Participants may be asked to provide 
the context or cues for a behaviour; or researcher-generated cues and/or researcher-specified 
context are used for the test. Participants are then assessed with a behaviour recognition task. 
This usually involve several behaviours presented as words or images on the computer screen in 
random order (the wording or images can be modified to take in account appropriate cues / 
context), whereby the participants respond to each behaviour by pressing a ‘yes’ key or a ‘no’ key 
on the keyboard.[338] Response times are recorded and processed by the software or webpage 
application. Quicker response times to a presented behaviour (i.e. lower response latencies) are 
considered to represent stronger impulse for that behaviour (i.e. stronger habits).  
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Association tests bypass the subjectivity of self-report and purport to clearly distinguish between 
implicit (i.e. automatic) vs deliberative processes.[337] However, they must be administered in a 
controlled environment; hence lack real-world applicability and ecological validity.[250] Large 
number of trials is required to detect subtle differences in the speed of response.[320] External 
validity is also a concern since other inter-individual and between cohort factors (e.g. age) could 
influence the reflex to a stimulus.[339]  
 
3.4.2.5 Self-report of ‘habit impulse’ 
Existing self-report habit measures (see Sections 3.4.2.1 to 3.4.2.3) infer habit from the stability of 
context in which a behaviour is enacted (BFCS) or from experiences of automaticity with enacted 
behaviour (SRHI and SRBAI). Therefore, these measures are insensitive to habit-generated 
impulses that are not enacted; and are not able to distinguish between strong and weak habit-
generated impulses when a behaviour is not enacted.[330] Measuring habit impulses offers new 
opportunities to predict, understand and influence health behaviours.[250, 330] For example, 
detecting presence of latent or inhibited habit impulses may identify people at risk of relapsing into 
unwanted habitual behaviours during periods of diminished self-regulatory capacity. This is 
important because behaviour change and habit formation may well involve substituting an old 
behaviour with a new one.[320] An impulse measure may also allow a more accurate evaluation of 
intervention techniques designed to inhibit unwanted habit impulses (e.g. to smoke).[330]  
The difficulties of perceiving and recollecting automatic processes are described in Section 3.4.2.2, 
but some habit impulses may be more open to self-report. Impulse is generated outside conscious 
awareness, but it may rise into consciousness (e.g. experienced as an urge to enact an action) if 
the impulse is blocked from being translated into action (see example in reference [330]). Self-
report measures specific for impulses to smoke when abstinent have been shown to predict 
relapse.[330] Therefore, generic measures of habit impulse that are independent of action could 
also be useful in other settings. An example of such items based on the format of SRHI might be: 
‘When in Context Y, I automatically find myself wanting to do Behaviour X’.[330] The example item 
is still unlikely to distinguish between habitual from non-habitual automatic responses, so more 
work is needed to develop and validate reliable measure of habit impulse.[330]  
 
3.4.2.6 All existing measures of habit are necessarily imperfect 
Unlike behaviours, habit is a process which cannot be directly observed. Existing self-report 
measures infer habit indirectly as described in Section 3.4.2.5 and rely on recall of subjective 
experience. Association tests (see Section 3.4.2.4) purport to directly assess the strength of cue-
behaviour associations. While these tests bypass the subjectivity of self-report in terms of the cue-
behaviour strength, they may still be subjected to the subjectivity of self-report in terms of 
identifying cues.[332] In addition, the speed of impulse generation and strength of impulse were 
still being measured indirectly (as speed of response to a primed target). Therefore, all existing 
habit measures are at best a surrogate measure of the very essence of habit i.e. a process which 
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generates an impulse towards action (see Section 3.4.1.1). Association tests may be the ‘most 
proximal’ measure for habit, thus may be considered the most theoretically valid measure 
(although it has been argued that speed of response in association tests may conflate non-habitual 
processes e.g. affective forces or familiarity [332]). However, theoretical validity is not the only 
necessary property for a useful measurement tool.[340, 341] 
The issues with habit measurement also apply to measurements of other psychological constructs. 
Many ‘proven valid’ measurement tools may actually lack validity, and how respondents interpret 
most questionnaire items (the dominant form of measurement tool within health psychology) is 
often unknown.[342] There are also problems with self-report even for a behaviour;[184, 186, 187] 
and it seems unlikely that self-reported psychological constructs would be more reliable than self-
reported behaviours.  
This is not to say that an imperfect measure cannot be useful. Imperfect measures can still be 
adequate, especially if potential biases from the imperfect measures are well understood. Progress 
has been made in understanding the role of habit within health behaviours since the introduction of 
SRHI and other habit measures;[332] and further work on habit measures could help to extend 
habit research and application. 
 
3.4.2.7 If all existing measures of habit are imperfect, what are the characteristics of an 
adequate measure of habit for nebuliser use among adults with CF? 
 
It could be argued that a habit measure for nebuliser use is “adequate” if it shows an adequate 
degree of validity and reliability in relation to the purpose of measurement. 
 
Validity: 
Validity is the extent to which a measure is linked to the construct that the measure is intended to 
assess.[342] Validity can be content-related (face validity i.e. a measure is measuring what it aims 
to measure; construct validity i.e. a measure is related to underlying theoretical concepts) and 
criteria-related (concurrent validity i.e. a measure is related to another similar measure; predictive 
validity; e.g. does the habit measure predict behaviour enactment?).[343] 
The main characteristics of habit are automaticity, cue-contingency and cue-stimulus response 
learned through context-dependent repetition.[250] At a simplistic level, a content-valid nebuliser 
habit measure should only measure the defining characteristics of habit and not something else 
(e.g. nebuliser adherence). However, it is also important to note that habit has several other 
characteristics, such as its cognitive efficiency and prediction of behaviour enactment.  
As discussed in Sections 3.4.2.1 to 3.4.2.6, all existing habit measures are able to capture parts of 
the habit construct but none (not even association tests) are able to reliably capture ‘habit’ without 
potential conflation with non-habitual processes. This does not invalidate all existing habit 
measures. “Validity” must be assessed as a continuum instead of a binary outcome; and these 
limitations may lessen, but do not necessarily nullify, the validity of habit measures.  
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Thus, all the measures described in Sections 3.4.2.1 to 3.4.2.5 have a degree of validity, but 
results from these measures should be interpreted in the context of possible limitations. For 
example, if the purpose of measuring habit is to investigate the moderating influence of habit on 
intention but such an effect was not detected using a frequency in context measure; it may be 
because the frequency in context measure failed to detect implicit habit rather than a genuine 
absence of habit-intention interaction. However, if the purpose of measuring habit is to investigate 
the relationship between habit and behaviour frequency (i.e. behaviours that are enacted), the 
inability to account for implicit habit using a frequency in context measure may not bias the results. 
 
Reliability: 
Reliability refers to the consistency of a measure.[344] Reliability can be internal (i.e. consistency 
within a measure, which can be evaluated with omega coefficient [342]) and external (test-retest 
i.e. stability of a test within a person over time; inter-rater i.e. consistency between different raters, 
judges, or observers).[344]  
Since association tests bypass the subjectivity of self-report, they may well have better reliability in 
terms of the measuring cue-behaviour strength if performed in a controlled environment. It is 
seems unlikely that the association tests can be reliable outside a controlled environment – even 
within a controlled environment, large number of trials are needed to detect subtle differences in 
the speed of response.[320] 
Thus, if the purpose of measuring habit is to provide corroborating evidence for self-report habit 
measures in a controlled environment, an association test would be a highly reliable measure. If 
the purpose of measuring habit is to track how habit of using nebuliser change from childhood to 
adulthood among people with CF in a real-world setting, an association test is unlikely to be a 
reliable measure. 
 
In this thesis, nebuliser habit was measured to explore the relationship between a broad range of 
potential adherence predictors (including habit) and objective nebuliser adherence. A variety of 
self-report items for the studies in Chapters 5 & 6 was used. SRBAI was used to measure habit in 
those studies to avoid excessive burden on participants, because SRBAI is more parsimonious 
compared to other self-reported habit measures.[336] None of the self-report measures used are 
perfect. However, all of those measures also provide some insights into the constructs that those 
measures are designed to assess, and using self-report measures for all the different 
psychological constructs at least provided a consistent approach. Therefore, it could be argued 






Chapter 3, Section 5: Summary of the gaps in current evidence and the specific objectives 
of subsequent thesis chapters to address these gaps  
 
Review of the current CF literature revealed that adherence levels among adults with CF are 
generally low (median adherence 30-50%), reasons for low adherence remain poorly understood 
and effective adherence interventions are lacking. A recent James Lind Alliance Priority Setting 
Partnership has identified effective ways to “improve and sustain adherence to treatment” as one 
of the top 10 research priorities in CF.[258] Thus, further research in this area is timely and 
important. There are two areas of limitations in the current evidence base, which this thesis aims to 
address. 
 
First, electronic data capture (EDC) is generally considered the ‘gold standard’ method to capture 
adherence data,[168] yet EDC data have only been used to explore a limited range of 
demographic / treatment factors that potentially influence nebuliser adherence among adults with 
CF. As discussed in Section 3.1.2, the CF community is fortunate in that I-neb® (which is a tamper-
proof intelligent nebuliser machine that automatically and accurately logs every time a drug is 
being nebulised) is available for routine clinical use. Therefore, the objective of Chapter 4 is to use 
adherence data captured via I-neb® among 126 adults with CF in Sheffield over a 4-year period to 
systematically explore a wide range of demographic / treatment factors that potentially influence 
adherence. Prior to the work under-taken in Chapter 4, the largest EDC adherence dataset in CF 
only consisted of 108 people over a 1-year period.[179, 345] 
 
Second, even after the extended literature review in Section 3.2, there is a paucity of research 
looking at the relevance of automatic processes in CF medication adherence. Understanding the 
role of both non-conscious motivation (e.g. habit) and conscious motivation (e.g. intention) in 
sustaining nebuliser adherence could lead to more effective adherence interventions. Therefore, 
the objective of Chapter 5 is to use a mixed methods design to explore a wide range of 
psychological factors that potentially influence adherence. Adherence data were accurately 
captured via I-neb® in this mixed methods study among 20 Sheffield adults with CF, thus the 
exploration of psychological factors is grounded upon reliable adherence data. Any single-centre 
study can be criticised for the lack of generalisability. Therefore, the objective of Chapter 6 is to 
replicate the findings in Chapter 5 with a secondary quantitative analysis using prospectively 
collected data during a pilot randomised controlled trial with 64 participants (ACtiF pilot, 
ISRCTN13076797). Participants in the pilot trial were recruited from the Wolfson CF Centre 
(Nottingham) and Wessex Adult CF Centre (Southampton); and nebuliser adherence data from the 
participants were captured via eTrack® (another form of EDC).  
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CHAPTER 4: AN OBSERVATIONAL STUDY EXPLORING THE RELATIONSHIP BETWEEN 
CLINICAL FACTORS AND OBJECTIVE NEBULISER ADHERENCE 
 
 
Chapter 4, Section 1: Introduction 
 
The literature review in Section 3.2 found that electronic data capture (EDC) data have only been 
used to explore a limited range of demographic / treatment factors that potentially influence 
adherence. Other than age, the influence of other demographic factors on nebuliser adherence is 
uncertain. Understanding the association between demographic factors and adherence could 
potentially allow clinicians to identify the subgroup of adults with CF that are particularly at risk of 
low adherence. This understanding is also important for case-mix adjustments to enable robust 
between-centre comparison and benchmarking using adherence data as quality indicator.[346] 
Understanding the association between treatment factors and adherence could help inform the 
therapeutic decisions of clinicians to support nebuliser adherence.[347] 
 
This chapter therefore sets out to systematically explore the relationship between objective 
nebuliser adherence and a range of demographic & treatment factors.  
 
 
Chapter 4, Section 2: Methods 
 
4.2.1 Design and setting 
 
This is a single-centre retrospective observational study. All adults with CF diagnosed according to 
the UK CF Trust criteria [348] in Sheffield aged ≥16 years and using I-neb® as part of their routine 
treatment were included, except those with lung transplantation or on ivacaftor. Both lung 
transplantation and ivacaftor have transformative effects on lung health,[349-351] such that their 
treatment requirements may no longer represent that of a typical adult with CF.[352, 353] This 
study was approved by the NHS Health Research Authority (IRAS number: 210313). 
 
4.2.2 Data collection and processing 
 
The following clinical data from 01 January 2013 to 31 December 2016 were extracted from paper 
notes and electronic patient record: 
• Age, in years  
• Gender at birth (male / female) 
• Best %FEV1, calculated using the Global Lung Function Initiative (GLI) equations [354]) – 
this is the highest %FEV1 reading in the calendar year period 
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• CF related diabetes (CFRD, present / not present) – CFRD was diagnosed by the clinical 
team on the basis of oral glucose tolerance test and continuous subcutaneous glucose 
monitoring results, in accordance to the UK CF Trust guideline.[355] 
• P. aeruginosa status (chronic / intermittent / no) – determined according to the Leeds 
criteria.[356]  
• Socioeconomic deprivation – calculated as Index of Multiple Deprivation (IMD) scores, 
which were derived from postcodes.[150] 
• Pancreatic status (pancreatic insufficient / pancreatic sufficient) – pancreatic insufficiency 
was diagnosed by the clinical team on the basis of ≥2 faecal pancreatic elastase levels 
<200µg/g stool, and symptoms consistent with maldigestion and malabsorption, in 
accordance to the UK CF Trust guideline.[357]  
• Genotype (‘severe genotype’ / not) – determined according to international consensus,[19] 
which defined ‘severe genotype’ as homozygous for Class I-III mutations 
• Annual total intravenous antibiotic days (in number of days) – data from 01 January 2012 to 
31 December 2012 were also collected 
• Nebuliser prescription details  
 
Extracted nebuliser prescription data included three aspects.  
First, a treatment regimen was considered “suboptimal” if the minimum required treatment 
definition was not met (e.g. a person with chronic P. aeruginosa infection who was only prescribed 
once daily dornase alfa),[182] and “minimum required treatment prescribed” if the minimum 
required treatment definition was met. Data related to P. aeruginosa status, %FEV1, pancreatic 
status, genotype and prior-year intravenous antibiotics were used to determine the minimum 
required treatment based on a normative definition.[182] 
Second, a treatment regimen was considered “short-term” if the intended treatment duration was 
three months or fewer (this regimen is typically used for P. aeruginosa eradication [80, 135, 358]), 
and “long-term” if the intended treatment duration was longer than three months (this includes 
eradication treatment for non-tuberculous mycobacteria which is typically two years in duration 
[359]).  
Third, a treatment regimen was considered “alternating” if on-off or continuous alternating 
nebulised antibiotics regimen was prescribed, and “continuous” for all other treatment regimens.  
 
Nebuliser adherence data were downloaded from I-neb®. Adherence was calculated as a 
percentage of total nebuliser doses taken against the agreed dose between clinicians and adults 
with CF. This corresponds with the method of quantifying the implementation of a dosing regimen, 
as outlined by the Ascertaining Barriers to Compliance (ABC) taxonomy for medication 
adherence.[156-158] Based on this method of quantifying adherence, adherence levels can vary 
from 0% to >100% (due to potential nebuliser overuse), with higher adherence being more 
desirable although nebuliser adherence >100% may not be optimum (this may vary with the 
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medications – hypertonic saline may be beneficial if used more frequently whereas antibiotics may 
cause toxicity if used substantially more frequently than the prescribed doses). 
 
Data were managed in a Microsoft Excel v.2010 (Microsoft) spreadsheet, and were checked for 
accuracy and completeness before analysis. Complete data were collected from all included adults 
– there is no missing data for any variables. Data extracted from paper notes were independently 
reviewed by two investigators to ensure accuracy. 
 
4.2.3 Data analysis 
 
Data were analysed using SPSS v24 (IBM Corp). Data for 2013-2016 were combined, and mixed-
effects modelling (random effect at individual level) was used to account for repeated measures 
within an individual. Appropriate descriptive statistics were generated, including tabulation of 
demographic data for adults on I-neb® (included in the study) and adults not on I-neb® (excluded 
from the study, since no adherence data). P-values <0.05 were considered statistically significant. 
 
4.2.3.1 Analysis of demographic factors 
The first part of the analysis involved demographic factors and used annual adherence (in a 
calendar year) as the unit of analysis. This is because demographic factors e.g. age are relatively 
stable and accounting for year-on-year changes in these factors is sufficiently granular.  
The analyses consisted of two steps with magnitude of adherence used as the dependent 
continuous variable in linear models. The first step was univariate linear regression using age (≤18 
years, 19–25 years, 26–34 years, ≥35 years), gender (male vs female), %FEV1 (<40%, 40–69.9%, 
70–99.9%, ≥100%), CF related diabetes (not present vs present), P. aeruginosa status (no P. 
aeruginosa, intermittent, chronic) and deprivation status (five quintiles as measured by Index of 
Multiple Deprivation, IMD, scores which were derived from postcodes [150]) separately as fixed 
effects.  
Age categories used in the analysis were based on previous studies which demonstrated clear U-
shape relationship between adherence and age.[5, 200] %FEV1 categories were based on 
previous ESCF studies.[360] Previous studies suggest that gender and disease severity (which 
may be indicated by %FEV1 and P. aeruginosa status) may influence adherence.[209, 273] 
Socioeconomic deprivation is of interest because studies have demonstrated that people from 
more deprived areas in the UK and uninsured adults in the US were less likely to receive 
preventative inhaled therapies.[150, 151] People with CF related diabetes typically have higher 
treatment burden since they need to incorporate insulin use in their treatment regimens.[355, 361-
363] Therefore, it is worth studying whether this increased burden is associated with lower 
adherence. 
The second step of the analysis was to perform multiple regression using demographic factors that 
were significantly associated with the outcome of interest as fixed effects. 
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4.2.3.2 Analysis of treatment factors 
The second part of the analysis involved treatment (prescription) factors and used weekly 
adherence as the unit of analysis. This is because nebuliser prescription is more fluid, and can 
change several times within a year. For example, it is possible for someone to undergo a P. 
aeruginosa eradication course for three months then spend the rest of nine months in the calendar 
year on “longer-term” treatments.  
The analyses of treatment factors involved the same two steps as described in Section 4.2.3.1. 
The binary treatment factors used as fixed effects were suboptimal treatment (if minimum required 
treatment definition [182] was not met) vs minimum required treatment prescribed, “short-term” vs 
“long-term” (>3 months) regimens, and continuous vs alternating regimens (which could be “on-off” 
nebulised antibiotics or continuous alternating antibiotics). 
Adequacy of prescription is of interest because treatment rationalisation and simplification (e.g. by 
dropping inhaled mucolytics in someone struggling to even use one out of three prescribed 
nebulisers per day) is often employed as a strategy to improve adherence among people with 
CF.[364] Yet a study found that changing twice daily colistin to two doses of once daily colistin did 
not result in sustained improvement of adherence.[176] “Short-term” vs “long-term” regimens are of 
interest because adherence in long-term conditions tend to decrease over time.[222, 223, 227] A 
person may cope better with short-term treatment regimens compared to longer-term treatment 
regimens if he / she relies mostly on conscious self-regulation to maintain nebuliser use, since self-
regulation is effortful and uses limited mental resources.[315] Continuous / alternating regimens 
are of interest because continuous alternating regimens (whereby two or more inhaled antibiotics 
are alternated) could be an important strategy to improve clinical outcomes especially among 
people with more severe lung disease.[148, 365] However, continuous alternating regimens are 
associated with greater treatment complexity and may impact on adherence. Two sequential 
multiple regressions were performed, each with weekly adherence as the unit of analysis. The first 
identified treatment factors that were independently associated with nebuliser adherence. The 




Chapter 4, Section 3: Results 
 
This analysis included 126 adults (55, 43.7% were females) over a 4-year period. The year-by-year 
baseline demographic data were summarised in Table 4.1. The Sheffield cohort was relatively 
young, with a mean age of 27.1 years (95% CI 25.4 to 28.8 years) in 2016. This may partly explain 





Of note, there was consistent year-on-year increase in mean nebuliser adherence from 43.6% 
(95% CI 37.1% to 50.2%) in 2013 to 55.1% (95% CI 48.5% to 61.7%) in 2016, although the 
proportion of I-neb® users on suboptimal treatment regimen also increased consistently from 
22.7% in 2014 to 29.4% in 2016. 
 














      Lung transplantation, N 
      On ivacaftor, N 



































Age in years, mean (95% CI) 
      ≤ 18 years, N (%) 
      19 – 25 years, N (%) 
      26 – 34 years, N (%) 
      ≥ 35 years, N (%) 
 
Gender 
      Male, N (%) 
      Female, N (%) 
 
% predicted FEV1 , mean (95% CI) 
      < 40%, N (%) 
      40 – 69.9%, N (%) 
      70 – 99.9%, N (%) 
      ≥ 100%, N (%) 
 
Presence of CFRD (CF related diabetes) 
      No CFRD, N (%) 
      CFRD present, N (%) 
 
P. aeruginosa status 
      No P. aeruginosa, N (%) 
      Intermittent P. aeruginosa, N (%) 
      Chronic P. aeruginosa, N (%) 
 
Deprivation quintile 
      1 i.e. most affluent, N (%) 
      2, N (%) 
      3, N (%) 
      4, N (%) 













































































































































Adequacy of prescription 
      Suboptimal treatment prescribed, N (%) 
      Minimum required treatment prescribed, N (%) 
 
Reason of prescription  
      Short-term use , N (%) 
      Long-term use, N (%) 
 
Nature of prescription 
      Continuous regimen, N (%) 



























































% adherence, mean (95% CI) 
 
 
43.6 (37.1 to 50.2) 
 
 
49.9 (42.9 to 56.9) 
 
 
53.3 (46.8 to 59.8) 
 
 
55.1 (48.5 to 61.7) 
 
 
I-neb® is typically reserved for people who require nebulised antibiotics. In comparison to those not 
on I-neb®, adults on I-neb® had more severe phenotype as evidenced by higher proportions of CF 
related diabetes and chronic P. aeruginosa infection (see Table 4.2). This suggests that older 
adults (≥35 years) with mild phenotype (thus less likely to be infected by P. aeruginosa) are 
unlikely to require I-neb®, and clinicians were appropriately targeting the use of I-neb® for those  
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with more severe lung disease. A smaller proportion of adults on I-neb® had normal FEV1 (≥100%); but also a smaller proportion had very low FEV1 
(<40%) since adaptive aerosol delivery device (e.g. an I-neb®), which only releases aerosol with an inhalation of sufficient quality,[170] is a struggle to 
use at such low levels of FEV1. Males were more likely to use I-neb® – for each calendar year, >60% of males were on I-neb® but <50% of females 
were on I-neb®. I-neb® use in Sheffield did not differ according to socioeconomic deprivation, even though a recent UK CF registry analysis found that 
adults from more deprived areas were less likely to be on preventative inhaled therapies.[150] 
 












On I-neb® † 
N = 89 
 
Not on I-neb® ‡ 
N = 77 
 
On I-neb® † 
N = 97 
 
Not on I-neb® ‡ 
N = 73 
 
On I-neb® † 
N = 104 
 
Not on I-neb® ‡ 
N = 81 
 
On I-neb® † 
N = 102 
 
Not on I-neb® ‡ 
N = 84 
 
 
Age in years, mean (95% CI) 
      ≤ 18 years, N (%) 
      19 – 25 years, N (%) 
      26 – 34 years, N (%) 
      ≥ 35 years, N (%) 
 
Gender 
      Male, N (%) 
      Female, N (%) 
 
% predicted FEV1 , ¶ mean (95% CI) 
      < 40%, N (%) 
      40 – 69.9%, N (%) 
      70 – 99.9%, N (%) 
      ≥ 100%, N (%) 
 
Presence of CF related diabetes 
      No CFRD, N (%) 
      CFRD present, N (%) 
 
P. aeruginosa status 
      No P. aeruginosa, N (%) 
      Intermittent P. aeruginosa, N (%) 
      Chronic P. aeruginosa, N (%) 
 
Deprivation quintile 
      1 i.e. most affluent, N (%) 
      2, N (%) 
      3, N (%) 
      4, N (%) 
      5 i.e. most deprived, N (%) 
 
 
































































































































































































































































† Each person “on I-neb®” had ≥3 months of I-neb® adherence data in a calendar year. 
 
‡ A person on I-neb® for <3 months in a calendar year (e.g. I-neb® only initiated in Dec ‘16) was considered as “not on I-neb®”. A person “not on I-neb®” might be using non-chipped nebulisers and/or using 
dry powder inhalers, or not using any form of preventative inhaled therapies.  
 
¶ One person “not on I-neb®” did not provide any %FEV1 readings from 2013 to 2016 due to the inability to perform spirometry. There is otherwise no missing data.
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The analysis for demographic factors using annual adherence as the unit of analysis included 392 
observations, whilst the analysis for treatment factors using weekly adherence as the unit of 
analysis included 18,303 observations. People within the 19–25 years age range tended to have 
the lowest levels of adherence across all four years (see Table 4.3).  
 
 































Age range ϕ 
      ≤ 18 years 
      19 – 25 years 
      26 – 34 years 
      ≥ 35 years 
 
Gender 
      Male 
      Female 
 
% predicted FEV1 ¶ 
      < 40%  
      40 – 69.9% 
      70 – 99.9% 
      ≥ 100% 
 
Presence of CFRD (CF related diabetes) 
      No CFRD 
      CFRD present 
 
P. aeruginosa status † 
      No P. aeruginosa 
      Intermittent P. aeruginosa 
      Chronic P. aeruginosa 
 
Deprivation quintile ‡ 
      1 i.e. most affluent 
      2 
      3 
      4 
      5 i.e. most deprived 
 
 
N = 89 
 
 
41.7 (25.9 to 57.5) 
38.2 (28.2 to 48.2) 
44.2 (30.5 to 57.8) 
61.4 (44.1 to 78.6) 
 
 
47.0 (37.9 to 56.1) 
38.8 (29.4 to 48.3) 
 
 
37.1 (10.8 to 63.3) 
42.6 (32.8 to 52.7) 
45.3 (34.9 to 55.6) 
44.0 (10.4 to 77.6) 
 
 
43.0 (35.2 to 50.8) 
45.4 (32.4 to 58.5) 
 
 
56.3 (38.0 to 74.6) 
37.0 (24.5 to 49.4) 
42.6 (34.0 to 51.1) 
 
 
65.9 (47.0 to 84.8) 
34.9 (2.7 to 67.1) 
43.6 (31.7 to 55.5) 
40.8 (27.7 to 53.9) 
38.5 (25.0 to 52.1) 
 
N = 97 
 
 
52.9 (33.8 to 72.0) 
40.9 (29.0 to 52.7) 
53.1 (39.3 to 66.8) 
59.6 (46.8 to 72.5) 
 
 
53.9 (44.5 to 63.3) 
43.9 (33.5 to 54.4) 
 
 
30.0 (2.1 to 57.8) 
54.6 (44.2 to 65.1) 
51.6 (41.2 to 61.9) 
28.0 (0 to 63.7) 
 
 
49.3 (40.8 to 57.8) 
51.5 (38.8 to 64.3) 
 
 
51.7 (35.1 to 68.4) 
46.0 (33.5 to 58.5) 
51.5 (41.2 to 61.8) 
 
 
69.9 (56.4 to 83.4) 
48.4 (20.4 to 76.3) 
45.5 (33.8 to 57.3) 
52.0 (35.5 to 68.4) 
41.6 (25.4 to 57.8) 
 
N = 104 
 
 
59.3 (40.1 to 78.5) 
38.7 (28.1 to 49.3) 
60.5 (47.4 to 73.6) 
60.0 (48.8 to 71.2) 
 
 
57.1 (47.9 to 66.3) 
47.9 (38.9 to 56.8) 
 
 
61.1 (33.4 to 88.8) 
45.7 (35.5 to 55.8) 
58.2 (49.0 to 67.4) 
35.7 (0 to 76.8) 
 
 
50.5 (42.8 to 58.3) 
61.9 (49.8 to 74.0) 
 
 
52.6 (38.6 to 66.6) 
60.1 (45.7 to 74.5) 
50.3 (41.5 to 59.1) 
 
 
69.0 (51.6 to 86.4) 
55.0 (27.5 to 82.5) 
49.5 (37.1 to 61.9) 
53.5 (40.8 to 66.1) 
47.0 (32.0 to 62.0) 
 
N = 102 
 
 
59.3 (39.0 to 79.7) 
40.3 (29.2 to 51.5) 
62.5 (49.7 to 75.2) 
62.6 (51.4 to 73.8) 
 
 
59.7 (51.0 to 68.4) 
48.5 (38.1 to 58.8) 
 
 
53.6 (13.6 to 93.6) 
50.3 (39.9 to 60.8) 
59.7 (49.9 to 69.5) 
43.1 (20.1 to 66.2) 
 
 
50.3 (42.5 to 58.1) 
65.6 (53.4 to 77.8) 
 
 
60.0 (47.0 to 73.0) 
57.3 (41.2 to 73.4) 
50.9 (41.9 to 59.9) 
 
 
72.4 (55.4 to 89.4) 
46.9 (33.0 to 60.9) 
58.9 (45.9 to 71.8) 
53.5 (38.1 to 69.0) 
46.7 (31.9 to 61.5) 
 
Treatment factors ▼ 
 
Adequacy of prescription § 
      Suboptimal treatment prescribed 
      Minimum required treatment prescribed 
 
Reason of prescription  
      Short-term use ᴪ (P. aeruginosa eradication) 
      Long-term use 
 
Nature of prescription 
      Continuous regimen 
      Alternating regimen 
 
 




31.2 (28.6 to 33.9) 
44.5 (43.2 to 45.8) 
 
 
49.9 (40.8 to 59.0) 
41.6 (40.5 to 42.8) 
 
 
38.6 (37.2 to 39.9) 
50.4 (48.0 to 52.7) 
 




45.5 (42.3 to 48.8) 
47.0 (45.7 to 48.3) 
 
 
58.6 (51.1 to 66.1) 
46.3 (45.0 to 47.5) 
 
 
40.2 (38.8 to 41.6) 
66.3 (63.8 to 68.7) 
 




34.4 (32.4 to 36.4) 
57.3 (56.0 to 58.6) 
 
 
62.6 (55.4 to 69.7) 
51.8 (50.6 to 52.9) 
 
 
48.7 (47.4 to 50.0) 
63.5 (61.1 to 65.9) 
 




38.6 (36.2 to 41.0) 
57.3 (56.0 to 58.6) 
 
 
63.9 (53.3 to 74.4) 
52.7 (51.5 to 53.8) 
 
 
49.3 (48.1 to 50.6) 
70.5 (67.8 to 73.1) 
 
ϕ The age categories were based previous studies which demonstrated a U-shaped relationship between adherence and age [5, 200] 
 
¶ The %FEV1 categories were based on previous ESCF studies [360] 
 
† P. aeruginosa status was determined using the Leeds criteria [356] 
 
‡ The deprivation quintile was measured as Index of Multiple Deprivation (IMD) scores, which were derived from postcodes [150] 
 
▼ The unit of analysis for treatment factor was weekly adherence. Therefore, the year-by-year descriptive data for adherence stratified 
according to treatment factors did not account for correlated data from repeated measures within an individual. 
 
§ Minimum required treatment according to clinical characteristics was determined based on a previously published normative 
definition.[182] Treatment was considered “suboptimal” if the minimum required treatment definition was not met for that week, e.g. a 
person with chronic P. aeruginosa infection who was only prescribed once daily dornase alfa. 
 
ᴪ A treatment regimen was considered “short-term” if treatment duration for that course of treatment was ≤3 months (this is typically 
used for P. aeruginosa eradication). Eradication treatment for non-tuberculous mycobacteria (NTM) is typically two years in duration and 
is therefore considered “long-term use”. 
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Adults without P. aeruginosa and those in the most affluent quintile also tended to have higher 
adherence. However, increase in adherence from 2013 to 2016 were similar for each deprivation 
quintile (~10% absolute increase in adherence), suggesting that deprivation status did not 
influence the likelihood for improvement in adherence.  There were no clear differences in 
adherence levels among those with or without CF related diabetes, and for different categories of 
%FEV1. Shorter-term treatments (for P. aeruginosa eradication), alternating regimens and 
prescriptions that met the minimum requirements of adequacy according clinical characteristics 
were associated with higher adherence. However the descriptive results for treatment factors 
should be interpreted with caution because the year-by-year descriptive data did not account for 
the correlation from repeated weekly measures within an individual. 
 
 
4.3.1 Results for demographic factors 
 
People aged 19–25 years had the lowest adherence whilst people aged ≥35 years had the highest 
adherence (see Table 4.4).  
 
Table 4.4: Summary of results from mixed-effects linear regression models (random effect at 




Magnitude of adherence 




Age range ϕ (≥ 35 years as reference) 
      ≤ 18 years 
      19 – 25 years 




% predicted FEV1 ¶ (≥ 100% as reference) 
      < 40%  
      40 – 69.9% 
      70 – 99.9% 
 
CF related diabetes present 
 
P. aeruginosa status † (No P. aeruginosa as reference) 
      Intermittent P. aeruginosa 
      Chronic P. aeruginosa 
 
Deprivation quintile ‡ (5 i.e. most deprived as reference) 
      1 i.e. most affluent 
      2 
      3 






–22.0 (–34.2 to –9.8) 
–26.3 (–37.4 to –15.3) 
–17.9 (–28.0 to –7.7) 
 
–9.7 (–20.7 to 1.3) 
 
 
5.1 (–12.2 to 22.4) 
4.6 (–9.5 to 18.8) 
7.4 (–5.3 to 20.1) 
 
7.6 (–2.4 to 17.5) 
 
 
–4.4 (–10.9 to 2.1) 
–10.3 (–18.6 to –1.9) 
 
 
11.2 (–4.8 to 27.1) 
–8.1 (–23.2 to 7.0) 
0.7 (–11.8 to 13.3) 



























Multivariate analysis, model 1: 
 
Age range ϕ (≥ 35 years as reference) 
      ≤ 18 years 
      19 – 25 years 




P. aeruginosa status † (No P. aeruginosa as reference) 
      Intermittent P. aeruginosa 






–25.3 (–37.8 to –12.9) 
–28.5 (–39.6 to –17.4) 
–18.7 (–28.8 to –8.7) 
 
–8.1 (–19.0 to 2.8) 
 
 
–4.5 (–10.8 to 1.8) 















∆ A coefficient of 1.0 in these analyses indicates an absolute increase of adherence by 1.0% (magnitude of adherence can vary from 0 
to >100%, with higher adherence being more desirable). 
 
ϕ The age categories were based previous studies which demonstrated a U-shaped relationship between adherence and age [5, 200] 
 
¶ The %FEV1 categories were based on previous ESCF studies [360] 
 
† P. aeruginosa status was determined using the Leeds criteria [356] 
 
‡ The deprivation quintile was measured as Index of Multiple Deprivation (IMD) scores, which were derived from postcodes [150]  
 
◊ Gender was included in the multivariate model although the p-value did not reach statistical significance in the univariate analysis 




Compared to people aged ≥35 years, adherence levels of people aged 19–25 years were on 
average 28.5% lower (95% CI 17.4% to 39.6%) after accounting for P. aeruginosa status and 
gender. P. aeruginosa status was also independently associated with adherence – people without 
P. aeruginosa tended to have the highest adherence levels whilst people with chronic P. 
aeruginosa infection tended to have the lowest adherence levels.  
 
Interestingly, there was no significant differences in adherence according to deprivation quintiles.  
Even by analysing deprivation as a binary variable (most affluent quintile vs others), the difference 
in adherence was still not statistically significant, with mean coefficient of 10.3% (95% CI –3.7% to 
24.3%), p-value 0.150. 
 
4.3.2 Results for treatment factors 
 
Most people were on long-term continuous treatments that met the minimum requirements for 
adequacy according to clinical characteristics. Among the 18,303 weeks of adherence data used 
for analysis; 3,898 weeks were suboptimal treatments given a person’s clinical characteristics 
(among 52 people), 4,181 weeks were alternating treatment regimens (among 49 people, eight of 
whom were on “on / off” regimens), and 469 weeks were eradication treatments (among 27 people, 
four of whom had >1 course of P. aeruginosa eradication).  
 
There was no difference between alternating (the vast majority were continuous alternating 
regimens whereby one nebulised antibiotic was alternated with another nebulised antibiotic, 
instead of “on / off” regimens whereby periods on one nebulised antibiotic was alternated with 
periods without inhaled antibiotics) vs continuous treatment regimens (see Table 4.5). Compared 
to longer-term regimens, shorter-term treatments (typically used for P. aeruginosa eradication) 
were associated with an average of 12.4% higher adherence (95% CI 9.5% to 15.3%). 
 
Inadequate prescriptions (e.g. prescribing only one dose of inhaled mucolytics instead of three 
doses of treatments per day for someone with chronic P. aeruginosa infection) may result in 
“higher adherence”. However, the apparent adherence increase of only 4% to 8% was modest in 
comparison to the reduction in denominator by a third or two-thirds.  
 
Both age and P. aeruginosa status remained as independent predictors of adherence in the 
multiple regression model using weekly adherence as the unit of analysis, which included relevant 
demographic and treatment factors (see Table 4.5, multivariate analysis Model 2). This suggests 
that the potential influence of age and P. aeruginosa status on adherence cannot simply be 
explained by older adults with milder phenotypes (thus less likely to be infected by P. aeruginosa) 
being prescribed less complex treatment regimens. This also suggests that similar results would be 





Table 4.5: Summary of results from mixed-effects linear regression models (random effect at 
individual level, to account for repeated measures within an individual) for treatment factors with % 
adherence per week as the dependent variable 
  
 Magnitude of adherence 




Minimum required treatment prescribed § 
 







–5.1 (–6.7 to –3.5) 
 
12.0 (9.1 to 14.9) 
 











Multivariate analysis, model 1: 
 
Minimum required treatment prescribed § 
 
Short-term use ᴪ (P. aeruginosa eradication) 
 
Multivariate analysis, model 2: 
 
Minimum required treatment prescribed § 
 
Short-term use ᴪ (P. aeruginosa eradication) 
 
Age range ϕ (≥ 35 years as reference) 
      ≤ 18 years 
      19 – 25 years 
      26 – 34 years 
 
P. aeruginosa status † (No P. aeruginosa as reference) 
      Intermittent P. aeruginosa 





–5.4 (–7.0 to –3.8) 
 




–6.1 (–7.7 to –4.5) 
 
14.9 (12.0 to 17.8) 
 
 
–37.4 (–41.8 to –33.1) 
–37.2 (–41.0 to –33.3) 
–26.8 (–30.1 to –23.4) 
 
 
–7.4 (–9.3 to –5.6) 























∆ A coefficient of 1.0 in these analyses indicates an absolute increase of adherence by 1.0% (magnitude of adherence can vary from 0 
to >100%, with higher adherence being more desirable). 
 
§ Minimum required treatment according to clinical characteristics was determined based on previously published normative 
definition.[182] Treatment was considered “suboptimal” if the minimum required treatment definition was not met for that week, e.g. a 
person with chronic P. aeruginosa infection who was only prescribed once daily dornase alfa. 
 
ᴪ A treatment regimen was considered “short-term” if treatment duration for that course of treatment was ≤3 months (this is typically 
used for P. aeruginosa eradication). Eradication treatment for non-tuberculous mycobacteria (NTM) is typically two years in duration and 
is therefore considered “long-term use”. 
 
ϕ The age categories were based previous studies which demonstrated a U-shaped relationship between adherence and age [5, 200] 
 




Chapter 4, Section 4: Discussion 
 
4.4.1 Why is the U-shape relationship between adherence and age relevant for CF clinical care?  
 
This study found a U-shape relationship between adherence and age (lowest adherence among 
people aged 19–25 years), even after accounting for various other demographic and treatment 
factors. This finding is in keeping with previous studies.[200, 283]  
 
This finding may partly explain why %FEV1 decline in CF is most pronounced during adolescence 
and young adulthood,[205, 366-368] although this is the age range when most people without CF 
actually reach their peak physical health.[369] There have been various quality improvement 
initiatives targeting the transition care arrangement of adolescents with CF.[370-375] Perhaps 
there is also a need to pay particular attention to the adherence of younger adults with CF, 
although adherence is important for everyone. 
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4.4.2 Is the association between adherence and P. aeruginosa status genuine, or merely an 
artefact of the method to define P. aeruginosa status? 
 
This study also found an association between adherence and P. aeruginosa status defined 
according to the Leeds criteria, which may indicate severity of lung disease. However, this result 
does not necessarily imply that disease severity influences adherence levels among adults with 
CF. Indeed, there was no association between adherence and %FEV1, which is generally 
considered the most important indicator for lung disease severity among people with CF.[205-208].  
 
The association between adherence and P. aeruginosa status in this study should be interpreted in 
light of the Leeds criteria’s potential limitations in defining P. aeruginosa status among adults with 
CF. The Leeds criteria is the most commonly used definition for P. aeruginosa status in CF 
epidemiology research.[356, 376] However, these criteria were developed in a paediatric 
population and there is emerging evidence to suggest that the Leeds criteria work less well among 
adults with CF.[377, 378] The Leeds criteria are based solely on the proportion of positive 
respiratory cultures [356] – recent studies using polymerase chain reaction (PCR) techniques have 
shown that the Leeds criteria are insensitive with a tendency to under-diagnose chronic P. 
aeruginosa as intermittent infection.[379, 380] Higher nebuliser adherence would be expected to 
suppress growth of P. aeruginosa,[378] hence it may be that people who did not culture P. 
aeruginosa in their respiratory samples (i.e. fulfilled the Leeds criteria for no P. aeruginosa) simply 
have higher adherence; instead of disease severity as indicated by P. aeruginosa status genuinely 
impacted on adherence levels.  
 
Therefore, this finding emphasises the need for a better definition of P. aeruginosa status among 
adults with CF. P. aeruginosa status drives the decision to initiate inhaled antibiotics among adults 
with CF [123, 358]  and inadequate prescription of efficacious treatment (“therapeutic inertia”) is 
the second biggest cause of treatment under-utilisation after low adherence.[153, 154] If the 
diagnosis of chronic P. aeruginosa infection were inadvertently missed among people with high 
adherence simply because their respiratory samples were less likely to be culture positive, their 
inhaled antibiotics may be inappropriately stopped with negative consequences on their lung 
health. There is perhaps a role for using formal consensus methods (e.g. nominal group technique 
or Delphi method [381]) in order to explicitly develop a pragmatic definition of chronic P. 
aeruginosa infection among adults with CF that moves beyond solely depending on standard 
microbiological results. 
 
4.4.3 What is the impact of treatment duration on adherence, and why is this relevant for CF care? 
 
In keeping with studies in other subject areas,[222, 223, 227] this study found that adherence to 
shorter-term treatments (for P. aeruginosa eradication) tended to be higher than adherence to 
longer-term treatments. Adherence between P. aeruginosa eradication and longer-term treatments 
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among people with CF had not been directly compared in the past. On one hand, this finding is 
reassuring in that adherence to eradication therapy could be higher than typical adherence levels 
to long-term therapies by 12% to 18%. P. aeruginosa eradication therapy have been shown to 
mitigate %FEV1 decline and delay onset of chronic infection,[358] hence high adherence to these 
therapies would be expected to have substantial long-term health benefits for people with CF. On 
the other hand, this finding emphasises the challenge of maintaining long-term adherence to 
preventative inhaled therapies among adults with CF.  
 
A potential explanation for higher adherence with shorter-term treatments is that people were able 
to summon adequate self-regulation and focus their attention on nebuliser use over a relatively 
brief period of time. Both self-regulation and attention are limited mental resources.[315] A 
potential response to limited resources is conservation,[315, 382] i.e. less effort is exerted in using 
nebuliser to sustain adherence over longer periods or to cope with other CF treatments. Thus, a 
potential ‘cost’ of relying on effortful self-regulation is suboptimal adherence. Qualitative studies 
have described the difficult trade-offs between using treatments and other life goals (e.g. people 
choosing to skip treatment every few days or when feeling well).[251, 252, 259]  
 
It is therefore worthwhile to explore the role of habit in the health behaviour of using nebuliser 
among adults with CF – this is the objective of the studies reported in Chapters 5 & 6. If habit can 
sustain nebuliser adherence, it may be possible to instigate nebuliser use automatically in the 
presence of environment cues, thus by-passing the cognitive effort in deciding whether to instigate 
nebuliser use or to pursue other activities.[250, 314] 
 
4.4.4 Treatment rationalisation (i.e. reducing the number of prescribed doses) is a common 
strategy to support adherence in CF, but is it actually associated with more effective adherence? 
 
Another finding of this study is that treatment rationalisation by reducing the number of prescribed 
nebulisers was only associated with modest increase in adherence by 4% to 8%. An example of 
treatment rationalisation is to reduce the agreed prescription from three nebuliser doses per day 
(i.e. twice daily antibiotics and once daily mucolytic) to just two nebuliser doses a per day (i.e. only 
twice daily antibiotics). If the number of nebuliser doses used remained the same, such a decrease 
in agreed prescription would be expected to increase adherence by 33% (e.g. from 67% to 100% if 
a person continued to use two nebulisers per day and the agreed prescription was reduced from 
three doses per day to two doses per day).  
 
Percentage adherence depends both on the numerator (i.e. the actual number of doses taken) and 
denominator (i.e. the target number of doses to be taken). The observed higher percentage 
adherence among adults on suboptimal prescriptions might be intuitively interpreted as more 
effective use of preventative inhaled therapy (i.e. an increase in the numerator). However, it is 
likely that the increase in percentage is simply driven by a decrease in denominator (i.e. decrease 
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in the target number of doses to be taken each day). Therefore, the observed higher percentage 
adherence among adults on suboptimal prescriptions may counter-intuitively represent a decrease 
in the effectiveness of preventative inhaled therapy. This then raises the question as to whether the 
current methods of quantifying the implementation phase of adherence is adequate to reflect 
effective medication use among people with CF.  
 
According to the ABC taxonomy for medication adherence, in operationalising the implementation 
of a treatment regimen, “clinically relevant definitions need to be developed, indicating which 
deviation from the prescribed medication regimen is sufficient to influence adversely the regimen’s 
intended effect”.[156] Focusing on inhaled therapies for asthma and COPD, the Respiratory 
Effectiveness Group has suggested that successful mastery of the inhaler-specific technique 
should be incorporated in adherence quantification to consider “successful medication adherence 
in a holistic way” because inhaler technique errors would result in failure to receive prescribed 
medications.[383] In other words, trying but failing to use an inhaler correctly should be reflected as 
an “implementation failure”. 
 
However, even with perfect technique, efficacious medications that are required but are not 
prescribed could never be successfully implemented by an adult with CF. In general, inadequate 
prescription of efficacious treatment (“therapeutic inertia”) is the second biggest cause of treatment 
under-utilisation after low adherence.[153, 154] Therapeutic inertia is a particular problem is CF 
because “treatment burden” is widely perceived to be an insurmountable barrier to adherence,[6] 
treatment rationalisation is often employed as a strategy to support adherence,[364] yet treatment 
rationalisation will involve dropping efficacious treatment(s) from an agreed prescription and hence 
reduce the effectiveness of a treatment regimen. At least in other respiratory conditions e.g. 
asthma or COPD, there is the option of using combination inhalers such that treatment 
rationalisation merely involve switching devices without necessarily reducing the effectiveness of a 
treatment regimen (e.g. Trelegy® Ellipta inhaler contains an inhaled corticosteroid, a long-acting 
muscarinic antagonist and long-acting β2-agonist, thus allows triple therapy to be delivered with a 
single puff once daily [384]).  
 
Empirical evidence suggests that therapeutic inertia is a large scale problem in CF. There remains 
substantial variation in the prescription of inhaled treatments,[149-151] and recent research 
showed that only around two-thirds of people with CF were prescribed the recommended 
preventative inhaled therapies.[149, 152] This study showed that at some point during each 
calendar year between 2013 and 2016, 22–29% of the adults using I-neb® in Sheffield were on 
suboptimal treatment regimen based on a normative definition using targets derived from 
consensus guidelines that are informed by randomised control trials.[182] Although this study 
found a consistent year-on-year increase in mean nebuliser adherence among Sheffield adults 
from 43.6% (95% CI 37.1% to 50.2%) in 2013 to 55.1% (95% CI 48.5% to 61.7%) in 2016 and 
there is a trend of improving adherence even after stratification according to age categories (i.e. 
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adherence increase is not merely a function of ageing population), it is still uncertain whether 
“effective adherence” has actually improved over the 4-year period. Since the proportions of adults 
with suboptimal treatment regimen have also increased from 2014 to 2016, the apparent 
adherence improvement may simply be an artefact of treatment rationalisation. After all, the only 
other adherence dataset which spanned over two years showed static adherence levels in a CF 
centre over a 5-year period,[177] and there are no effective interventions to support adherence in 
routine clinical practice. These examples add to the argument that perhaps there is a need to 
quantify CF “adherence” in a way that reflects effectiveness of a treatment regimen, by taking into 
account a person’s clinical characteristics in defining the minimum required treatment. Such a 
method of quantifying adherence may allow the actual impact of “treatment rationalisation” among 
people with CF to be better understood, and could potentially guide prescribing decisions.  
 
4.4.5 Is a more complex treatment regimen associated with lower adherence? 
 
Previous observational studies found that adherence tended to increase with higher numbers of 
prescribed medications (i.e. increasing regimen complexity) [283] and that adherence levels were 
similar regardless of number of prescribed nebuliser doses.[116, 176] This study found that 
alternating regimens (usually more complex than continuous regimens because the vast majority of 
these consisted of continuous alternating regimens which involved alternating between different 
nebulised antibiotics at fixed time intervals) and continuous regimens tended to achieve similar 
adherence levels. On a similar note, adherence among people with CF related diabetes (who 
typically have higher treatment burden since they need to incorporate insulin use in their treatment 
regimens [355, 361-363]) also did not differ from people without CF related diabetes. 
 
While these findings within observational datasets indicate that treatment complexity does not offer 
sufficient explanation for low adherence, this is certainly not to say that increasing the number of 




Prescribing decisions in the real world may be biased by clinicians prescribing more complex 
regimens only to those most able to cope.[212] Therefore, the lack of association between nature 
of treatment regimen and adherence should be interpreted with caution in this observational study. 
Likewise, it is also premature to conclude that treatment rationalisation would cause a decline in 
actual number of nebuliser doses taken (i.e. the “clinical effectiveness of adherence”), although 
treatment rationalisation is definitely not associated with an increase in the number nebuliser doses 
taken. This is because most of the ‘suboptimal prescriptions’ in this dataset are likely to be a 
response to low adherence, with treatment reductions agreed in an attempt to try increase the 
confidence or self-efficacy of people who were struggling to adhere with their previous treatment 
regimen. Previous studies in other long-term conditions have also shown that therapeutic inertia 
67 
 
was more likely among patients with low adherence (who were perceived by clinicians as less 
willing to accept efficacious treatments).[212] It may be that the number of nebuliser doses taken 
by adults with CF would also continue to decline if an effective treatment regimen was maintained 
instead of lowering the treatment targets. These important empirical questions are difficult to 
answer using observational datasets. Current methods of quantifying CF “adherence” without 
accounting for the effectiveness of a treatment regimen is another barrier to answering these 
important empirical questions.  
 
The second limitation of this study is the relatively small sample size. An effect can only be 
detected in a small study if the effect size is sufficiently large.[232] For example, based on the 
confidence intervals reported in Table 4.4 (–20.7 to 1.3 for gender difference in adherence), this 
study is not adequately powered to detect difference in adherence of 10% between males and 
females. A 10% difference in adherence may well be clinically relevant and this study certainly 
does not exclude the possibility that females have lower adherence than males, especially since 
females were also less likely to be on I-neb® compared to males (for each calendar year, >60% of 
males were on I-neb® but <50% of females were on I-neb® – this is likely to reflect patient 
preference rather than indication bias because there is no clinical reason to target nebuliser type 
according to gender).  
 
On the same note, the small number of people in the most affluent socioeconomic quintile (~15% 
of the sample) meant that the analysis was not powered to detect an adherence difference of 10% 
between people in the most affluent quintile and other deprivation quintiles. The lack of clear 
differences in adherence among the four other quintiles may also be the result of the way CF care 
is delivered in Sheffield, where frequent multidisciplinary team meetings develop explicit strategies 
to support people living in more deprived areas using interventions such as home visits, rather than 
a generalisable finding in other datasets. Throughout 2013 to 2016, the socioeconomic deprivation 
profile of adults on I-neb® is similar to adults not on I-neb®, which suggests an equitable structure 
in terms of using appropriate devices to deliver preventative inhaled therapies in Sheffield. There is 
also a trend of improving adherence across all deprivation quintile, which suggests that no 
Sheffield adult is being left behind on the basis of socioeconomic deprivation.  
 
Recognising the limitations of the Sheffield dataset, this thesis did not seek to separate out the 
potential influence of the two different forms of alternating treatment regimens – “on-off” regimen 
(which might represent the lowest “treatment burden” since a month on nebulised antibiotics is 
followed by a month off nebulised antibiotics which may allow self-regulatory resources to be 
replenished) vs continuous alternating regimen (which might represent the highest “treatment 
burden” since a person is continually on nebulised antibiotics and is required to alternate between 
different forms of antibiotics at a regular interval, which may require slightly different methods of 
administration, hence may undermine a stable context to maintain behaviour). Only eight out of 
126 adults provided adherence data during on-off antibiotics treatment regimens, hence it would 
not be possible to reliably detect a difference. 
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Chapter 4, Section 5: Conclusions 
 
Despite the limitations listed, this is the first systematic exploration of the relationship between a 
range of demographic & treatment factors and objective nebuliser adherence over a four year 
period. The Sheffield dataset is currently the largest EDC adherence dataset in CF with 18,303 
weeks of adherence data from 126 adults with CF. Since all eligible adults receiving care at the 
Sheffield Adult CF centre are included in the dataset, this study has a lower risk of selection bias 
compared to other CF-related studies. Inclusion of all eligible adults also allows more appropriate 
interpretations of the findings from a whole system perspective. For example, the lack of clear 
differences in adherence between different socioeconomic deprivation quintiles noted in Sheffield 
could be interpreted in light of evidence suggesting an equitable structure to deliver preventative 
inhaled therapies in Sheffield whereas the UK CF registry data suggest that adults from more 
deprived areas were less likely to receive preventative inhaled therapies;[150] i.e. there may be 
care delivery reasons for that particular finding in Sheffield, rather than assuming the finding is 
generalisable to other datasets.     
 
Nonetheless, by confirming the important relationship between adherence and age found in 
previous studies using MPR data, it is clear that young adults with CF are particularly at risk of low 
adherence and perhaps targeted intervention is required for the 19–25 years age range. It is also 
important to account for age as a potential case-mix confounder when comparing adherence levels 
between different CF centres. Given the role of centre-comparisons and benchmarking in 
transforming the care of people with CF,[346, 385-387] it is likely that comparisons using 
adherence as a quality indicator has the potential to drive improvement in medication adherence. 
However, centre-comparison is only meaningful and useful if confounding factors are appropriately 
adjusted for.  
 
In addition, this study highlights the challenge of sustaining longer-term adherence and points 
towards the importance of exploring the potential role of habit to sustain long-term self-care – this 
is the objective of Chapters 5 & 6. There are also findings from this study which raise questions 
regarding the suitability of using the Leeds criteria to define P. aeruginosa status among adults 
with CF, and the adequacy of quantifying the implementation phase of adherence without taking 
into account the effectiveness of prescribed treatment regimens. Methods to define P. aeruginosa 
status and to quantify adherence are further explored as part of the PhD research, but are beyond 
the scope of this thesis.  
  
Since a single-centre analysis such as this study may lack generalisability, further analyses using 
larger prospectively collected objective adherence datasets among other cohorts of adults with CF 
would be desirable. The on-going CFHH RCT (ISRCTN55504164) and CFHH improvement 
collaborative (ISRCTN14464661), which has recruited more than 500 and 200 participants 
respectively, will offer the opportunity to better understand how demographic and treatment factors 
can influence nebuliser adherence among adults with CF. 
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CHAPTER 5: AN EXPLORATORY MIXED METHODS STUDY COMPARING LOW AND HIGH 
NEBULISER ADHERERS 
 
The literature review in Chapter 3 identified that most studies of adherence determinants among 
people with CF eschewed explicit psychological theory, focusing instead on the practical barriers 
and facilitators to adherence. Treatment burden, often operationalised as the duration, frequency 
and complexity of treatment regimens, is the focus of many studies seeking to explain low 
adherence in CF.  
 
The Capability, Opportunity and Motivation (COM-B) model posits three factors necessary for any 
behaviour to occur: perception of capability, opportunity and motivation.[305] Hence, there is a 
need to understand adherence determinants from a broader perspective. Understanding nebuliser 
adherence also requires focusing not only on the barriers among people with low adherence, but 
those who consistently adhere. In Chapter 4, the Sheffield dataset found that some people can 
maintain consistently high adherence over many years. Similar findings have also been shown in 
other cohorts of people with CF.[176] 
 
High-adherers may have better self-regulatory skills or resources (i.e. greater psychological 
capability), which may explain why the analyses in Chapter 4 found higher adherence to shorter-
term P. aeruginosa eradication therapy compared to longer-term regimens. Previous studies have 
identified people with CF intentionally not using nebulisers [251, 252, 259] to cope with concurrent 
CF treatments while others have reported “on-off” inhaled antibiotics regimen to be more 
tolerable,[245] which may reflect a need to replenish self-regulatory capacity during non-use 
periods.[315]  
 
High-adherers may perhaps be better able to routinise nebuliser use. ‘Routinisation’ (i.e. fostering 
of contextually stable and persistent behaviour patterns) has been reported as a facilitator of CF 
nebuliser use.[251, 259] This raises the possibility that long-term nebuliser adherence may be 
sustained by non-reflective motivational processes such as habit. Habit, i.e. a process by which 
situational cues (e.g. time) automatically generates an impulse towards enacting a behaviour (i.e. 
using nebuliser) [250] was discussed in Section 3.4. Habitual behaviours can be discerned into 
habitually instigated sequences (e.g. nebuliser use episodes that are triggered at the same time of 
day) and habitually executed actions (e.g. nebuliser use performed in an automated and unvarying 
sequence). While habitual instigation tendency is likely to predict the frequency of nebuliser use 
episodes,[328, 329] habitual execution tendency may perhaps also support adherence by making 
progression through the procedural intricacies of nebuliser use easier to perform.[328]   
 
Habit forms through a process of ‘context-dependent repetition’, whereby repeated performance in 
the consistent presence of environmental cues (e.g. location or mood) reinforce the mental cue-
action association.[250] Unstable contexts may thus preclude habit formation.[388] This may be 
one reason that ‘chaotic’ lifestyles, which lack structure and predictability, are associated with 
lower medication adherence.[389, 390] 
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Chapter 5, Section 1: Introduction 
 
Previous studies of the determinants of nebuliser adherence among people with CF have been 
limited by a focus on self-reported adherence, reflective motivational constructs, and barriers 
among low adherers, rather than facilitators among high adherers. Theory suggests that both 
reflective and non-reflective processes influence medication adherence among adults with CF, but 
this has yet to be empirically explored.  
 
The present study used objective adherence data to identify both low and high adherers, and 
investigated potential factors that may discriminate between these two groups with a focus on both 
reflective and non-reflective processes. Treatment burden (treatment complexity and perceived 
treatment burden), self-regulation, life chaos, habit (‘non-specific’, instigation, execution), intention, 
capability and opportunity were the hypothesised adherence predictors explored in this study. A 
mixed methods design [391] was used to quantify relationships between potential determinants 
and adherence, and also to offer in-depth insights into the specific beliefs, attitudes and values that 
may underpin such relationships. 
 
 




This was a mixed methods cross-sectional exploratory study among adults with CF, selected to 
represent high nebuliser adherence (≥80% annual adherence), and low nebuliser adherence 
(<50% annual adherence). Adherence of ≥80% is considered ‘high’ because such an adherence 
rate yields better health outcomes.[200, 392] Adherence of <50% indicates a general tendency not 
to adhere, and is considered ‘low’. 
 
People with CF aged 16 or over were identified by their clinical team and sent a study information 
pack two weeks before their routine clinical visits. Data collection was timed to coincide with 
routine review visits at the CF centre. After review by their usual clinical team, which in accordance 
with standard procedures involved provision of personalised feedback on objective nebuliser 
adherence level, the PhD student (HZH) approached potential participants and invited them to take 
part. Those who consented were asked to verify the veracity of prescribed treatments as recorded 
in the medical notes. Next, they completed a questionnaire comprising measures of potential 
adherence predictors, and subsequently a face-to-face semi-structured interview. Interviews lasted 
30-60 minutes to broadly explore participants’ experiences around nebuliser use. The interview 
topic guide was sufficiently open to allow emergence of new insights (see Table 5.1). The topic 
guide was informed by the extant literature in similar clinical areas [259] and the clinical experience 
and expertise of the research team. It was refined after the first four interviews, taking into account 
the results of the initial four interviews.  
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Table 5.1: Topic guide for the semi-structured interview 
 









(A) Have you made any 
adaptations / changes to 
help you use your 
nebuliser? 
• Clarify what adaptations / changes 
were made e.g. changes to 
routines, changes to lifestyle. 
• Clarify what makes it difficult for 
the participant to use his / her 
nebuliser … 
• Clarify what strategies the 
participant use to overcome those 
difficulties … 
• Clarify what makes it easier for 
the participant to use his / her 
nebuliser … 
• Any suggestions / advice from the 
participant to help others use their 
nebuliser?  
• Can you please 
clarify what you 
meant by …? 
• Can you please 
expand a little on 
…? 
• Can you please 
give some 
examples of …? 
• In particular, what 
do you think of 
…? 
(B) Have you used reminders 
/ cues / routines to help 
you remember to use 
your nebuliser? 
• Clarify what reminders / cues / 
routines that the participant has 
tried … 
• Clarify what reminders / cues / 
routines work best for the 
participant  … 
• Any perceived advantages of a 
particular reminders / cues / 
routines?  
• Any perceived disadvantages of a 





Additional questions for the iterated topic guide: 
 
 
• Check whether in work / study. 
• What is the relationship between work / study with routine? 
• How does the use of nebuliser vary with the day of the week? Why? 
• How does the use of nebuliser vary with the time of day? Why? 
• What happens when “out of routine” – e.g. holidays 
• What is the support from family to manage nebuliser use (parents / partners / others)? 
• What is the support from the clinical team? What is the role of individual team members? 
Helpful / not? 
• If people describe symptoms – explore more. 






Digitally recorded interviews were transcribed verbatim. Participants were offered the option to 
review their own interview transcript for data verification.  
 
All the participants were known to the PhD student who performed the interviews and analysed the 
data, since he worked as a doctor with the CF clinical team for ~18 months prior to data collection. 
However, nebuliser adherence is not typically an issue that entails detailed discussion between 
doctors and adults with CF in the centre, with physiotherapists taking a lead on this for the 
multidisciplinary team.  
 





Participants were recruited from the Sheffield Adult CF Centre, which at the time of data collection 
(May to August 2015) had 203 registered patients aged ≥16 years diagnosed, to the UK CF Trust 
criteria,[348] as having CF. Eligible participants with CF used I-neb® as part of their routine 
treatment and had baseline objective annual adherence of either ≥80% or <50%. People in the 
palliative phase of disease, pregnant women, those with transplanted lungs or actively listed for 
lung transplantation, or lacking capacity to consent were excluded. 
 
A target sample size of 20–24 participants (i.e. 10–12 people with ≥80% adherence, 10–12 with 
<50% adherence) was set. This was deemed sufficient to achieve theoretical saturation in 
qualitative analysis,[393] while also feasible given a limited pool of eligible participants within a 
single CF centre. Of 36 eligible adults with CF (18 high, 18 low adherence) attending clinical 
reviews from May to August 2015, 20 participated (10 high, 10 low adherence; 56% recruitment 




5.2.3.1 Demographic data and health outcomes  
Demographic data were obtained from medical notes.  
Best lung function was operationalised as the highest %FEV1 calculated with the Knudson 
equation [394] for a 1-year period up to the day of recruitment.  
Severity and frequency of pulmonary exacerbations were captured via total intravenous (IV) 
antibiotic days over the same 1-year period. 
 
5.2.3.2 Nebuliser adherence  
Objective nebuliser data were downloaded from I-neb®. The implementation phase of adherence 
was calculated as a percentage between total amount of medications used against the dose 
agreed between clinicians and adults with CF.  
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5.2.3.3 Hypothesised predictors of adherence  
Unless stated, all hypothesised predictors were self-reported using items with which participants 
rated agreement from 1 (strongly disagree) to 7 (strongly agree). These items are listed in Table 
5.2. 
 
Table 5.2: The 28 items used in the questionnaire 
 
1. Pleasure and fun sometimes keep me from getting work done – to measure self-regulation 
 
2. I do not like to make appointments too far in advance because I do not know what might come up – to measure life 
chaos 
 
3. My life is unstable – to measure life chaos 
 
4. I do certain things that are bad for me, if they are fun – to measure self-regulation 
 
5. Keeping a schedule is difficult for me – to measure life chaos 
 
6. I often act without thinking through all the alternatives – to measure self-regulation 
 
7. I am good at resisting temptation – to measure self-regulation 
 
8. My life is organised – to measure life chaos 
 
9. I wish I had more self-discipline – to measure self-regulation 
 
10. I have a hard time breaking bad habits – to measure self-regulation 
 
11. My routine is the same from week to week – to measure life chaos 
 
12. My daily activities from week to week are unpredictable – to measure life chaos 
 
13. People would say that I have iron self- discipline – to measure self-regulation 
 
14. Sometimes I can’t stop myself from doing something, even if I know it is wrong – to measure self-regulation 
 
15. Using my nebuliser is something I do without thinking – to measure non-specific habit 
 
16. My nebuliser treatment is too time-consuming to manage within my daily life – to measure ‘subjective’ treatment 
burden 
 
17. Using my nebuliser is something I do without having to consciously remember – to measure non-specific habit 
 
18. If I wanted to, nothing gets in the way of me using my nebuliser – to measure opportunity 
 
19. If my nebuliser is working properly, I would feel capable of using my nebuliser – to measure capability 
 
20. I intend to use my nebuliser – to measure intention 
 
21. Using my nebuliser is something I do automatically – to measure non-specific habit 
 
22. I feel I have adequate opportunity to use my nebuliser – to measure opportunity 
 
23. Using my nebuliser is something I start doing before I realise I’m doing it – to measure non-specific habit 
 
24. I want to use my nebuliser – to measure intention 
 
25. My nebuliser treatment makes my daily life more difficult – to measure ‘subjective’ treatment burden 
 
26. I could overcome barriers to using my nebuliser if I invest the necessary effort – to measure capability (self-efficacy) 
 
27. Deciding to use my nebuliser is something I do without having to consciously remember – to measure instigation 
habit 
 
28. Once I have decided to use my nebuliser, using my nebuliser is something I do without having to consciously 
remember – to measure execution habit 
 
 
Treatment burden was measured in two ways. ‘Objective’ burden was measured via the Treatment 
Complexity Score,[213] which assigns a value of 1, 2 or 3 (3 = highest burden) to the 37 CF 
maintenance therapies, producing a single score from 0 (no burden) to 72 (highest burden). 
‘Subjective’ burden was self-reported using two items modified from the CF Questionnaire-
Revised,[395] e.g. “My nebuliser treatment makes my daily life more difficult”; α = 0.74. 
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Self-regulation was measured with eight items from the Brief Self-Control Scale,[396] e.g. “I am 
good at resisting temptation”; α = 0.68.  
 
Life chaos was measured via six items from the Modified Confusion, Hubbub and Order Scale 
Life,[389] e.g. “My life is organised”; α = 0.68.  
 
Habit strength was measured in three ways. The habitual nature of nebuliser use was measured 
using items from the Self-Report Behavioural Automaticity Index (SRBAI).[336] A sequence of 
‘habitual’ behaviour can be habitually triggered (habitual instigation) and/or automatically 
performed to completion after being triggered (habitual execution).[328] As originally formulated 
however, the SRBAI does not distinguish between habitual instigation or execution, but rather 
offers a non-specific habit measure that potentially incorporates elements of instigation and 
execution.[328] The original SRBAI wording formulation was used to measure non-specific habit 
with four items (e.g. “Using my nebuliser is something I do without thinking”; α = 0.82). To aid 
identification of the precise location of habit in nebuliser use sequences, habitual instigation and 
habitual execution were also measured. To minimise participant burden, habitual instigation and 
execution were each measured using a single item from the SRBAI, which differed only in the item 
stem (instigation: “Deciding to use my nebuliser …”; execution: “Once I have decided to use my 
nebuliser, using my nebuliser …” [“… is something I do without having to consciously 
remember”].[328] This item was selected on the basis that, of four SRBAI items, it showed the 
strongest item-total agreement in pilot data among 15 adults with CF.[397]  
 
Intention (e.g. “I intend to use my nebuliser”; α = 0.88), opportunity (α = 0.38) and capability (α =         
–0.43) were each measured using two items adapted from the COM-B Self-Evaluation 
Questionnaire.[398] Lack of reliability suggested that items were measuring different facets of 
opportunity and capability (e.g. control over external barriers vs self-efficacy [399]). Opportunity 
and capability were thus represented in the analysis by two single items, labelled according to 
which specific facet was assessed (opportunity: “If I wanted to, nothing gets in the way of me using 
my nebuliser” [hereafter, ‘opportunity, absence of obstacles’], “I feel I have adequate opportunity to 
use my nebuliser” [‘opportunity, generic’]; capability: “If my nebuliser is working properly, I would 
feel capable of using my nebuliser” [‘capability, external control’], “I could overcome barriers to 




5.2.4.1. Integration between quantitative and qualitative components  
Quantitative and qualitative data were collected concurrently.[391] The “following a thread” 
technique was used to integrate analyses.[400] Key differences (‘threads’) observed in initial 
quantitative analysis between high and low adherers prompted consultation of qualitative data to 
aid interpretation and key insights (‘threads’) obtained from initial qualitative analysis prompted 
consultation of quantitative data.  
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5.2.4.2 Quantitative data analysis 
Quantitative analysis involved describing and comparing characteristics of ‘high’ and ‘low 
adherers’. Due to the pragmatic but small sample size, null-hypothesis significance testing was not 
performed. Thus, effect sizes and confidence intervals are reported, but not p values.[401] Due to 
a non-normal data distribution and presence of outliers, non-parametric methods [402] were used 
to estimate group differences and confidence intervals for all continuous variables. This method 
assumes the two groups have the same distribution shifted by a fixed parameter. The shift 
parameter is not necessarily the difference in medians, rather it is the median of all possible 
differences. For categorical data, difference in proportions and confidence intervals were 
calculated using the Wilson procedure without continuity correction.[403] Linear correlation 
between continuous variables was determined using non-parametric method (Spearman’s 
rho).[404]  
Due to the strong association between age and adherence found in the analyses of Chapter 4, 
adherence levels were mapped across the four age categories used in previous studies [200, 283] 
and in Chapter 4: ≤18 years (N = 5), 19–25 years (N = 5), 26–34 years (N = 6), ≥35 years (N = 4). 
For variables shown to differentiate high and low adherers, follow-up analyses documented scores 
of these variables across the four age categories. All pertinent effects observed for non-specific 
habit were also followed up with analyses to determine whether such effects were attributable to 
habitual instigation or habitual execution. 
In light of a ‘thread’ that emerged from qualitative analysis, further exploratory analyses of habit 
were run. In these analyses, the sample was dichotomised into those who ‘had habit’ (high level of 
automaticity, habit score ≥4, i.e. at or above the scale midpoint [405]) or ‘had no habit’ (habit score 
<4), on each of the three habit measures (i.e. had non-specific habit vs no non-specific habit, had 
instigation habit vs no instigation habit, had execution habit vs no execution habit).  
All quantitative analyses were run using R v3.3.0 (www.r-project.org). Graphs were generated 
using Prism v7 (GraphPad Software). 
 
5.2.4.3 Qualitative data analysis 
Qualitative data were thematically analysed using a general inductive approach [406] involving 
data familiarisation, generating initial codes, and iteratively searching for, reviewing, defining and 
naming themes. NVivo v10 (QSR International) was used to organise analysis. Data were collected 
and analysed concurrently by the interviewer (the PhD student), with two experienced qualitative 
researchers verifying the appropriateness of data interpretations (JB, BG).  
The PhD student read all transcripts several times for familiarisation and generated initial codes. 
JB independently analysed six (30%) transcripts to search for themes and verified that theoretical 
saturation had been reached at 17 interviews, as no further insights emerged from subsequent 
analyses. A shared analytic framework was agreed upon through discussions between the two 
coders. The PhD student then extracted pertinent data using the agreed coding framework. At this 
stage, it was apparent that some of the emergent themes tied up closely with the concept 
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addressed in the questionnaire, and this helped the organisation of codes into broader themes. 
Finally, these themes were reviewed and refined in discussion with BG.  
 
 
Chapter 5, Section 3: Results 
 
5.3.1 Quantitative results 
 
Low adherers tended to be younger and had higher %FEV1, yet had more severe or frequent 
pulmonary exacerbations, i.e. greater IV antibiotics use; median of differences 10 days (95% CI     
–4 to 31 days); see Table 5.3.  
 
Table 5.3: Clinical characteristics and outcomes of high (N = 10) and low (N = 10) adherers 
 
 
Low adherers (N = 10) 
Median (IQR) 
 




Median of differences 
between groups (95% CI) 
 




28.0 (5.3 to 46.0) 
 
94.9 (86.7 to 108.5) 
 
–69.1 (–92.6 to –48.9) 








0.20 (–0.20 to 0.53) 
 
Best %FEV1 for the 
previous year  
 
88.0 (80.0 to 96.3) 
 
77.0 (56.0 to 86.0) 
 
13.0 (–4.0 to 31.0) 
 




13 (0 to 50) 
 
7 (0 to 16) 
 
10 (–4 to 31) 
  
‡ For gender, the proportion of female participants in each group and difference in proportion (95% CI) were displayed 
 
In keeping with the findings in Chapter 4, median adherence was lowest among participants aged 
19–25 years (25.3%, IQR 3.3% to 93.8%), and highest among those aged ≥35 years (94.9%, IQR 
58.4% to 96.2%). Participants of this study have similar clinical characteristics in comparison to 
other non-participating adults in the CF centre (see Table 5.4), suggesting that the samples within 
each adherence group are representative of the wider Sheffield population. 
 
Table 5.4: Clinical characteristics of the participants in comparison to the local population of adults 




participants (N = 10) 
median (IQR) 
 
Low adherers,  
non-participants †  








(N = 18) 
median (IQR) 
 
% Nebuliser adherence 
in previous year 
  
 
28.0 (5.3 to 46.0) 
 
23.1 (10.7 to 34.6) 
 
94.9 (86.7 to 108.5) 
 
96.7 (89.8 to 99.3) 












Best %FEV1 for the 
previous year  
 
88.0 (80.0 to 96.3) 
 
80.5 (61.0 to 96.0) 
 
77.0 (56.0 to 86.0) 
 
85.0 (73.3 to 89.5) 
 




13 (0 to 50) 
 
22 (9 to 35) 
 
7 (0 to 16) 
 
2 (0 to 22) 
  
† For non-participants, data from 01 January 2015 to 31 December 2015 were used. 
‡ For gender, the proportion of female participants in each group and difference in proportion (95% CI) were displayed 
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Scores on most potential predictors were similar across both groups (see Table 5.5 and Figure 
5.1). However, low adherers had slightly lower self-regulation scores (median of differences –0.8, 
95% CI –1.4 to 0.0). There were moderate to large differences in opportunity and non-specific habit 
scores between the two groups of participants, and a strong positive correlation between those two 
variables (‘Opportunity, absence of obstacles’ r = 0.66, 95% CI 0.30 to 0.85; ‘Opportunity, generic’ 
r = 0.75, 95% CI 0.46 to 0.90). Follow-up analyses suggested that opportunity-habit correlations 
were for instigation habit (‘Opportunity, absence of obstacles’ r = 0.47, 95% CI 0.03 to 0.75; 
‘Opportunity, generic’ r = 0.51, 95% CI 0.09 to 0.78), rather than execution habit (‘Opportunity, 
absence of obstacles’ r = 0.43, 95% CI –0.01 to 0.73; ‘Opportunity, generic’ r = 0.34, 95% CI –0.11 
to 0.68). 
 
Table 5.5: Psychological factors among high (N = 10) and low (N = 10) adherers 
  
Low adherers (N = 10) 
Median (IQR) 
 




Median of differences 
between groups (95% CI) 
 
Treatment complexity  
        score 
  
 
14.5 (10.0 to 15.3) 
 
15.5 (10.0 to 16.5) 
 
–1.0 (–5.0 to 4.0) 
Perceived treatment  
        burden 
 
2.3 (1.4 to 3.6) 
 
1.8 (1.0 to 3.5) 
 




4.6 (3.7 to 4.9) 
 
5.4 (4.5 to 5.8) 
 
–0.8 [–1.4, 0.0] 
 
Life chaos  
 
4.5 (3.8 to 5.3) 
 
5.4 (4.7 to 5.7) 
 





6.8 (6.4 to 7.0) 
 
7.0 (6.3 to 7.0) 
 
0.0 [–0.5, 0.5] 
 




6.0 (4.0 to 7.0) 
6.0 (4.8 to 6.0) 
 
7.0 (7.0 to 7.0) 
6.5 (2.5 to 7.0) 
 
–1.0 (–3.0 to 0.0) 
–1.0 (–1.0 to 3.0) 
Opportunity, absence of  




3.5 (2.0 to 6.0) 
 
5.0 (2.8 to 6.0) 
 
6.5 (5.8 to 7.0) 
 
6.0 (5.0 to 7.0) 
 
–3.0 (–4.0 to –1.0) 
 
–1.0 (–3.0 to 0.0) 
 
Habit: 
        Non-specific habit 
        ‘Instigation habit’ 




3.1 (2.2 to 4.0) 
4.0 (2.8 to 5.0) 
5.0 (4.8 to 5.3) 
 
 
5.6 (4.4 to 6.3) 
6.5 (4.8 to 7.0) 
7.0 (6.6 to 7.0) 
 
 
–2.3 (–3.5 to –1.0) 
–2.0 (–3.0 to –1.0) 
–2.0 (–2.0 to –1.0) 
 
 
Low adherers reported non-specific habit scores that were on average 2.3 points lower than high 
adherers on a 1 to 7 scale (95% CI –3.5 to –1.0). ‘Instigation habit’ may have better differentiated 
between high adherers (median 6.5, IQR 4.8 to 7.0) and low adherers (median 4.0, IQR 2.8 to 5.0); 
median of differences 2.0 (95% CI 1.0 to 3.0), than did ‘execution habit’ (high adherers median 7.0, 
IQR 6.6 to 7.0; low adherers median 5.0, IQR 4.8 to 5.3; median of differences 2.0, 95% CI 1.0 to 
2.0). High adherers were more likely to ‘have non-specific habit’ (9/10 high adherers vs 3/10 low 
adherers; difference in proportion 0.60, 95% CI 0.17 to 0.81). High adherers (9/10) tended to be 
more likely to ‘have instigation habit’ than did low adherers (6/10; difference in proportion 0.30 95% 





Figure 5.1: Scatter-dot plots displaying the differences in nebuliser adherence, habit and opportunity scores 
for low vs high adherers 
 
Follow-up analyses of habit and opportunity scores according to age showed that participants aged 
19–25 years (lowest adherence) reported the lowest instigation habit scores (median 3.0, IQR 2.5 
to 4.5), whilst adults aged ≥35 years (highest adherence) reported correspondingly high instigation 
habit scores (median 6.0, IQR 2.8 to 7.0). In contrast, opportunity scores were relatively similar for 
the different age groups (see Figure 5.2). 
 
Figure 5.2: Scatter-dot plots displaying the differences in nebuliser adherence, habit and opportunity scores 
according to the four age groups 
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5.3.2 Qualitative results 
 
Four themes underpinned participants’ experience of using inhaled therapy: ‘awareness & 
experiences of health consequences’, ‘cues, routinisation & automaticity’, ‘prioritisation’ and 
‘coping with treatment burden’. 
 
5.3.2.1 Awareness and experiences of health consequences 
 
Knowledge and experience of the health benefits of using, and not using nebulised treatments 
appeared important in motivating nebuliser use for both low and high adherers, regardless of age. 
  
[Not using] my DNase will [make it] harder to cough up and get rid of bugs, get rid of all the mucus. [Not using] my 
Promixin means my Pseudomonas will probably come back again and I don’t want to get down that route again. 
P17, high adherence, ≤18 years 
 
Symptoms during acute periods of ill health (for example during pulmonary exacerbations) 
reportedly made nebuliser use seem more effortful. However, high adherers took steps to persist 
with their treatments in spite of such difficulties (‘If I’ve got to take it, doesn’t matter if I’m unwell or well, I’ve 
still got to take it in that day’; P3, high adherence, ≥35 years), and indeed for some, ill-health increased 
motivation to use nebuliser treatment, as a means to avoid further worsening of health. 
 
Two low adherers (one 19–25 years, another 26–34 years) relied exclusively on experiencing 
symptoms to prompt their nebuliser treatment, such that they did not use nebulisers when they felt 
well.  
 
I can have good days where I feel good for a week, where doing any treatment doesn’t come into mind. [But on other 
days] I might wake up and feel shocking. That’ll prompt me [to use my nebuliser], and then it’ll take me a bit to recover. 
P15, low adherence, 26–34 years 
 
Most nebulised treatments have no immediate noticeable impact, and both the two low adherers 
reported that the relative ‘invisibility’ of health benefits made it difficult for them to appreciate the 
necessity of using nebuliser. 
 
If somebody sees me at gym, I just want to do gym. I want to get in shape more. You can see a physical shape in 
yourself. You can’t see your lung, can you? You can’t see what’s going off there. It’s not like you can look [inside] them. 
P7, low adherence, 19–25 years 
 
Some participants preferred treatments with more immediate and tangible benefits (i.e. hypertonic 
saline, which typically stimulates vigorous coughing and increases sputum expectoration) over a 
treatment with less visible consequence (dornase alfa or DNase, which more effectively improves 
lung function but generally produces no immediate perceivable changes [407, 408]). 
 
Hypertonic saline makes an instant difference. Whereas DNase I don’t know if it does [make a difference] or not, but I 
just believe in it. […] Hypertonic saline definitely has a massive positive effect on my chest. So for that reason, I don’t 
miss [opportunities to use my hypertonic saline] … but [this is] not [necessarily the case for] my DNase 
P13, high adherence, ≥35 years  
 
High adherers often reported experiencing benefits of nebulised treatments, or had experienced 




When I first started [using my nebuliser] I remember the benefit with your lung function … it also means that you don’t 
have to go in [to hospital] for [intravenous antibiotics] as often. 
P9, high adherence, 26–34 years 
 
I don’t get half as chesty using [my nebuliser regularly] now, than when I didn’t use it. 
P1, high adherence, ≥35 years 
 
While high adherers reported having in the past been prompted by experiencing symptoms, for 
most, nebuliser motivation appeared to have shifted towards being regulated by anticipation of ill-
health arising from non-use. For example, two high-adherers (one 19–25 years, another 26–34 
years) reported having experienced highly aversive severe pulmonary exacerbation in the past due 
to non-adherence, and this served as a motivational reminder of the importance of nebuliser use. 
However, experiencing symptoms or recalling symptomatic episodes did not appear to be the 
predominant trigger for high adherers; rather, for most high adherers, nebuliser use had become 
embedded within their everyday routines and was no longer directed by deliberative reasoning 
processes: 
 
If I’ve missed my morning [nebulised treatment], by about 3 o’clock I can feel in me that I need to have [my nebulised 
treatment]. 
P13, high adherence, ≥35 years 
 
5.3.2.2 Cues, routinisation and automaticity 
 
Establishing a ‘treatment routine’ appeared important and the term “routine” was spontaneously 
mentioned by most participants. Nebuliser use was commonly incorporated into existing CF-related 
treatment routines or as a standalone medication activity routine within ostensibly unrelated daily 
activities. 
 
If I’m taking my Promixin, I’ll take it with my other medication at night, because I have other medication at night as well. 
P1, high adherence, ≥35 years 
 
First thing in a morning, I take my dogs out, come back, then the first thing I do is go to the fridge, get my DNase out. It’s 
just a habit, every day. 
P3, high adherence, ≥35 years 
 
All high adherers described automatically ‘remembering’ to use their nebuliser. High adherers 
seemed to have more durable routines and described finding their treatments less burdensome 
due to routinisation. 
 
Once I have fixed a routine that works for me …, I can [use my treatments] all the time. I suppose I don’t have to think 
about it. […] I am not constantly having to make adjustments. 
P12, high adherence, 26–34 years  
 
Although low adherers also described automaticity to a certain extent, they tended to describe a 
more ‘reflective’ process of remembering to use their nebulisers. 
 
[Nebulised medication] is probably the only drug I have to think about doing it, I have to gear myself up to using it. With 
my oral medications, basically I just incorporate that into my lifestyle … but with my nebulisers, I have to sort of prepare 
myself to have them. 




Some low adherers struggled to incorporate nebuliser use into their existing routines due to 
irregular lifestyle, sometimes due to busy and unpredictable working patterns. 
 
I’d have to finish work, because that’s work. Then I’d come home tired and exhausted ... and that’s why I normally 
[missed my evening nebuliser], because I’m asleep. […] When I’m on the routine of taking the nebuliser, [I always bring 
it] to work but I don’t always get the opportunity to use it during work because it’s busy up to [the point of] me going 
home. 
P15, low adherence, 26–34 years 
 
In the absence of routine, low adherers were more dependent on external reminders, such as 
reminders from family and friends, or typically short-lived motivational boosts arising from 
discussions with health professionals. 
 
My partner reminds me [to take my nebulisers]. [I also get reminders] from clinic visits, with getting prompts to take my 
nebuliser. [The effects from those reminders] will last for a week or so. 
P15, low adherence, 26–34 years 
 
Historical experience of consistent nebuliser use, such as in childhood, may have contributed to 
the development of a good ‘nebuliser routine’ among high adherers. Childhood experience 
appeared more relevant for adolescents and younger adults, compared to older adults. 
 
I do my DNase in the afternoon […]. It is just how I have always done it, because when I was younger I always did my 
Promixin before school and then as soon as I got home from school about four o’clock, I used to do my DNase. 
P20, high adherence, ≤18 years 
 
Both low and high adherers also described using self-regulatory techniques, such as using 
objective feedback from the nebuliser to monitor their adherence, or environmental restructuring to 
support their nebuliser routines (‘I always put my I-neb near where I sit for my breakfast in the morning as a 
prompt’; P10, low adherence, 26–34 years). Similarly, both low and high adherers reported that weekends, 
evenings out, holidays, or other ‘unexpected’ events had the potential to disrupt typical behaviour 
patterns. 
 
When I go out with my mates, I still try to have my morning Promixin and DNase. I’ll have all my [oral medications first] 
and go about with my business. Comes to seven, eight o’clock I think alright, I’ll start getting ready. But, suppose one of 
my mates is picking me up at half past seven and its quarter to seven, I think you know, I’ve got to get ready [so I can’t 
use my nebulisers now]. 
P18, low adherence, 19–25 years 
 
I do miss some [of my nebulisers], I am not perfect but that’s normally because I am going to be late for work, or I have 
done something at night which I have not expected to do and I am really tired when I get in. They are they times when I 
normally miss it, but it is very rare. 
P17, high adherence, ≤18 years 
 
Such disruptions removed contextual triggers to nebuliser use, and by so doing also increased the 
amount of conscious effort required to use the nebuliser, both of which increased the likelihood of 
forgetting to use nebulisers: 
 
It is just your time, your working days and other commitments. When you have other things, you sit down thinking of 
other things and the time goes on and you become tired. Then the time starts ticking away and it becomes a bit of a 
chore if you are tired. 




The only time it gets hard is if I have been out all day, or have been out late at night. Then if I have got my DNase to do, I 
have to wait another 45 minutes before I can do my Promixin or TOBI, but I still never really find it difficult to fit it in. 
P20, high adherence, ≤18 years 
 
However, high adherers seemed to be better able to create routines that were less amenable to 
potential disruption, or to shield their routines against experienced disruptions. They reported 
anticipating disruptions and overcoming these disruptions by planning of preparatory behaviours 
within newfound circumstances. 
 
Even on the drive home, I will make sure I’ll have the flutter valve in the car, so I get home and just to have the nebuliser, 
so I don’t have to get home then have the flutter valve and then have the nebuliser. 
P11, high adherence, 26–34 years 
 
One low-adherer acknowledged the need to mitigate the impact of contextual changes, but did not 
view adaptation as necessary to short-term contextual changes: 
 
If I was going on holiday for a week or two weeks, I would then obviously take my equipment and medication with me. If 
just for a few days you might think “I’ll be all right, I’ll not [bring my equipment]”, then it’s the matter of getting back into 
that routine. 
P14, low adherence, 26–34 years 
 
Perhaps as a consequence of better planning, high adherers reported that their lifestyle was more 
‘supportive’ of nebuliser use. 
 
5.3.2.3 Prioritisation  
 
High adherers reportedly prioritised their nebulised treatments over other activities, sometimes 
even over other equally important tasks (‘Say for example I overslept, I would do my [nebuliser] treatment but I’ll 
skip breakfast’; P9, high adherence, 26–34 years). A high adherer reported prioritising her treatment routine 
when taking a new job: 
 
When I started the new job, [the employers] did say when is best for you to do the hours and I suppose I kind of 
answered that knowing that it would be better for me to be around in the afternoons and I do actually quite like the 
routine that I have got going now, so I do sort of try and fit around other people but ultimately, I wouldn’t commit to a 
routine that I know that I couldn’t manage whilst also doing all my treatments. […] My work routine has some advantages 
because my treatment can always come first. 
P12, high adherence, 26–34 years  
 
Placing a low priority on nebuliser use was problematic for two reasons. Firstly, pursuit, and at 
least temporary prioritisation, of other tasks could lead them to forget using their nebulised 
treatments. For some, forgetting on one occasion could lead to a longer-term derailment of 
adherence: 
 
When I’m having [my nebulised treatment] and I’m constantly having them, then it’s constantly on your mind all the time. 
But if maybe I had a couple of days off nebulisers, because I forgot it or run out, or left my nebuliser at home … then it 
just snowballs from there, and you just forget. 




Secondly, the completion of prioritised tasks could mentally exhaust adults with CF, so that by the 
time all higher-priority tasks were completed they lacked the motivation or self-regulatory capacity 
to use nebulised treatments. 
 
We have exams at the minute and, as much as [using nebuliser] should have been important, I think it just seemed less 
important because I’ve had a lot of exams and University, stuff like that.   
P6, low adherence, 19–25 years 
 
Low mood or depression, and stressful life circumstances such as preparing for university 
examinations reportedly led to temporary shifts in goal prioritisation, or depleted self-regulatory 
capacity to use nebulised treatment, so potentially leading to participants ‘losing [their] routine’ (P4, low 
adherence, ≤18 years): 
 
I think it’s just when I’m tired … I’m stressing out over Uni and stuff like that, I just kind of blanked out what I’m not doing 
at that minute. 
P6, low adherence, 19–25 years 
 
A participant with high adherence also mentioned attending to stressful other tasks as a potential 
barrier to nebuliser use, but reported having a strategy for coping with the effects of stress. 
 
Doing the other [tasks unrelated to nebuliser use] makes me more stressed, so I try and take a step back and calm 
down, do a bit less. 
P12, high adherence, 26–34 years 
 
5.3.2.4 Coping with treatment burden 
 
Using nebulised treatment involves multiple steps, which can be time-consuming. Treatment was 
seen as burdensome by both high and low adherers, who reported burden related to the number of 
nebulised medications required, the sequence and timing of nebulised medications, and time and 
effort required to prepare and use nebuliser machine and along with other concurrent CF 
treatments.  
 
Cleaning [the nebuliser] is definitely something that gets side-lined … I just don’t do that enough. And I think it’s because 
it’s about priorities and I definitely prioritise actually doing the nebuliser over the maintenance side of it. 
P12, high adherence, 26–34 years 
 
Perceived treatment burden was heightened when participants were tired, stressed or otherwise 
mentally depleted. However, those with high adherence appeared to cope better with the burden. 
 
[The amount of treatment] wouldn’t influence how I take [my treatment]. I think I would try to take it even if [there are lots 
of treatments]. If I need to take, I would. 
P8, high adherence, 19–25 years 
 
Those with significant amounts of other CF treatments also reported struggling to understand and 
resolve potentially inconsistent information from health professionals about using their nebuliser, 
and balancing nebuliser with other forms of CF treatments. 
  
There is a bit of, sort of, argument [among the healthcare professionals] about whether I should or should not start this 
treatment that I would normally have on a regular basis. I think things like that can interfere with my [adherence]. It’s like 
[someone asking me to check my] diabetes control every day and having to do my I-neb® every day. It’s just difficult [to 
be doing everything]. 
P10, low adherence, 26–34 years 
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Due to perceived burden, both high and low adherers also described various other ‘short-cuts’ to 
help them make their treatments more manageable. Examples include using technology or pre-
mixing nebulised medications to reduce treatment time, compensating for missed doses by using 
extra medications when able, taking ‘treatment holidays’ to replenish self-regulatory capacity and 
using distractions to deal with boredom experienced when inhaling nebulised medication. 
 
With my promixin ‘…’ sometimes what I find myself doing is when I’ve run out, I’ll mix 30 vials up or so. […] Mixing them 
all up and doing them so I know they’re all here ready to go, makes me think: “right, I’ll have them, I’ll take them.” 
P18, low adherence, 19–25 years 
 
Several high adherers described effective time management and planning as key adaptations to 
minimise treatment burden and so enable nebuliser use. Time management strategies took the 
form of altering leisure or work routines, and creating an optimal time window of nebuliser use to 
both facilitate remembering and allow adequate time to complete use. 
 
For example, if I know the latest I can be in at work is nine o’clock, I’ll make sure to get up in time to allow me plenty of 
time to get up, have a shower, do my physio, nebuliser, have breakfast, so I’m not missing that, and basically then get 
ready as I normally would. 
P9, high adherence, 26–34 years 
 
I had a paper round, so it was as soon as I got in from my paper round, I used to do my DNase and my Promixin in the 
morning, so I did my DNase, did my paper round and do my Promixin when I got back. But now I have changed it round 
so I do Promixin and DNase at night because I have got more time at night and I do my Promixin first thing in the 
morning. 
P17, high adherence, ≤18 years 
 
Social support from family and friends offered another way of reducing treatment burden, with 
some participants receiving direct practical help with the processes involved in using the nebuliser, 
for example with cleaning the nebuliser, or indirect help to free up time to use their nebulised 
treatments. 
 
For instance my mum comes and cleans for me every Friday so that means that I can spend time doing my treatment, 
doing all the other things that I need to do and not getting frustrated by sitting doing my treatment in a dirty chaotic 
house. Nobody can do my nebulisers for me or do me Acapella for me, but there is lots of other stuff that can be done to 
help me dedicate my time to that, and that is essential. 
P12, high adherence, 26–34 years 
 
5.3.3 Follow-up quantitative analysis 
 
In light of qualitative findings that routinisation reduced perceived treatment burden, follow-up 
quantitative analyses were run to explore whether relationships between treatment complexity and 
perceived burden differed according to the presence or absence of non-specific habit and 
instigation habit. No such analysis was run for execution habit, since every participant ‘had 
execution habit’. Participants ‘with no non-specific habit’ (N = 8) showed a moderately strong linear 
correlation between objective treatment complexity and perceived treatment burden (r = 0.64, 
9%% CI –0.12 to 0.93), see Figure 5.3. Those ‘with non-specific habit’ (N = 12) showed no such 
relationship (r = –0.29, 95% CI –0.74 to 0.34).  
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Figure 5.3: Scatter plots displaying the relationships between perceived treatment burden and 




Similar results were obtained according to instigation habit, with a strong linear correlation between 
treatment complexity and perceived burden (r = 0.79, 95% CI –0.31 to 0.99) among those ‘with no 
instigation habit’ (N = 5), but no relationship between the two variables (r = 0.04, 95% CI –0.48 to 
0.54) among those ‘with instigation habit’ (N = 15).  
 
The consistency of findings across the two habit measures suggests that effects of non-specific 
habit on burden may be more precisely attributed to habitual instigation. 
 
 
Chapter 5, Section 4: Discussion 
 
Adults with low (<50%) annual nebuliser adherence patterns were typically younger and had better 
lung function (and so generally healthier), yet still required more intravenous antibiotics than did 
‘high adherers’ (≥80%). High adherers reported stronger habit and described habit helping to 
alleviate treatment burden. Habitual instigation – i.e. automatically ‘remembering’ to use nebulisers 
– appeared to differentiate between high and low adherers, and reduced the impact of treatment 
complexity on perceived burden, such that even complex treatment was not seen as burdensome. 
High adherers reported having and seizing more opportunities to use nebuliser, and perceived 
opportunities correlated positively with habit. Due to small sample size, findings should be 
considered preliminary, and require replication in adequately powered studies. Nonetheless, they 
offer tentative evidence that adherence interventions in adults with CF might be more effective by 




Echoing previous studies among people with CF,[5, 197, 199, 200] this study found that young 
adults aged 19–25 years had lowest adherence. Age-related differences in adherence may reflect 
the social, cognitive and contextual turbulence that characterises adolescence and early 
adulthood.[409] Partaking in ‘risky behaviours’ has been hypothesised to be part of identity 
explorations among younger adults, as one may desire to experience a wide range of experience 
before settling into the responsibilities of adult life.[410] Adolescents also spend more time with 
peers and those with CF might prioritise socialising and ‘appearing normal’ (i.e. not making CF 
visible) over nebuliser use.[252] Major life events such as moving home or starting employment are 
common [409] and may deplete self-regulation resources,[411] making it more difficult for younger 
adults to consistently use their nebuliser. Interestingly, in interviews, all participants regardless of 
age showed awareness of nebuliser use importance and reported strong intentions. This is also 
corroborated by the quantitative analysis of intention scores. Age differences in adherence 
therefore do not appear attributable to differences in treatment beliefs or intention strength.  
 
There was, however, potential evidence of different motives for nebuliser use between high 
adherers and low adherers. First, high adherers with lower lung function (who tended to be older) 
reported they were often symptomatic when they missed their nebuliser, whereas low adherers 
with higher lung function (who tended to be younger) were unlikely to notice any short-term 
difference when not using their nebuliser. Salient negative health outcomes thus appear to trigger 
nebuliser use. Second, some of the low adherers depended almost exclusively on the actual 
experience of ill-health to prompt nebuliser use, such that nebuliser was used only when 
pulmonary exacerbation has occurred. By contrast, high adherence was more typically motivated 
by the anticipation of ill-health arising from non-use, such that nebulisers were actually used to 
prevent exacerbation. This echoes a literature demonstrating that anticipating regret for choosing 
one course of action (or inaction) can serve as a powerful motivator for choosing alternative 
actions.[412]  
 
It may be that the source of motivation for nebuliser use shifts over the lifespan due to the accrual 
of experiences of aversive ill-health episodes arising from non-adherence, such that people with 
CF come to better understand and fear the consequences of non-adherence, which in turn 
stimulates adherence. Life experience may thus represent an important determinant of adherence. 
Encouraging young adults with better lung function to anticipate ill-health arising from not using 
nebulised treatments, before they actually experience such ill-health, might therefore offer a fruitful 
technique for them to persist with more consistent nebuliser use.  
 
In terms of life experience with nebuliser use, it is often assumed that habits developed at a 
younger age will be sustained into adulthood with minimal conscious effort. However, there is 
actually little empirical evidence about durability of habits over time.[250] During interviews, 
younger participants reported that childhood experience influenced their nebuliser use but this was 
not the case among older participants. It may be that experience during or following the turbulent 
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period of late adolescence and young adulthood is more relevant for nebuliser adherence among 
older adults, since it is known that nebuliser adherence declined during this life stage.[194] How 
objective nebuliser adherence, habit and other behaviour determinants among people with CF 
change over time in a real-world setting requires further exploration using a longitudinal study 
design. However, it is clear that adherence intervention during childhood alone is unlikely to 
prevent low adherence in later life. Effective adherence intervention is just as important in adult CF 
services, especial interventions to target young adults who are most at risk for low medication 
adherence and poor health outcomes. 
 
Three key findings speak to the importance of habit formation in sustaining nebuliser use. Firstly, 
high and low adherers notably differed in their habit strength, and in particular, the strength of 
tendencies to habitually instigate nebuliser use. All high adherers described, in interviews, having 
‘routinised’ nebuliser use, such that they automatically ‘remember’ to use their nebulisers, and 
reported markedly stronger tendencies to habitually instigate nebuliser use episodes than did low 
adherers. This supports theoretical propositions that habit formation may maintain behaviour,[413] 
and empirical research suggesting habitual instigation supports frequent action.[328, 329] As habit 
forms, control over initially deliberative and effortful action is delegated to environmental cues, and 
instigating action becomes easier.[388, 405] Our data suggest that some low adherers may be 
stuck in the effortful early stages of habit formation, unable to develop the automaticity that 
sustains high adherence. Indeed, younger participants – who were typically less adherent – 
reported lesser habitual instigation than did older participants. Secondly, high adherers reported 
that habitual instigation made treatment less burdensome. Participants ‘with instigation habit’ – i.e., 
tending to agree that nebuliser use episodes are triggered automatically, without thinking – 
reported low perceived treatment burden regardless of the objective complexity of their treatment 
regimens. Conversely, participants ‘without instigation habit’ – i.e. tending to disagree with such 
statement – reported higher perceived treatment burden as treatment complexity increased. CF is 
a multi-system condition requiring multiple treatment types to maintain health, so requires a 
complex and potentially burdensome treatment regimen.[213] By automating the initiation of 
nebuliser use, instigation habit may reduce burden by bypassing deliberation processes.[328] 
Thirdly and relatedly, a moderately strong positive correlation was also found between habitual 
instigation of nebuliser use and perceived opportunity scores. Qualitative analysis suggested that 
high adherers ‘with habit’ experienced greater opportunities for nebuliser use (such as flexible 
working patterns), and also adapted more effectively to generate opportunities for using nebuliser 
when faced with challenges. It is not possible to determine the temporal relationship between 
opportunities and habit strength due to the cross-sectional design of this study. It may be that 
participants with greater opportunities were better able to form habits. Indeed, greater opportunity 
to act makes action more likely,[305] thus enhancing the likelihood of habit formation.[388] 
Alternatively, participants who form habits may have been better placed to subsequently act on 
opportunities, where such opportunities operated to automatically activate stored cue-behaviour 
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associations. The habit-opportunity relationships could also be bi-directional. Together, these 
findings suggest that nebuliser adherence interventions might usefully focus on habit formation. 
Specifically, people with CF should be encouraged to identify opportune moments in their everyday 
routines, and plan to respond to such moments so that nebuliser use might be consistently 
triggered, thus fostering habit associations.[388] Our data suggest that forming instigation habit 
would support adherence by not only automating nebuliser use, but also alleviating the perceived 
burden of using nebuliser. 
 
Other limitations of this study must be acknowledged. The hypothesised behaviour predictors were 
measured via self-report. A problem inherent in any self-report survey study is careless or 
inattentive responding.[414] By randomly ordering the statements of the questionnaire used in the 
study (see Table 5.2) and including some statements that were reversely scored,[415] participants 
should be more attentive in providing their responses and less likely to provide identical response 
for consecutive statements.[415] Self-reporting habit is particularly problematic, as discussed in 
Section 3.4.2.6 – it has been argued that people may not reliably reflect on non-reflective 
processes such as habit.[334] Participants may also have been confused by the subtly different 
wordings of instigation and execution habit items. However, the two previous studies in this domain 
suggest that people can reliably discern between the concepts of habitual instigation and 
execution.[328, 329] Secondly, participants’ familiarity with the interviewer (the PhD student) may 
perhaps have prompted socially desirable responses.[416] Conversely however, familiarity 
between the PhD student and the participants may have encouraged participants to speak more 
freely and openly. Indeed, between-participant variation was found on predictor variables scores, 
indicating that participants did not consistently self-report values to portray themselves in a positive 
light. Although nebuliser use was objectively measured, only the proportion of doses taken was 
considered in the calculation of adherence. Inadequate prescription, brief periods of nebuliser 
overuse or taking nebulised antibiotics with insufficient dose spacing could inflate the calculated 
adherence level,[182] and it is possible that a person with moderate levels of effective adherence 
was inadvertently labelled as a high adherer in this study. Technique errors with using nebuliser 
were also not considered, although I-neb® is a third generation adaptive aerosol delivery system 




Chapter 5, Section 5: Conclusions 
 
Previous research in CF has focused predominantly on treatment burden and reflective motivation 
concepts such as treatment beliefs. This mixed methods study, which investigated a broader range 
of potential adherence predictors distinguishing high and low adherence patterns, demonstrates 
the importance of both reflective and automatic processes in determining adherence among adults 
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with CF. This is the first study which demonstrates the association between habit and objectively 
measured medication adherence – in previous studies investigating this association in other long-
term conditions, adherence was self-reported and therefore measured with error.[7-11] This is also 
the first study which demonstrates the association between habitual instigation and objectively-
measured health behaviour. 
 
In addition, this study highlights the need to explore how nebuliser adherence and habit among 
people with CF change over time, especially during the late adolescence and young adulthood 
stage. Such studies would benefit from a parsimonious habit measure that can unobtrusively 
assess habit at various time points over prolonged periods. Longitudinal changes in objective 
nebuliser adherence over a 4-year period has been explored, and a pragmatic method of inferring 
‘habit’ from routinely available adherence data (which allows ‘habit’ to be measured without any 
additional effort from adults with CF) was developed as part of the PhD research, but these are 
beyond the scope of this thesis. 
 
Due to the preliminary and exploratory nature of this mixed methods study, our findings do require 
replication among larger samples to reduce the uncertainty of evidence – hence the study that is 
reported in the next chapter (Chapter 6). Nonetheless, the findings suggest that nebuliser 
adherence interventions for adults with CF might usefully target the development of routines to 
instigate nebuliser use, identify opportune moments for using nebuliser, and utilise anticipated 
regret as a technique to support asymptomatic low adherers, especially among younger adults with 





CHAPTER 6: A SECONDARY QUANTITATIVE DATA ANALYSIS TO REPLICATE SOME OF 
THE FINDINGS IN CHAPTER 5 
 
 
Chapter 6, Section 1: Introduction 
 
Replication studies are studies that re-perform previous experiments or analyses to determine if 
consistent results were reached.[417] These type of studies, though they may be dismissed as 
lacking originality or innovation, are important for scientific progress by reducing the uncertainty of 
evidence and confirming the validity of scientific conclusions.[418] Since the publication of a 
provocative essay by Ioannidis in 2005 which claims that “most published research findings are 
false”,[419] there have been several high-profile projects that showed high rates of replication 
failure in a broad range of subjects including social science, economics, clinical research and 
psychology.[420-423] In this context, the mixed methods study reported in Chapter 5 requires 
replication due to the small sample size and the findings within a single cohort may not be 
generalisable.  
 
The ACtiF pilot (ISRCTN ISRCTN13076797) provides an opportunity for replication because 
nebuliser adherence were also objectively measured using electronic data capture (EDC) and a 
broad range of potential adherence predictors were measured at baseline (prior to the delivery of 
any intervention). The ACtiF pilot is a two-centre external pilot trial primarily designed to evaluate 
the feasibility of a full-scale nebuliser adherence intervention RCT (CFHH RCT, 
ISRCTN55504164). The ACtiF pilot recruited 64 participants and randomised 32 participants to 
CFHealthHub, a software platform which delivers a complex intervention to support habit formation 
and self-management with inhaled therapies among adults with CF. The other 32 participants were 
randomised to usual care. 
 
Some of the potential adherence predictors collected during the ACtiF pilot were similar to the 
potential predictors collected during the mixed methods study reported in Chapter 5. These were 
treatment burden (treatment complexity and perceived treatment burden), instigation habit and 
intention. Other potential adherence predictors collected during the ACtiF pilot included severity of 
anxiety, severity of depressive disorder and beliefs about treatment (which is a component of 
reflective motivation).  
 
Although anxiety and depression have been hypothesised to reduce adherence, the evidence for 
this is inconclusive. A recent study found that the effect of depressive symptoms on medication 
adherence was mediated by ‘medication beliefs’ (see Sections 3.3.7 and 3.3.10).[290] Two 
previous studies using the Beliefs about Medication Questionnaire (BMQ) to evaluate treatment 
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beliefs found that lower treatment adherence was associated with necessity beliefs rather than 
concerns beliefs (Section 3.3.7).[277, 278] Of note, adherence were not objectively measured in 
both those studies; hence the association between adherence and treatment beliefs among people 
with CF remains uncertain.  
 
This chapter therefore sets out to replicate two of the main findings from mixed methods study 
reported in Chapter 5 (i.e. habit is associated with nebuliser adherence and habit has the potential 
to attenuate perceived treatment burden) by performing secondary quantitative analysis using data 
from ACtiF pilot. The third main finding from the mixed methods study (i.e. positive correlation 
between habit scores and perceived opportunity) could not be replicated, since opportunity score 
was not collected during ACtiF pilot. In addition, this chapter also sets out to explore the potential 
effects of anxiety, depressive disorder and treatment beliefs on nebuliser adherence. 
 
 
Chapter 6, Section 2: Methods 
 
6.2.1 Setting and participants 
 
This is a secondary quantitative analysis using data prospectively collected during the ACtiF pilot. 
The ACtiF pilot was approved by the London – Brent Research Ethics Committee (REC reference: 
16/LO/0356). 
 
Of the 64 participants recruited during ACtiF pilot, three participants were excluded because a 
participant withdrew consent, a participant died during the pilot and a participant did not provide 
data for potential adherence predictors at baseline. All included participants were aged ≥16 years, 
diagnosed as having CF according to the UK CF Trust criteria [348] and were using preventative 
inhaled therapies as part of their routine treatment. Participants were recruited from the Wolfson 




6.2.2.1 Demographic data and health outcomes  
Demographic and health outcomes data e.g. age, gender, %FEV1, intravenous (IV) antibiotics use 
and quality of life were collected as part of the trial procedure during the baseline visit.  
Baseline %FEV1 data were collected at the time of recruitment. FEV1 was measured during a 




Severity and frequency of pulmonary exacerbations were captured via total IV antibiotic days over 
the 1-year period prior to recruitment, and for 6 months during the ACtiF pilot. 
Quality of life at baseline was self-reported on a 1 (‘a great deal’) to 4 (‘not at all’) scale using all six 
relevant items from the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain,[395] 
e.g. ‘Have you been coughing during the day?’; α = 0.90. The respiratory domain of CFQ-R score 
was calculated from the six relevant CFQ-R items using previously described methods,[395] and 
ranged from 0 (lowest quality of life) to 100 (highest quality of life). 
 
 6.2.2.2 Nebuliser adherence 
Objective nebuliser data were downloaded from chipped nebulisers (eTrack®) in the 3-month 
period following the point of recruitment. The implementation phase of adherence was calculated 
as a percentage between total amount of medications used against the agreed dose between 
clinicians and adults with CF. Based on this method of quantifying adherence, adherence levels 
can vary from 0% to >100% (due to potential nebuliser overuse), with higher adherence being 
more desirable although nebuliser adherence >100% may not be optimum (this may vary with the 
medications – hypertonic saline may be beneficial if used more frequently whereas antibiotics may 
cause toxicity if used substantially more frequently than the prescribed doses). 
 
 6.2.2.3 Hypothesised predictors of adherence 
 
Treatment burden was measured in two ways. ‘Objective’ burden was measured via the Treatment 
Complexity Score (TCS),[213] which assigns a value of 1, 2 or 3 (3 = highest burden) to the 37 CF 
maintenance therapies. The individual values were summed up to produce a single TCS score 
ranging from 0 (no burden) to 72 (highest burden). ‘Subjective’ burden was self-reported on a 1 
(‘not at all’) to 4 (‘a lot’) scale using all three relevant items from the CF Questionnaire-Revised 
(CFQ-R),[395] e.g. “To what extent do your treatments make your daily life more difficult?”; α = 
0.45. ‘Subjective’ burden score was calculated from the three relevant CFQ-R items using 
previously described methods,[395] and ranged from 0 (lowest perceived burden) to 100 (highest 
perceived burden). 
 
Severity of anxiety at baseline was self-reported on a 0 (‘not at all’) to 3 (‘nearly every day’) scale 
using all seven items from the General Anxiety Disorder 7-item anxiety scale (GAD),[424] e.g. 
“Feeling nervous, anxious or on edge”; α = 0.83. All seven GAD items were summed to create a 
anxiety score ranging from 0 (lowest anxiety severity) to 21 (most severe anxiety). 
 
Severity of depressive disorder at baseline was self-reported on a 0 (‘not at all’) to 3 (‘nearly every 
day’) scale using all eight items from the Patient Health Questionnaire depression scale (PHQ-
8),[425] e.g. “Little interest or pleasure in doing things”; α = 0.84. All eight PHQ-8 items were 
summed to create a depressive disorder score ranging from 0 (lowest depressive disorder severity) 
to 24 (most severe depressive disorder). 
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Intention at baseline was self-reported using an item adapted from the Capability Opportunity 
Motivation Behaviour (COM-B) Self Evaluation Questionnaire.[398] The item used was “I want to 
do all my prescribed nebuliser treatments in the next two weeks” with which participants rate 
agreement on a scale of 1–7, where 7 represents strongest intention. 
 
Necessity at baseline was self-reported on a 1 (‘strongly disagree’) to 5 (‘strongly agree’) scale 
using all seven ‘necessity items’ from the Beliefs about Medicines Questionnaire – specific 
(nebuliser adherence) (BMQ),[426] e.g. “My life would be impossible without this nebuliser 
treatment”; α = 0.84. All seven ‘necessity items’ from the BMQ were averaged to create a necessity 
score ranging from 1 (lowest perceived necessity) to 5 (highest perceived necessity). 
 
Concerns at baseline was self-reported on a 1 (‘strongly disagree’) to 5 (‘strongly agree’) scale 
using all 14 ‘concern items’ from the Beliefs about Medicines Questionnaire – specific (nebuliser 
adherence) (BMQ),[426] e.g. “I sometimes worry about becoming too dependent on this nebuliser”; 
α = 0.84. All 14 ‘concern items’ from the BMQ were averaged to create a concerns score ranging 
from 1 (lowest perceived concern) to 5 (highest perceived concern). 
 
Habit strength at baseline was self-reported on a 1 (‘strongly disagree’) to 5 (‘strongly agree’) scale 
using all four items from the Self-Report Behavioural Automaticity Index (SRBAI),[336] e.g. 
“deciding to use my nebuliser is something I do automatically”; α = 0.93. Each item begins with 
“Deciding to use my nebuliser …” to capture habitual instigation, since the mixed methods study 
reported in Chapter 5 suggested that effects of non-specific habit on adherence may be more 
precisely attributed to habitual instigation. Other studies have also demonstrated that habitual 
instigation tendency is more likely to predict behaviour frequency, compared to habitual execution 
tendency.[328, 329] Only habitual instigation was measured to minimise participant burden, 
especially since the CFQ-R questionnaire alone consists of 50 items.[395] All four SRBAI items 





All analyses were run using SPSS v24 (IBM Corp) and R v3.3.0 (www.r-project.org). Appropriate 
descriptive statistics were generated, including effect sizes and confidence intervals. P-values 
<0.05 were considered statistically significant. 
 
6.2.3.1 Exploring the potential effects of hypothesised adherence predictors on adherence 
Characteristics of ‘high’ (adherence ≥80%), ‘moderate’ (adherence 50-79.9%) and ‘low’ (adherence 
<50%) adherers were compared, to mirror the analysis of the mixed methods study reported in 
Chapter 5. These adherence categories were also used in various other CF adherence-related 
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studies [200, 283] and were chosen based on the relationship with health outcomes. For example, 
a previous study found that adults with adherence ≥80% had total annual healthcare costs of 
$34,432; whereas those with adherence 50-79.9% and <50% had costs of $45,239 and $54,190, 
respectively.[283]  
Due to the non-normal data distribution and the presence of outliers, non-parametric analysis 
methods were used. Again, this mirrors the quantitative analysis method used for the mixed 
methods study reported in Chapter 5. If two or more hypothesised adherence predictors were 
significantly associated with adherence, multiple ordinal regression would be performed using the 
relevant hypothesised adherence predictors as fixed effects and the three adherence categories as 
the dependent variable. 
 
6.2.3.2 Exploring whether habit attenuated perceived treatment burden  
For this analysis, the sample was dichotomised into those who ‘had habit’ (i.e. high level of 
automaticity, habit score ≥12, that is, at or above the scale midpoint [405]) or ‘had no habit’ (habit 
score <12) to explore whether relationships between treatment complexity and perceived burden 
differed according to the presence of absence of habit. This is similar to the analysis of the mixed 
methods study reported in Chapter 5. 
Of note, the Cronbach’s alpha for perceived treatment burden was only 0.45 whilst the values were 
>0.80 for all other self-reported measures. Although a high Cronbach’s alpha value does not imply 
the measure is unidimensional,[342] such a low value indicates a lack of internal consistency. All 
three perceived treatment burden items were retained for the main analysis as described in 
Section 6.2.3.1; but the perceived treatment burden measure was further explored to determine 
whether the two items deemed to have the best face validity (“To what extent do your treatments 
make your daily life more difficult?” and “How difficult is it for you to do your treatments, including 
medications, each day?”) differed from the third statement (“How much time do you currently 
spend each day on your treatments?”). The first two items, but not the third item, were used to 
measure perceived treatment burden in the mixed methods study reported in Chapter 5. 
 
 
Chapter 6, Section 3: Results 
 
This analysis included 61 adults (28, 45.9% were females). The overall baseline adherence level 
was low, with median 38.5% (IQR 7.4% to 66.3%) and most participants (N = 40, 65.6%) had 
adherence <50%. High adherers (N = 9, 14.8%) had lower prior-year IV use and tended to have 
higher %FEV1 at baseline, see Table 6.1. 
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Table 6.1: Clinical characteristics and psychological factors among three groups of adults with CF 

























Age in years, median (IQR) 
 
Female, n (%) 
 
Baseline %FEV1, median (IQR) 
 
Prior-year IV days, median (IQR) 
 
IV days during trial, median (IQR) 
 
Quality of life (CFQ-R), median (IQR) 
 





Perceived burden (CFQ-R), median (IQR) 
 
Anxiety (GAD) score, median (IQR) 
 
Depression (PHQ-8) score, median (IQR) 
 
Intention (COM-B) score, median (IQR) 
 
Necessity (BMQ) score, median (IQR) 
 
Concerns (BMQ) score,‡ median (IQR) 
 
Habit (SRBAI) scores,‡ median (IQR) 
 
 










51.2 (43.6 – 68.0) 
 
28 (11 – 46) 
 
14 (0 – 23) 
 
56 (33 – 78) 
 






44 (33 – 56) 
 
4 (1 – 8) 
 
7 (3 – 12) 
 
7 (5 – 7) 
 
3.1 (2.8 – 3.7) 
 
2.3 (1.9 – 2.6) 
 
8.0 (4.0 – 10.0) 
 










47.7 (42.8 – 90.1) 
 
17 (14 – 55) 
 
17 (0 – 31) 
 
47 (28 – 79) 
 






56 (44 – 67) 
 
2 (0 – 5) 
 
5 (3 – 8) 
 
7 (7 – 7) 
 
3.2 (2.7 – 3.7) 
 
2.2 (1.5 – 2.6) 
 
14.5 (12.0 – 17.5) 
 










79.7 (51.1 – 89.7) 
 
0 (0 – 12) 
 
0 (0 – 15) 
 
67 (42 – 86) 
 






44 (33 – 56) 
 
0 (0 – 4) 
 
4 (2 – 5) 
 
7 (6 – 7) 
 
4.0 (2.9 – 4.6) 
 
1.5 (1.3 – 1.7) 
 








































Results from the mixed methods  
Sheffield study (reported in  
Chapter 5) included for comparison 
 
Number of participants ¶ 
 
% Adherence, median (IQR) 
 











28.0 (5.3 – 46.0) 
 






















94.9 (86.7 – 108.5) 
 














† All p-values were calculated using Kruskal-Wallis H test, except the p-value for gender was calculated using Fisher’s exact test. 
 
‡ Since concerns and habit scores were associated with adherence, both scores were included as covariates in a multiple ordinal 
regression model with adherence categories as the dependent variable (see Table 6.2 for the results of the ordinal regression analysis). 
 
¶ By design, the mixed methods study reported in Chapter 5 only included adults with adherence <50% or ≥80%. 
 
Ω In the mixed methods study reported in Chapter 5, habit (SRBAI) scores were collected using a 1–7 Likert scale. For the purpose of 
this comparison, the score of each Sheffield participant was transformed linearly to a 4–20 scale, to mirror the scoring system used in 
the ACTiF pilot. 
 
6.3.1 The relationship between hypothesised adherence predictors and adherence 
 
High adherers (N = 9) reported stronger habit (median 18.0, IQR 13.0 to 19.5) than did low 
adherers (N = 40; median 8.0, IQR 4.0 to 10.0), see Table 6.1. Conversely, high adherers reported 




In a multiple ordinal regression model with both habit and concerns scores (see Table 6.2), only 
habit was independently associated with adherence – the adjusted odds ratio indicates that 1 unit 
increase in habit score (which can vary from 4, weakest habit to 20, strongest habit) was 
associated with an increase in the odds of moving up one level of adherence category (e.g. from 
<50% to 50–79.9%, or 50–79.9% to ≥80%) by 39% (95% CI 19% to 62%), once concerns score 
was taken into account.  
 
Table 6.2: Summary of the multiple ordinal regression model § with the three adherence categories (<50%, 









Concerns (BMQ) score 
 
Habit (SRBAI) score ∆ 
 
 
0.35 (0.11 to 1.06) 
 








§ For this ordinal regression model: pseudo-R2 = 0.505 (Nagelkerke); model χ2 (2) = 33.0, p <0.001. This suggests that 50.5% of the 
variance in the adherence categories were explained by concerns and habit scores. 
 
∆ An adjusted odds ratio of 1.39 indicates an increase in 1 unit of habit score (which can vary from 4, weakest habit to 20, strongest 
habit) was associated with an increase in the odds of moving up one level of adherence category (e.g. from <50% to 50–79.9%, or 50–
79.9% to ≥80%) by 39% (95% CI 19 to 62%), once concerns score was taken into account. 
 
Ω The different scales used for habit and concerns scores meant that it is difficult to directly compare effect sizes for these two 
covariates. The scales can be ‘standardised’ by averaging the four SRBAI items to calculate the habit score, which would create a habit 
strength score ranging from 1 (weakest habit) to 5 (strongest habit). This is directly comparable to the concerns score, which ranged 
from 1 (lowest perceived concern) to 5 (highest perceived concern).  
Using the ‘standardised habit score’ and the concerns score as fixed effects covariates in the multiple ordinal regression model, the 
adjusted odds ratio for habit score = 3.71 (95% CI 2.01 to 6.82). This indicates a greater effect size for habit score – a 1 unit increase in 
habit score was associated with an increase in the odds of moving up one level of adherence category by 271% whereas a 1 unit 
decrease in concerns score was associated with an increase in the odds of moving up one level of adherence category by 65%.  
 
6.3.2 The potential attenuation of perceived treatment burden by habit 
 
Both scatter plots for participants ‘with no habit’ (N = 34) and ‘with habit’ (N = 27) showed no linear 
relationship between perceived treatment burden and treatment complexity, see Figure 6.1.  
 
Figure 6.1: Local Polynomial Regression (LOESS) curves § depicting the relationship between treatment 











§ Local Polynomial Regression (LOESS) curve is a non-parametric method for fitting smooth curves to empirical data, to depict the 
relationships between variables.[427] Both LOESS curves were generated using default SPSS v24.0 setting (Kernel: Epanechnikov, 
50% of points to fit). 
 
† Treatment complexity score can vary from 0 to 72, with higher scores indicating more complex treatment regimen [213] 
 
‡ Perceived treatment burden as measured using CFQ-R can vary from 0 to 100, with higher scores indicating higher perceived 
treatment burden [395] 
Scatter plot of perceived burden vs treatment 
complexity for participants ‘with no habit’ 
 
Scatter plot of perceived burden vs treatment 
complexity for participants ‘with habit’ 
 
LOESS curve 





















The Spearman’s rho also showed no clear linear relationship between perceived burden and 
treatment complexity for participants ‘with no habit’ (r = –0.09, 95% CI –0.42 to 0.25) and ‘with 
habit’ (r = 0.21, 95% CI –0.18 to 0.55) since the 95% confidence intervals included the value of 
zero. 
 
6.3.3 Further exploration of the perceived burden score (and treatment complexity score) 
 
For reporting purposes, the item “To what extent do your treatments make your daily life more 
difficult?” was denoted as Statement 1 (S1); “How much time do you currently spend each day on 
your treatments?” as Statement 2 (S2) and “How difficult is it for you to do your treatments 
(including medications) each day?” as Statement 3 (S3).  
 
The Cronbach’s alpha for S1-S2, S2-S3 and S1-S3 pairs were 0.35, –0.12 and 0.64 respectively. 
This finding is unlikely to be a fluke or due to inappropriate use of the CFQ-R questionnaire. In the 
original 2005 validation study for CFQ-R, the S1-S2 pair had Cronbach’s alpha of only 0.18; hence 
a third item (S3) was added in an attempt to improve the scale-level reliability.[395] The 
psychometric properties of CFQ-R was re-evaluated among 4,679 teenagers and adults as part of 
the Epidemiologic Study of Cystic Fibrosis (ESCF) in 2012, yet the Cronbach’s alpha for the 3-item 
burden domain was only 0.51 – the perceived burden domain still has the lowest Cronbach’s alpha 
among all 13 domains of the CFQ-R.[428] 
 
This suggests that S2 may be measuring a different dimension from S1 and S3, i.e. how much time 
an adult with CF spend on treatment may not necessarily correlate with how burdensome that 
person finds the treatment regimen. However, generating a perceived burden score based only on 
S1 and S3 still found no clear linear relationship between perceived burden and treatment 
complexity for participants ‘with no habit’ (r = –0.24, 95% CI –0.54 to 0.10) and ‘with habit’ (r = 
0.22, 95% CI –0.18 to 0.55). 
 
At a group level, the Sheffield participants of the mixed methods study reported in Chapter 5 had 
less severe disease as evidenced by higher %FEV1 (even after accounting for the differences in 
measurement methods) and lower proportion of people with CF related diabetes, see Table 6.3. 
The adherence levels were higher in the Sheffield mixed methods study, due to the purposive 
nature of sampling for the mixed methods study which requires equal numbers of high vs low 
adherers. Given the higher adherence in the mixed methods study and the strong habit-adherence 
association observed in Chapter 5, it is not surprising that participants in the mixed methods study 
also reported stronger habit. However, the perceived burden was substantially higher among 
participants of the ACtiF pilot, even though treatment complexity scores among both cohorts of 
participants were similar. It is also surprising that the treatment complexity scores were similar 
among both cohorts of participants, since participants of the ACtiF pilot clearly had more severe 
lung disease (which would be expected to increase the complexity of treatment regimen) and 
higher prevalence of CF related diabetes (which is typically managed with insulin). 
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Table 6.3: The comparison between two cohorts of participants 
  
Mixed methods study (N = 20) 
 
 
ACtiF pilot (N = 61) 
 
Age in years, median (IQR) 
 
 
27 (19 to 32) 
 
27 (21 to 50) 
 
% predicted FEV1, median (IQR) 
 
 
83.5 (69.0 to 90.8) a 
 
52.8 (43.3 to 78.9) b 
 







% Adherence, median (IQR) 
 
        Low adherence, n (%) 
        Moderate adherence, n (%) 
        High adherence, n (%) 
 
 












Habit score, median (IQR) 
 
 
12.0 (8.8 to 16.5) ‡ 
 
10.0 (6.5 to 15.0) 
 





16.7 (0.0 to 41.7) ¶ 
 
44.0 (33.0 to 56.0) § 
50.0 (25.0 to 66.7) Ω 
Treatment complexity score, 
median (IQR) 
 
15.0 (10.3 to 16.0) 
 
15.0 (12.0 to 18.0) 
 
a %FEV1 for the mixed methods study participants were the best %FEV1 in the previous 12 months prior to recruitment, as calculated 
using the Knudson equation.[394] 
 
b %FEV1 for the ACtiF pilot participants were stable %FEV1 at baseline, as calculated using the Global Lung Function Initiative (GLI) 
equation.[354] 
 
† This group level figure is only a guide because there were two distinct adherence groups in the Sheffield cohort. 
 
‡ In the mixed methods study reported in Chapter 5, habit (SRBAI) scores were collected using a 1–7 Likert scale. For the purpose of 
this comparison, the score of each Sheffield participant was transformed linearly to a 4–20 scale, to mirror the scoring system used in 
the ACtiF pilot. 
 
¶ In the mixed methods study reported in Chapter 5, perceived treatment burden (CFQ-R) scores were collected using a 1–7 Likert 
scale. For the purpose of this comparison, the score of each Sheffield participant was transformed linearly to a 0–100 scale, to mirror 
the scoring system used in the ACtiF pilot. 
 
§ This score was calculated using all three relevant items from the CFQ-R. 
 
Ω This score was calculated using two items from the CFQ-R: “To what extent do your treatments make your daily life more difficult?” 
and “How difficult is it for you to do your treatments (including medications) each day?”. This was similar the method of measuring 




Chapter 6, Section 4: Discussion 
 
Secondary analysis of the ACtiF pilot data has replicated the habit-adherence association finding 
from the Sheffield mixed methods study reported in Chapter 5. In the mixed methods study, 
adherence was assessed retrospectively in the 1-year pre-recruitment period. In the secondary 
analysis of ACtiF pilot data, adherence was assessed prospectively over the 3-month post 
recruitment period in the study. Adherence data was analysed over the 3-month post recruitment 
period because baseline objective adherence data (i.e. prior to adherence intervention) was 
unavailable, sampling adherence over shorter periods is an unreliable measure of stable behaviour 
[181] and adherence levels were similar in both arms of the pilot for the first three months (median 
38.5%, IQR 8.7% to 71.8% for intervention, N = 33; median 37.9%, IQR 5.5% to 54.6% for usual 
care, N = 28). Sampling adherence over a 6-month post recruitment period would be complicated 
by the divergence in adherence at month 4–6 (median 33.7%, IQR 7.2% to 75.0% for intervention, 
N = 31; median 21.2%, IQR 7.0% to 55.9% for usual care, N = 27). This trend of declining 
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adherence levels among ACtiF pilot participants from month 1–3 to month 4–6 also reiterates the 
finding in Chapter 4 that adherence to longer-term treatment regimen is lower than shorter-term 
regimen.  
 
Although the group-level habit scores were higher for the Sheffield mixed methods study cohort, 
the scores were similar between both cohorts following stratification according to adherence levels. 
This suggests that habit – that is automatically experiencing an urge to use the nebuliser in certain 
settings, due to learned associations between nebuliser use and cues within those settings – may 
be consistently associated with nebuliser adherence among adults with CF.  
 
Due to the cross-sectional nature of the data, the directionality of the association between habit 
and adherence cannot be determined for certain. The relationship between adherence and habit 
over time is complex; initial adherence episodes (undertaken in consistent settings) cause habit to 
form, and as habit forms, it acquires the potential to direct subsequent adherence.[250] While the 
habit scores analysed were collected at baseline, prior to the delivery of any intervention during the 
ACtiF pilot, the detailed data on participants’ adherence (or intervention) histories were 
unavailable. It may be possible that some of the participants to have been “successfully intervened 
upon” in the past, and so may have achieved higher adherence prior to entering the study, and 
maintained these throughout the study. Assuming stability of adherence and habit over time, high 
adherence prior to entering the study may have caused higher habit scores at baseline, which then 
subsequently predicted (in a statistical sense) higher adherence over the following three months. 
 
The habit measure used for both the Sheffield mixed methods study and the ACtiF pilot is the 
SRBAI, which is an automaticity subscale of the SRHI (see Sections 3.4.2.2 and 3.4.2.3 for 
detailed explanation about both habit measures). Unlike SRHI, SRBAI does not enquire about 
behaviour frequency.[336] It means that SRBAI scores are less likely to be just acting as proxy 
measures for behaviour frequencies. Although changing adherence could potentially change habit 
(since habit is strengthened through consistent repetition of a specific action in a specific context, 
i.e. content-dependent repetition),[250] it is important to note that habit is not synonymous with 
behaviour (e.g. adherence). It is possible that someone using his or her nebuliser frequently to 
have weak habit if he or she does not use the nebuliser in a consistent setting, and instead rely on 
consciously remembering to use the nebuliser. It is also, in theory, possible to strengthen habit 
without directly increasing the frequency of nebuliser use, by instead encouraging more consistent 
performance.[388] For example, adults with CF might be encouraged to identify cues that they 
encounter reliably and regularly in everyday routines, in the presence of which they should use 
their nebuliser.[314] Such habit-based advice would therefore focus on harnessing potential 
contextual cues, not increasing the frequency of nebuliser use per se. 
 
Although habit was found to be the only independent predictor of nebuliser adherence in the ACtiF 
pilot cohort, this is not to say that habit is the only relevant determinant of adherence. Due to 
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modest sample size, the ACtiF pilot could only detect differences if the effect size is sufficiently 
large.[232] For example, a 1 unit decrease in concerns score (concerns score could vary from 1, 
lowest perceived concern to 5, highest perceived concern) could be associated with an increase in 
the odds of moving up one level of adherence category (e.g. from <50% to 50–79.9%, or 50–
79.9% to ≥80%) by 65% but the ACtiF pilot was not sufficiently powered to detect that effect with a 
conventional α level of 0.05.  
 
It is likely that both reflective (e.g. treatment beliefs) and automatic (e.g. habit) processes influence 
adherence levels, which would be detected with larger sample sizes. In particular, reflective 
motivation is crucial in the early stages of habit formation because reflective motivation is important 
for a person to start repeating the behaviour in a specific context (i.e. context-dependent repetition) 
to strengthen the context-behaviour association. The initial process of habit formation is 
effortful.[314] Barriers to the behaviour must be overcome to initiate context-dependent repetition. 
Conscious attention or reflective processes are also needed to persist with context-dependent 
repetition (see Figure 6.2).[250, 314, 398]  
 













The Perceptions and Practicalities Approach (PAPA) proposes that non-adherence can be unintentional (“can’t”), 
arising from practical barriers (e.g. lack of time) or intentional (“won’t”), arising from attitudinal barriers (e.g. lack of 
necessity, overwhelming concerns).[429] Within the COM-B model (Capability, Opportunity, Motivation and 
Behaviour), those who “can’t” adhere lack capability and/or opportunity, whilst those who “won’t” adhere lack 
motivation.[398]  
 
Overcoming these barriers allows context-dependent repetition. Context-dependent repetition gradually shifts the 
cognitive control of a behaviour from reflective to automatic processes, i.e. the process of habit formation. Habit 
should sustain a behaviour but disruption of habitual behaviour is possible, e.g. discontinuation of cue exposure 
with alteration of the environment. If adherence has relapsed, it is important to overcome barriers to start habit 
formation again. 
 
However, working effortfully on a new behaviour (e.g. using nebuliser) is worthwhile if it results in 
habitual behaviour. The gradual shifting of a behaviour’s cognitive control from reflective to 
automatic processes means that as habit develops, it can cue further context-dependent 
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repetitions which in turn further strengthens the habit.[250] Behaviour enactment becomes 
progressively easier with this positive feedback loop, even though the initial process of habit 
formation is effortful.[314] Other components of COM-B model also interact and change over time 
during the process of habit formation (see Figure 6.3),[398] which highlight the theoretical potential 
of habit formation to sustain behaviour change. 
 



















The increasing ratio of automatic vs reflective motivation over time depicts the gradual shifting of a behaviour’s 
cognitive control from reflective to automatic processes as habit is formed.  
 
The increasing size of the ‘capability’ and ‘opportunity’ circles over time depicts increasing capability and 
opportunities as habit is formed. This is in keeping with the Sheffield mixed methods study reported in Chapter 5, 
which found a strong positive correlation between habit scores and perceived opportunity. The qualitative data of 
the mixed methods study suggested that those with high habit not only experienced more opportunities, but they 
also adapted more effectively to seize opportunities for using nebuliser. 
 
Replication of the Sheffield mixed methods study finding in an independent cohort nonetheless 
provides empirical evidence that the habit-adherence association is potentially generalisable 
among adults with CF. The modest sample size for both studies is a limitation, but studies with 
larger sample sizes could still find that habit has a stronger effect on nebuliser adherence 
compared to other adherence determinants. There is only one previously published study 
examining the association between respiratory medication adherence and habit strength. The 
study among 139 asthma patients also found that medication adherence was more strongly 





Two findings from the ACtiF pilot hinted that adults with CF may not necessarily equate greater 
length of time spent time on treatment or greater complexity of treatment regimen as “more 
difficult”. First, the item “How much time do you currently spend each day on your treatments?” 
was not internally consistent with the two other CFQ-R treatment burden items (“To what extent do 
your treatments make your daily life more difficult?” and “How difficult is it for you to do your 
treatments, including medications, each day?”). Second, there was a lack of relationship between 
treatment complexity and perceived burden among participants of the ACtiF pilot.  
 
However, there was no clear evidence of habit moderating perceived treatment burden within the 
ACtiF pilot cohort. Four differences between the mixed methods study and ACtiF pilot may explain 
the non-replication of the ‘habit moderating treatment burden’ result. First, the measure for 
perceived treatment burden in the ACtiF pilot using all three relevant items from the CFQ-R 
appeared to lack internal consistency with α = 0.45. The Cronbach’s alpha improved to 0.64 by 
using just two out of the three relevant items from CFQ-R with the best face validity (both these 
statements were used to measure perceived treatment burden in the mixed methods study), but 
there was still no clear relationship between perceived treatment burden and treatment complexity. 
This suggests that the perceived burden measure may contribute to, but is not the only reason for 
the non-replication of the results. Second, less accurate treatment complexity scores from the 
ACtiF pilot could potentially obscure the moderating influence of habit on perceived treatment 
burden. The ACtiF pilot cohort has more severe lung disease and higher prevalence of CF related 
diabetes compared to the mixed methods study cohort, yet treatment complexity was similar for 
both cohorts. CF related diabetes is typically treated with insulin,[355, 361-363]  which scores a “3” 
on the Treatment Complexity Score [213] and should have a substantial impact on a cohort with 
median treatment complexity score of only 15. Prescription data for the mixed methods study were 
collected by a clinician who carefully checked all the prescription details. The interventionists in 
ACtiF pilot who collected the data could only rely on prescription records, which may or may not be 
accurate. Third, participants of the mixed methods study were fed back their objective nebuliser 
adherence data prior to completing the questionnaires (which included measure for perceived 
treatment burden). Participants of the ACtiF pilot could potentially be “less well calibrated” since 
objective nebuliser data was unavailable prior to that study. This could potentially influence the 
results, although it is uncertain whether better calibration to a behaviour (adherence) would confer 
better calibration to a psychological factor (e.g. perceived treatment burden). Fourth, there may be 
inherent differences in the characteristics between the two cohorts. The ACtiF pilot cohort reported 
similar levels of anxiety compared to the UK adult CF population (8/61, 13.1% of the ACtiF pilot 
cohort reported moderate-severe anxiety as measured by GAD score of ≥10, which is roughly 
equivalent to HAD score ≥11 for anxiety items; ~13% of the adults with CF in the UK reported HAD 
score ≥11 for anxiety items according to the large study by Duff et al [284]). However, moderate-
severe depression was much more common among the participants of ACtiF pilot (18/61, 29.5% of 
the ACtiF pilot cohort reported moderate-severe depression as measured by PHQ-8 score of ≥10, 
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which is roughly equivalent to HAD score ≥11 for depression items;[430] only ~4% of the adults 
with CF in the UK reported HAD score ≥11 for depression items according to the large study by 
Duff et al [284]). These GAD and PHQ-8 readings were taken at baseline and thus unrelated to the 
research procedures or intervention delivery during the pilot. The high levels of depression may 
partly explain the substantially higher perceived treatment burden among participants of ACtiF pilot 
in comparison to the participants of the mixed methods study, although it should be noted that a 
previous study found no correlation between depression and perceived treatment burden,[288] and 
participants of ACtiF pilot also reported lower habit scores compared to participants in the Sheffield 
mixed methods study 
 
 
Chapter 6, Section 5: Conclusions 
 
Despite the limitations of both the Sheffield mixed methods study and the secondary analysis of 
ACtiF pilot data, replication of the habit-adherence association suggests this association is not just 
a peculiarity specific to a single adult CF centre. Replication of results reduces the uncertainty of 
evidence, hence these studies provide tentative evidence for the role of habit in the health 
behaviour of using nebuliser among adults with CF. This finding is particularly pertinent in the 
context of difficulties with sustaining longer-term nebuliser adherence among adults with CF.  
 
Although the finding from the Sheffield mixed methods study that habit can potentially moderate 
perceived treatment burden was not replicated, the non-replication may be related to limitations of 
the ACtiF pilot data rather than the initial finding being spurious. Given the paucity of habit-related 
research in respiratory medication adherence, further investigation of habit as an adherence 
determinant, the mechanism of habit in sustaining long-term adherence and habit-formation as a 
potential adherence intervention should be seen as a priority within cystic fibrosis and other areas 
of respiratory medicine.  
 
Two further studies are now underway to explore habit formation in more detail using CFHealthHub 
in a 19-centre RCT (ISRCTN55504164) and a three-centre improvement collaborative 
(ISRCTN14464661). These studies should extend our understanding of the role of habit in 






CHAPTER 7: DISCUSSION & CONCLUSIONS 
 
This chapter summarises the overall findings of the thesis, explains the context of the findings in 
relation to other research work of the PhD, discusses the relevant learning points, and provides 
suggestions for future research.  
 
 
Chapter 7, Section 1: A summary of the findings 
 
The aims of the thesis are to explore the clinical and psychological factors associated with 
objective nebuliser adherence among adults with CF. 
 
The literature review in Chapter 3 highlighted the paucity of research using objective adherence 
data to understand nebuliser adherence among people with CF. The extant literature in CF 
adherence has also mainly focused on presumed barriers to treatment (especially “treatment 
burden”) and conscious deliberation (e.g. treatment beliefs), instead of exploring a broad range of 
potential adherence determinants. The three inter-related studies reported in the subsequent 
chapters of this thesis seek to address these evidence gaps. 
 
In Chapters 4, relevant demographic and treatment factors were explored using routinely collected 
objective adherence data among 126 adults in Sheffield over a 4-year period. This study found that 
age and the type of treatment regime (shorter term regimen for P. aeruginosa eradication vs longer 
term maintenance treatment) were associated with nebuliser adherence. There was a U-shape 
relationship between adherence and age, with lowest adherence among adults aged 19–25 years. 
Lower adherence was also noted for long-term nebuliser regimen (i.e. treatment duration >3 
months) in comparison to shorter term regimen (typically used for P. aeruginosa eradication).   
 
In Chapter 5, relevant psychological factors were explored using mixed methods design among 20 
adults in Sheffield (10 high and 10 low adherers). This study has three main findings. First, both 
the qualitative and quantitative results indicate that high adherers were more likely to make 
nebuliser use habitual. Second, high adherers adapted more effectively to using nebulisers by 
creating and seizing opportunities for nebuliser use. Third, habit has the potential to attenuate 
perceived treatment burden among adults with CF. 
 
In Chapter 6, replication for two of the three main findings from Chapter 5 (i.e. the habit-adherence 
association, and the potential of habit to attenuate perceived treatment burden) were attempted 
with a secondary analysis of the ACtiF pilot data. The ACtiF pilot, which recruited 64 participants 
from Nottingham and Southampton, is a two-centre external pilot trial to evaluate the feasibility of a 
full-scale nebuliser adherence intervention RCT. Analysis of ACtiF pilot data replicated the habit-
adherence association observed in Chapter 5. However, the moderating effect of habit on 
perceived treatment burden was not replicated, in part due to limitations with the ACtiF pilot data. 
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Another finding from the ACtiF pilot data is the trend of declining adherence over time – this is 
consistent with the finding of lower adherence for long-term nebuliser regimen in Chapter 4. 
 
Taken together, the studies reported in Chapters 4–6 point towards the difficulty of sustaining 
adherence to long-term nebuliser treatments, especially among younger adults with CF; and also 
highlights the role of habit in maintaining adherence.     
 
 
Chapter 7, Section 2: How the research work presented in this thesis relates to other 
research work undertaken as part of the PhD and other work by the wider research group  
 
Understanding the determinants of nebuliser adherence among adults with CF is important to 
design effective interventions, but it is only one cog in the wheel to develop, evaluate and 
implement effective adherence interventions for adults with CF. There are at least three other steps 
involved in the development of an effective adherence intervention. 
 
First, evidence for specific behaviour change techniques (BCT) to target relevant behaviour 
determinants [431, 432] should be reviewed. This would allow the appropriate BCTs to be selected 
and combined in an adherence intervention, especially since interventions with more than one BCT 
tended to be more potent.[433-435] This piece of work has been undertaken by the wider research 
team during the development and iteration of a complex adherence intervention for ACtiF pilot 
(ISRCTN13076797) and CFHH RCT (ISRCTN55504164).   
 
Second, a method should be developed for personalising the use of the various BCTs for an 
individual, instead of delivering a generic intervention with a ‘one size fits all’ approach. There is 
evidence that targeted behaviour change interventions tended to be more potent.[436-439]  
Variation in adherence during an intervention period could be used to identify response and guide 
intervention delivery.[440, 441] Statistical process control (SPC) is a visual form of time series 
analysis based on the statistical methods introduced by Shewhart in the 1920’s to help understand 
variation of a process with time.[442] Thus, SPC could potentially be used to personalise the 
delivery of BCTs; but the type I and type II errors associated with different SPC strategies as 
applied to nebuliser adherence data need to be clarified. The use of different SPC strategies to 
detect changes in nebuliser adherence have been explored using the Sheffield dataset and ACtiF 
pilot data as part of the PhD research. 
 
Third, there is a need to understand the level of adherence which is adequate to sustain lung 
health and the minimum amount of improvement in adherence required to improve health 
outcomes. In the context of developing an effective adherence intervention, this understanding is 
critical to agree an explicit adherence target that is beneficial and clinically relevant for adults with 
CF. There is evidence that “100% adherence” may not be necessary to achieve health benefits, for 
example using ≥80% of prescribed anti-hypertensives is adequate to control blood pressure.[443] 
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To begin the journey towards understanding ‘how much adherence is enough’, some of the 
required background work include identifying important clinical characteristics that determine 
treatment requirements, developing an adherence measure which reflects effectiveness of 
medication use, developing a better understanding of health outcomes in CF, and systematically 
exploring the interplay between clinical characteristics, prescribed treatments, adherence and 
health outcomes. Preliminary exploration of these issues has been performed using the Sheffield 
dataset as part of the PhD research, with the aim of replicating the analyses using data from the 
CFHH RCT. 
 
The next step after developing an adherence intervention is to evaluate the efficacy and 
effectiveness of the intervention. Having completed the ACtiF pilot, the wider research team is 
currently evaluating a complex adherence intervention in the CFHH RCT. 
 
Although evaluation follows on from intervention development, the learning required to develop an 
effective adherence intervention rarely occurs in a linear fashion.[444, 445] An experimental design 
is typically used to evaluate adherence interventions. Such design, which yields the least 
ambiguous cause and effect conclusions, is also useful to generate further knowledge regarding 
behaviour determinants, impact of specific BCTs on behaviour determinants, and the relationships 
between adherence and health outcomes;[446, 447] especially if adherence is carefully defined, 
and key outcomes and adherence determinants are accurately measured. Secondary data 
analysis following a clinical trial of adherence intervention can yield further learning to guide the 
iteration of adherence interventions, before subjecting the iterated intervention to further evaluation 
cycles. Therefore, secondary analyses using data from CFHH RCT (ISRCTN55504164) have been 
planned to further refine the complex adherence intervention, and also to try answer the ‘how much 
adherence is enough’ question. 
 
Even a robust evaluation study providing incontrovertible evidence that a behaviour change 
intervention is effective does not necessarily guarantee the successful implementation of that 
intervention. A case in point is the Diabetes Prevention Program which has yet to be translated into 
clinical practice,[448] despite a landmark trial published in 2002 demonstrating a reduced 
incidence of diabetes by 58% for the lifestyle-modification programme compared to usual care 
among at-risk population.[449] By re-positioning the healthcare delivery sector as a set of nimble 
organisations focusing on on-going system improvement (i.e. as a ‘learning health system’ [450-
453]), there is potential for quicker integration of an effective adherence intervention into routine 
clinical practice.[454] Therefore, the CFHH improvement collaborative (ISRCTN14464661) has 
been set up by the wider research team as a learning health system, in which adherence data are 
routinely and accurately collected via electronic data capture. The adherence data are used to 
inform on-going clinical practice, improve care over time with continuous learning and accelerate 




Chapter 7, Section 3: Highlights and discussion points  
 
Since this PhD was nested within a NIHR adherence programme grant, a national group of health 
services researchers was an immediate audience for outputs of the research. The findings of the 
PhD research have therefore influenced the design of the ACtiF pilot (ISRCTN13076797), CFHH 
RCT (ISRCTN55504164) and CFHH improvement collaborative (ISRCTN14464661). For example, 
the habit measure in these studies focused on habitual instigation, since the mixed methods study 
reported in Chapter 5 of the thesis found that effects of non-specific habit on nebuliser adherence 
may be more precisely attributed to instigation habit. The adherence metric used in these studies 
to reflect effective adherence is based on the method to quantify adherence [181, 182] that was 
developed as part of the PhD research. Likewise, the method to diagnose chronic P. aeruginosa 
infection in the CFHH RCT and CFHH improvement collaborative is based on a consensus 
definition [455] that was developed as part of the PhD research.   
 
The studies presented in this thesis have also added to the current knowledge of factors 
associated with nebuliser adherence among adults with CF, especially in highlighting that nebuliser 
adherence among adults with CF is not just about “treatment burden”. 
 
We often believe what we can sense. In the past, bacteria could not be seen but putrid odour could 
be smelt; hence the miasma theory (that noxious “bad air” is responsible for the spread of disease) 
was assumed to be true.[456] Currently, there is a temptation within the CF community to believe 
that “treatment burden” must be an insurmountable barrier to medication adherence because CF 
treatment regimens are complex and that complexity can be easily observed (e.g. as the number of 
medications to take or as time spent on treatments).  
 
However, low adherence in CF is multi-factorial and more complex than it first seems. The 
literature review in Chapter 3 summarised a list of potential factors that may influence nebuliser 
adherence including age, gender, socioeconomic status, prescription factors, treatment burden, 
routine, disease severity, illness perception, disease / treatment knowledge, psychopathology, 
ways of coping, family relationship, relationship with the CF care team, other social relationship, 
self-efficacy and treatment beliefs. Over-coming one barrier may unearth another, hence simple 
strategies focusing only on one barrier to treatment have typically not achieved sustained 
improvement in adherence.   
 
For example, treatment rationalisation (e.g. dropping inhaled mucolytic to “reduce treatment 
burden”) is often employed as a strategy to try improve adherence,[364] yet the few studies which 
looked at this strategy found no evidence of efficacy.[176] Treatment rationalisation might even be 
detrimental to health outcomes – the analysis in Chapter 4 found that treatment rationalisation was 
only associated with a modest increase in adherence by 4% to 8%, which probably represent less 
effective treatment (due to reduced target number of nebuliser doses to be taken) rather than more 
effective treatment (increase in the actual number of nebuliser doses taken). Other interventions 
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based solely on “reducing treatment burden” such as switching nebulised therapy to dry powder 
inhalers also did not demonstrate improvement in adherence beyond one year. More recent data 
showed similar adherence for nebulised therapy and dry powder inhalers.[219, 269]  
 
Other forms of adherence intervention in CF include problem-solving to help people with CF 
overcome practical barriers to using nebuliser,[234, 236] whilst motivational interviewing [236] and 
providing education [234, 235] engaged reflective processes to change behaviour. Data in 
Chapters 4 & 6 show that sustaining long-term adherence is particularly challenging. There is also 
increasing recognition that effective means of initiating behaviour change may not necessarily 
sustain that change.[457] Yet the interventions used in previous CF studies lack a built-in 
mechanism to sustain improved adherence. Not surprisingly, the gains in adherence are often 
transient.[14, 15]  
 
No study among people with CF has specifically investigated a habit-based behaviour change 
strategy to support nebuliser adherence or used habit strength to tailor intervention techniques. 
There is evidence in other long-term conditions to suggest that it may be more worthwhile for 
adherence interventions to target automatic processes such as habit. For example, a recent meta-
analysis on 771 trials found medication adherence interventions that included habit formation were 
more effective than those that did not.[249]  
 
Among people with CF, routinisation has been reported as a facilitator of nebuliser use.[251, 252, 
259] Objective adherence data collected using electronic data capture have demonstrated that 
adolescents with CF are most adherent during school term-time weekdays.[171] This finding 
suggests that habit and routines (routine is more inherent during school term-time) may trump 
treatment burden (adolescents are likely to be busiest during school term-time, so should be most 
susceptible to lapse in adherence due to treatment burden) in regards to influencing adherence 
among people with CF. Both the studies in Chapters 5 & 6 add to the current evidence by 
demonstrating the association between habit and nebuliser adherence, and highlighting the 
potential for habit to moderate perceived treatment burden among adults with CF.  
 
While evidence accumulates on the relevance of habit to nebuliser adherence, it is sufficiently clear 
that to change behaviour at the scale needed to improve the overall population health of people 
with CF, minds need to be changed about how to achieve this. The ineffectiveness of current 
adherence interventions for adults with CF should prompt the CF community to reflect on 
strategies to support adherence. Instead of merely focusing on treatment burden and reflective 
processes, habit formation among adults with CF warrants further investigations. Habit-formation 
advice could be part of a comprehensive and individualised package of intervention to support 
adherence, especially among people with low habit strength. Such advice – i.e. encouraging the 
use of treatments in specific and unchanging contexts, so that associations may develop between 
those contexts and treatment adherence – is simple to deliver.[314] In addition, habit strength 
should be assessed as an intervention outcome and habit formation might be prioritised as a goal 
for adherence interventions. 
109 
 
Chapter 7, Section 4: Future directions 
 
The ineffectiveness of current adherence interventions for adults with CF is not just a call for action 
– it is also a call for better evidence. The studies presented in this thesis have identified three 
areas that requires further work, in order to generate more robust evidence for advancing the field 
of CF medication adherence. 
 
The first area is the quality of research studies. Previous studies evaluating adherence 
determinants in CF have tended to find conflicting results, in part due to small sample sizes. 
Recruiting an adequate number of participants in a rare disease is challenging – despite the prolific 
increase in the number of CF clinical trials over the past three decades, quality of clinical trials 
(especially the sample size) has not improved.[458, 459] To achieve an adequate sample size 
which can provide more reliable findings, multi-centre (or even multi-national) studies would be 
needed. In a rare disease area, there is a particular need for the use of more efficient trial designs 
(especially efficient methods to recruit participants),[460-462] e.g. ‘master protocol’,[463] adaptive 
designs,[464] randomised registry trials,[465] and trials within cohort.[466] Since longer-term 
adherence is particularly problematic, studies with long term follow-up periods (e.g. more than two 
years) are also needed to understand the change in adherence over time. 
 
The second area is taking a whole system perspective to investigate and improve CF medication 
adherence. The literature review in Chapter 3 showed that existing CF studies have only focused 
on understanding adherence of individual adults with CF and have not systematically included the 
entire cohort within a centre to understand adherence at a centre-level. Unlike most other long-
term conditions whereby care are predominantly delivered by general practitioners in the 
community, healthcare for people with CF are delivered almost exclusively by multi-disciplinary 
teams through specialist CF centres.[124] The CF community is tight knit with cohesiveness 
enhanced by national CF Trusts / Foundations, which are patient and clinician advocacy 
organisations that support equity and quality of care with structures such as national CF registries. 
This cohesiveness provides a platform for system-wide learning and quality improvement.[467] As 
stated in Section 2.3, one of the key CF treatments is high calorie diet. The importance of 
aggressive nutritional support was not discovered via randomised controlled trials, but through 
comparisons of CF centres in Toronto and Boston back in the 1980’s.[468] Other quality 
improvement initiatives also have had profound impact on the lives of people with CF by 
transforming the delivery of healthcare.[467, 469, 470] Examples of successful quality 
improvement initiatives include reduced variation in screening rates for CF related diabetes, 
improved clinic attendances, streamlined approach to managing acute exacerbation, better 
infection control, seamless transition process and increased prescription of efficacious preventative 
inhaled therapies.[145, 374, 471-474] Although low levels of medication adherence and the 
potential health benefits from improved adherence should represent a low-hanging fruit to further 
improve CF clinical care, a large scale systematic quality improvement initiative around medication 
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adherence has not yet been published. The continuous quality improvement techniques e.g. 
benchmarking and the use of small tests of change (plan-do-study-act, PDSA) which have been so 
effective in transforming other aspects of CF care could also be harnessed to improve adherence 
at a centre level and drive quality improvement using adherence as a quality indicator. Therefore, 
there is also a need to better understand CF adherence from the whole system perspective.  
 
The third area is the challenge of measuring psychological constructs and behaviour. Measuring 
psychological constructs that cannot be directly observed is especially challenging. None of the 
existing habit measures can fully capture the construct of habit as “a process by which a stimulus 
automatically generates an impulse towards enacting a behaviour”.[250] Striving for a “perfect” 
measure of habit is aspirational, but perhaps it is more pragmatic to develop a suite of habit 
measures that are adequate to provide insight even if that insight cannot be perfect. In terms of 
perceived treatment burden, the Cystic Fibrosis Questionnaire-Revised (CFQ-R) treatment burden 
domain is limited by a lack of internal consistency, as highlighted by the analysis in Chapter 6 and 
also in other studies.[395, 428] To better understand perceived treatment burden among people 
with CF, a robust and comprehensive CF-specific treatment burden scale should be developed by 
taking into account the ‘taxonomy of treatment burden’ framework.[475-477]   
 
Since CF is a multi-system disorder which necessitates multiple treatment modalities, it is 
imperative to understand whether increasing adherence to a specific treatment modality has the 
unintended consequence of reducing adherence to another treatment modality. Progress is being 
made in terms of objectively measuring adherence to other CF-related treatments. For example, 
physiotherapy adjuncts for airway clearance have been chipped (similar to an intelligent nebuliser 
device) to measure both adherence and quality of airway clearance techniques.[478, 479] Oral 
medications (e.g. pancreatic enzyme replacement therapy) can be monitored indirectly using 
intelligent pill bottles that can track the date and time of each bottle opening (e.g. the Medication 
Event Monitoring System, MEMS),[167] or directly using ingestible event marker which can detect 
if medication was actually ingested (e.g. Abilify MyCite, which is aripiprazole with an embedded 
sensor).[480] More self-monitoring devices are likely to be commercially available with advances in 
technology. However, further work is needed to embed these devices within routine clinical 
practice so that overall adherence to CF treatments can be better understood. 
 
Further work is also required to enhance the adherence metric which was designed to reflect 
effectiveness of treatment regimen. A consensus exercise involving a broad group of CF clinicians 
could potentially identify other relevant factors that influence treatment effectiveness and methods 
considered acceptable for processing adherence data. A broad engagement in a consensus 
process would improve the acceptability of the adherence metric and make it more likely for the 
metric to be universally adopted. In addition, seeking the opinions of people with CF and their 
relatives / carers are important, since being fed back lower than expected levels of adherence 
might be perceived negatively and thus discourage engagement.[481] The think aloud method 
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[482] could be applied to systematically explore the views of people with CF and their relatives / 
carers. Different adherence metrics should also be empirically tested in a suitably large dataset 
with objective adherence data and carefully measured key outcomes. This will allow different data 
processing methods to be tested and help identify the optimum method of processing adherence 
data that most accurately reflect effective adherence. 
 
 
Chapter 7, Section 5: Concluding remarks 
 
The improvement in CF survival from less than 6 months in 1940’s to 45–50 years in the 2010’s is 
a testament to the increasing availability of efficacious treatment options and advances in care 
quality. Few other long-term conditions can match such improvements and advances. Yet not all 
the expected rewards from increasingly efficacious treatment options have been realised because 
treatment adherence in CF is generally suboptimal. 
 
This thesis has provided an in-depth analysis of a broad range of clinical and psychological 
adherence determinants among adults with CF. Some of the new insights provided by this thesis 
may stimulate future research, in particular the potential for habit to moderate perceived treatment 
burden among adults with CF. A natural next step would be to extend my current research by using 
larger datasets from CFHH RCT and CFHH improvement collaborative for replication of findings 
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